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Abstract 
This thesis presents the development and in-vivo applications of wearable and 
portable devices for the investigation of light interaction with tissue involved in 
Photodynamic therapy (PDT) and during contraction of muscles. 
A hand-held device and a clinical method were developed for time course in-vivo 
imaging of the fluorescence of the photosensitizer Protoporphyrin IX (PpIX) in healthy 
and diseased skin with the aim to guide improvement of PDT protocols. The device was 
used in a small clinical study on 11 healthy volunteers and 13 patients diagnosed with 
non-melanoma skin cancer (NMSC). Two types of PpIX precursors were administered: 
Ameluz gel and Metvix® cream. The fluorescence was imaged with a 10 minute time 
step over three hours which was the recommended metabolism time before commencing 
PDT treatment at Ninewells Hospital, Dundee. The fluorescence time course was 
calculated by integrating the areas with the highest intensity. The fluorescence continued 
to grow in all subjects during the three hours. The time course varied between 
individuals. There was no statistical significance between either healthy volunteers or 
patients in Ameluz vs Metvix® groups; nor was there statistical difference between the 
three lesions groups (Actinic keratosis (AK) Ameluz vs AK Metvix® vs Basal cell 
carcinoma (BCC) Metvix®). The p-value was larger than 0.05 in a two sample t-test with 
unequal variances for all the groups. However, there was strong body site dependence 
between the head & neck compared to the lower leg & feet, or the trunk & hands body 
site groups (p-value<0.01). One of the possible explanations for this was temperature 
and vasculature variation in skin at different body sites: the temperature is higher and the 
vasculature structure is denser at the head and the neck compared to the lower leg or 
the trunk. The temperature was not measured during the study. So in order to support 
this hypothesis, typical skin temperatures at the lesion sites were taken from the IR 
thermal images of healthy skin available in literature. PpIX fluorescence had a positive 
correlation to temperature. If this hypothesis is true, it will be highly important to PDT 
treatment. Increasing the temperature could speed up the metabolism and reduce the 
waiting time before starting the treatment; ambient temperature should be taken into 
account for daylight PDT; cooling air as pain management should be administered with 
caution.  
Potential improvements for wearable PDT light sources were investigated by 
modelling light transport in skin for the current LED-based Ambulight PDT device, a 
commercial OLED for future devices and a directional OLED developed in the group. 
The optical models were implemented in commercial optical software (with intrinsic 
Monte Carlo ray tracing and Henyey-Greenstein scattering approximation) which was 
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validated on diffuse reflectance and transmittance measurements using in-house made 
tissue phantoms. The modelling was applied to investigate the benefits from diffusive 
and forward scattering properties of skin on light transmission in treatment light sources. 
1 mm thick skin can only compensate approximately 10% of non-uniform irradiance. It 
means that uniform illumination is crucial for the treatment light sources. Forward 
scattering in skin showed a 10% improved light transmission from a collimated emission 
compared to a wide angle Lamberian emission. However, depth-dependent transmission 
measurements of directional vs Lambertian emission from organic light emitting films (a 
nano-imprinted grating was fabricated to provide directional emission in one of the films), 
collimated vs diffused HeNe laser light through fresh porcine skin did not show the 
expected improvement. This could be explained by skin roughness which was previously 
found to change the optical properties and may also affect light coupling. 
The modelling was applied to guide an optical design of another wearable device 
– a muscle contraction sensor. Muscle is fibrous and because of that scatters light 
differently in different directions. The sensor detects the change in backscattered light in 
parallel and perpendicular directions with respect to muscle fibres. The sensor was 
implemented on a wearable bandage on fully flexible substrate with flexible OLED and 
organic photodiodes. The major advantages of organic optoelectronic sensing compared 
to conventional electromyography (EMG) sensors are the ability to distinguish two types 
of contractions (isotonic and isometric), insensitivity to electromagnetic interference and 
the absence of an immune response due to non-invasive electrode-free sensing. Optical 
modelling was performed to understand the operation of the sensor. A 3D anisotropic 
optical model of scattering in muscle was created by geometrical manipulations with the 
standard Henyey-Greenstein scattering volumes. The penetration depth from the Super 
Yellow OLED was found to be 20-25 mm; the optimal separation between the source 
and the detector was found to be 20 mm. This distance provided a still detectable signal 
along with the best discrimination between the two backscatterings. When a 2 mm thick 
layer of skin and a 2 mm thick layer of adipose tissue were added to the model, the 
signal was hugely diffused. The discrimination between the two backscatterings 
decreased by three orders of magnitude, the penetration depth in muscle was reduced, 
and the intensity of the signal dropped down but was still detectable. With 5 mm thick 
adipose tissue and 2 mm thick skin the signal was too diffused and interacted with very 
shallow layers of muscle which approached the limits of the optical sensing of muscle 
activity. 
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Chapter 1 
From the visible cognize the invisible. 
― Gregory Skovoroda (Григорій Сковорода), (1722 - 1794)  
Ukrainian educator, humanist, philosopher, poet, composer 
 
 Introduction 1.1
Allegedly, as far back in history as before Christianity, the Egyptians and the Greeks split 
sunlight into colours through gems and built temples to expose the sick to individual colours of 
light believing that such heliotherapy (treating disease by sunlight) or chromo-therapy (treatment 
by colour) can heal illnesses1,2. The first scientific discovery that light could be used for treatment 
of diseases was made in 1893 by Finsen when he published his dissertation "On Light's Effect 
on the Skin." Later he used artificial light – an arc lamp to treat cutaneous tuberculosis (lupus 
vulgaris) (Figure 1).    In 1896 Finsen’s work "On the 
application of concentrated chemical light beams in medicine" was published and the Finsen 
Institute for Phototherapy was founded. In 1903 he was awarded the second Nobel Prize in 
Physiology or Medicine 1903 "in recognition of his contribution to the treatment of diseases, 
especially lupus vulgaris, with concentrated light radiation, whereby he has opened a new 
avenue for medical science"3. 
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Figure 1: Finsen light treatment for Lupus, 1900 
 
Further improvement after the development of artificial light was the application of 
photosensitising agents in combination with light to treat tumours. Finsen, Raab and Von 
Tappeiner were pioneers of light therapy and photobiology4. However, at that time there were a 
number of limitations in drugs and light delivery systems which delayed the widespread use of 
light therapy for decades. Light therapy saw renewed interest in the 1950s with the use of 
hematoporphyrin as a photosensitiser. The first governmental approval of PDT in clinic was in 
1993 in Canada for treatment of bladder cancer using purified hematoporphyrin – Photofrin5. 
Now PDT has been used to treat about 30 types of skin diseases6, and other cancers which are 
localized and do not proliferate such as cancer of the oesophagus and lung cancer 7,8.  
Blue light alone can treat acne. The bacteria in sebaceous glands which cause acne 
generate endogenous porphyrins similar to the ones used from precursors in classical PDT 
treatment9,10. Blue light excites those porphyrins which results in a photodynamic reaction and 
toxic effect to the bacteria11. Although blue light is a part of the daylight spectrum; more intense 
and wavelength-specific blue light is more effective in fighting acne12.  
There is evidence that light can treat fungal infection of nails. Infrared laser light was 
reported to decrease trans-membrane potentials and generate reactive oxygen species (ROS) 
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which result in oxidative stress and death of bacteria and fungi13. It is listed as a 90% effective 
treatment for fungal nail infection on the NHS website14. 
Low Level Light therapy began in 1989 and suggested that IR and visible monochromatic 
light affects respiratory mitochondrial chains and ATP energy transport in cells15. At the start it 
was used to stimulate healing, reduce inflammation17, and repair function for hair re-growth18. 
Current reports show that LLLT has clinical significance in treating herpes19 and even brain 
injury20. 
Lasers are used to treat venous malformation and birth marks mostly due to overheating 
of tissue21,22. The same controlled overheating effect induced by the lasers is widely used in 
aesthetics for hair and tattoo removal23, skin resurfacing for scar removal and rejuvenation24. 
UVA and UVB light have been widely used for treating psoriasis25. The mechanisms of 
how UV light slows down the growth of psoriasis cells is not completely understood. Some of the 
reports found evidence that UV light slows down signal pathways in epidermal RNA gene 
expression which is responsible for proliferation of prosirasis26. This supports the theory that 
living cells may in fact use biophotons for communication27,28. Biophoton or ultra-weak 
spontaneous photon was described as a spontaneous weak emission of light by biological 
cells29. It is claimed to be a non-stimulated emission which is supposedly different and 
distinguishable from bioluminescence, fluorescence, phosphorescence or black body 
radiation30,31. Biophoton emission can be imaged with highly sensitive cooled CCD cameras in a 
controlled environment32 to detect viability of cancer tissue33,34, oxidative metabolic, intrinsic and 
stimulated antioxidant processes in skin as a response to UV radiation and other environmental 
factors35,36. 
This brings us to the use of light for sensing. There is a virtually limitless number of 
applications starting from fluorescence and finishing with optical coherence tomography. 
Naturally fluorescent proteins have revolutionised biology by visualising important aspects of 
diseases including tumour cell mobility, invasion, metastasis and angiogenesis37. Fluorescence 
can be excited in many biological molecules and studied using relatively simple microscopes or 
fluorescence cameras38. Among recent advances are: fluorescence life time imaging which can 
be used to study protein-protein interaction39; and FRET-based biosensors for real time imaging 
of HIV virus penetration in cells40. Another fluorescence imaging technique is based on tagging 
cells with green fluorescent protein (GFP). This was discovered in 2008 by Shimomura, Chalfie 
and Tsien who received a Nobel prize in Chemistry for GFP41. GFP is a fluorescent marker 
which enabled to the study of cell dynamics42. Nowadays GFP is used for single molecular super 
resolution imaging43. Betzig,Hell and Moerner were awarded the Nobel Prize for Chemistry in 
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2014  "for the development of super-reolved fluorescence microscopy44. Another advance is 
novel GFP synthesis suitable for two-photon absorption; potentially this could be used for non-
invasive optical imaging of deep in tissue and in brain45.  
All the above demonstrates the enormous number of applications where light can be 
used for sensing, treatment and aesthetics employing various mechanisms of light-tissue 
interactions (Figure Error! No text of specified style in document..2).  
 
Figure Error! No text of specified style in document..2: Major light-tissue interactions and 
examples of their applications in treatment and sensing 
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Technological advances in light sources, electronics and mobile technology gave rise to 
the development of cheap wearable sensors and treatment devices. Wearable technology and 
devices based on cell phones is a booming field nowadays46. R&D/venture creation firm 
PureTech published a review on digital medicine's emergence and listed some brand companies 
(not all!) working on the development of wearable sensors and mobile applications (Figure 
Error! No text of specified style in document..3) 47.  
 
Figure Error! No text of specified style in document..3: Wearable sensors under 
development47 
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Some of the examples of wearable devices based on smart phone technology include a 
Apple Watch which can track your daily activity now48. Smartphones can be used for sensing in 
ophthalmology, bodily fluids, monitoring bacteria, allergens and hormones in food49. 
Smartphones have also been recognised as providing reliable imaging devices for telemedicine 
to evaluate stroke patients in remote locations50; smartphone-based applications could help to 
prevent and manage cardiovascular disease and rehabilitation in groups of people with low 
socioeconomic status and developing countries51.  
Our Organic Semiconductor Centre has contributed to the field of wearable devices by 
developing and bringing to market ambulatory light sources for skin cancer6,52,53 and acne 
treatment12; and the development of an optical muscle contraction sensor54,55. It is worth 
mentioning that organic electronics was used in both cancer treatment light sources and a 
muscle contraction sensor. The application of organic electronics in wearable technology and 
healthcare is another emerging field, offering appealingly thin, flexible, repeating the body shapes 
devices, and also tuneable properties for many applications56,57. Fabrication technology for 
organic devices is potentially cheap simply by spin-coating from solution58,59.  
PDT and PpIX fluorescence assisted cancer diagnostics were not left aside. Light 
sources based on a smartphone camera flash with some external accessories were reported to 
deliver the PDT treatment dose; also there is an accessory which enables PpIX imaging for 
assisting with PDT diagnostics or cancer detection60. Another portable device for PpIX 
fluorescence imaging was tested with a combination of cameras from a Sony Xperia® model “P” 
mobile phone and an Apple Ipod® to potentially assist with the display and imaging during the 
cervical intraepithelial neoplasia treatment61. 
The interest of this thesis only refers to a small part of this exciting area: Photodynamic 
therapy, fluorescence diagnostics and wearable devices. The concern of the thesis was mostly 
to pave ways to improve photodynamic treatment; the focus was on the development of portable 
instruments for convenient clinical studies and wearable light sources for ambulatory treatment 
and point-of-care diagnostics.  
 Thesis outline 1.2
The work in this thesis is connected by the theme of light tissue-interaction and 
developing wearable light sources for treatment and sensing. However, the application 
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described in each chapter relates to slightly different areas. Therefore each chapter has its own 
introduction and methods sections.  
Chapter 2  
This chapter is fully devoted to the development of a portable fluorescence imaging 
camera for the clinical study of protoporphyrin IX photosensitizer (PpIX) formation used for PDT. 
A number of fast prototyping techniques for developing optical and mechanical designs, 3D 
plastic printing, registering and working with images in Matlab, fabricating tissue phantoms and 
testing fluorescence imaging devices for clinical studies is outlined in the Methods section. The 
chapter will guide the reader through the important considerations for the development of a 
clinical research device with the focus on the NHS Good Clinical Practice (GCP) regulation for 
non-drug/device studies in terms of electrical safety, optical power output for implication in eye 
and skin safety, infection control, and allergic reactions. The results of the testing of the device 
on fluorescent phantoms, standard fluorescent solutions, PpIX fluorescence developed in the 
skin of a healthy volunteer administered Ameluz gel and two patients diagnosed with Actinic 
keratosis (AK) administered Ameluz PDT and biopsy-confirmed Basal cell carcinoma (BCC) 
administered Metvix® PDT are presented. 
Chapter 3  
This chapter describes the application of the developed hand-held fluorescence imaging 
camera in a small clinical study of healthy volunteers and patients representing non-melanoma 
skin cancer (NMSC). The reader can find guidance for developing clinical study protocols, 
ethical requirements and procedures to conduct a research study at Ninewells hospital, Dundee. 
There is a description of a the development of a fluorescence time course imaging method which 
is integrated in the routine PDT treatment of patients with NMSC at the Photobiology unit at 
Ninewells hospital. Observations from 11 healthy volunteers and 13 patients diagnosed with AK 
and BCC and administered two types of creams (Ameluz and Metvix®) are discussed. The 
images were processed in Matlab; the peak fluorescence areas were selected and the 
fluorescence was integrated for the time course analysis. The statistical significance in the 
fluorescence time course was calculated using two sample t-test with unequal variances. There 
results report on the statistical significance between two healthy volunteers groups: Ameluz v.s. 
Metvix®, three patients groups: AK Ameluz v.s. AK Metvix® v.s. BCC Metvix® groups, and three 
body side dependence patients groups: Head & Neck v.s. Trunk v.s. Lower leg & Hands. Body 
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side dependence which was discovered during this study was attributed to the temperature 
dependence and the vascularization density of the skin. 
Chapter 4 
This chapter is fully devoted to developing optical modelling, measurements and 
regression testing for characterising optical properties of tissue phantoms. The development of 
this apparatus was a necessary step for developing and testing devices and concepts for 
improving light propagation in skin. The approach taken was to use commercial optical design 
software for modelling light transport in comparison to previous groups which used custom 
programs in C or open source software. The capabilities of the software to model light 
propagation in tissue was tested on the previous results from one of the predecessors groups 
who used a custom Monte Carlo program in C programming language and diffuse reflectance 
measurements. The results of the simulations were in good agreement with the modelling and 
measurements from that group. The next step was to fabricate optical phantoms and build a 
diffuse reflectance measurements set up. The modelling was validated on the measurements on 
scattering silicone solid phantoms; the initial optical properties of the phantoms were adjusted 
with the help of regression (reverse) Monte Carlo modelling. This completed the development of 
optical apparatus for the development of the device and studying light transport in tissue. This 
apparatus was used for assisting with a feasibility study on wireless optical power transmission 
through gel brain phantom for potential application in implantable robotics. In this project an 
absolute power comparison was carried out and the conclusions were drawn on the most 
effective design of the solar panel. The final application of the optical apparatus which will be 
presented in this chapter was investigation of light propagation from ambulatory wearable 
devices (Ambulight PDT) through skin. The uniformity of light distribution, compensation of non-
uniformities by diffusion in skin and the precautions in the drop of intensity at the edges was 
evaluated. The uniformity of the illumination field was cross-referenced with a commercial PDT 
lamps and compered with a potential OLED device. At the end there is an outline of important 
considerations for future devices. 
Chapter 5 
This chapter investigates the potential of directional OLEDs as improved light sources for 
PDT treatment. Skin has very strong forward scattering properties. So structured laser-like 
emission or collimated light could potentially improve penetration depth in the skin. This concept 
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was tested by the modelling and measurements of structured light from organic emitting films 
through porcine skin. The intention for this measurement was to obtain a comparison in the 
transmission from the two light sources which would have an impact on the medical community. 
Porcine skin seemed to be the best analogue to human skin. Although, surprisingly there was 
very little information in the literature on transmission measurements using porcine skin for the 
visible range. Also there was huge variation among the groups; the groups also reported that 
they observed large variations in their own measurements. However, considering that the 
experiment in this chapter did not intend to characterise porcine skin but have comparable 
measurements on the same skin samples for two light sources, the variation in the previous 
reports seemed to be not relevant for this experiment. Nonetheless, there were a few challenges 
to overcome First was how to dissect fresh porcine skin to enable depth dependent 
measurements. The thickness of the skin relevant to PDT treatment is 1-2 mm, so the step had 
to be at least 0.5 mm. Fresh skin is very greasy, stretchable and flexible which makes it 
challenging to fix and cut. In order to use standard dissection tools available in the School of 
Neurology or Biology the skin had to be frozen which would change the optical properties. So 
fresh tissue was dissected with a surgical scalpel with 0.5, 1.0, 1.5, 2.0, 2.5, 3 mm thickness. 
Another question was the change in optical properties of skin when the experiment was 
conducted in air. Due to the fact that there was a significant change over 3.5 hours, samples 
were placed in ultrasound gel. The transmission was imaged with a CCD camera using the 
organic films. The experiment was complemented with imaging the transmission from collimated 
and diffused laser light. Transmission was integrated over a few millimetres on the skin (30-150 
pixels on the images). This area corresponded to the centre of the incident beams. The result 
was normalised on the incident power and compared with the modelling.  
Chapter 6 
The work in this chapter is an application of the optical modelling developed. Optical 
modelling was applied to understand the design of a wearable optical muscle contraction sensor. 
Due to the fibrous nature of muscle it scatters light in different proportions along and across the 
muscle fibres. When muscle contracts the fibre aspect ratio changes: the fibres become shorter 
and thicker. In the contracted muscle more light scatters across the muscle compared to the 
relaxed or elongated muscle. Measuring the relative difference in light scattering along and 
across the fibres enabled the development of an optical muscle contraction sensor62. The 
reported inorganic sensor was then implemented on a wearable bandage using fully flexible 
substrates and organic devices. It was used to drive a robotic arm to demonstrate the potential 
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of actuating prosthetic devices. My work was to investigate in the literature optical modelling and 
measurements for muscle tissue. First, a standard model of muscle with one dimensional 
Henyey-Greenstein scattering approximation was implemented in the same optical software. 
Light propagation from OLED made of Super Yellow polymer was modelled through individual 
layers of the tissue and then for the layered tissue. This helped to find penetration depth; study 
the effect of skin and fatty tissue to the probed signals, evaluate appropriate distance between 
the light source and the detectors. Then it was established what was responsible for 3D 
anisotropic scattering in muscle from the literature and this led to the implementation of a 3D 
optical model of muscle in the software. This model helped to better understand light 
propagation in layered tissue and make final conclusions for the best design of the sensor. 
Chapter 7 
This chapter presents the colclusions. The work outlined in this thesis looks at two major 
factors which are responsible for PDT treatment outcomes: the metabolism of PpIX and light 
transport. A prototype device developed to study PpIX formation in healthy and diseased skin 
was used in a small clinical study; the results of this study made a few interesting discoveries 
one of which is the effect of skin temperature on drug metabolism which can guide 
improvements in treatment protocols. 
An optical apparatus developed during the PhD project was applied to investigate the 
possibility of wireless optical power transmission in brain phantoms and study the light 
transmission in skin for potential improvements in treatment PDT devices. A transmission 
measurements set up and a measurements procedure in fresh pork samples were developed to 
support the modelling results. In the end optical modelling was used to understand the design of 
a wearable fully organic muscle contraction sensor for potential application in a new generation 
of improved prosthetic devices.  
 
The biggest ambition would be to integrate all the developed instruments and techniques 
(the regression (reverse) modelling for extracting optical properties, diffuse reflectance 
measurements and fluorescence imaging) with a treatment light source and add an oximeter to 
it. This configuration would enable measuring optical properties, PpIX concentration and 
oxygenation in real time. Information about the combination of these three parameters would 
enable the adjustments of light delivery in real time. In addition it would be useful to have 
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thermal imaging as well as it seems to correlate with the fluorescence. This is a subject for future 
investigation. 
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Chapter 2 
2 Instrument development for measuring 
fluorescence and assisting with the monitoring of 
Photodynamic therapy (PDT) of skin cancer 
You can't connect the dots looking forward; you 
can only connect them looking backwards. So 
you have to trust that the dots will somehow 
connect in your future 
― Steve Jobs, Entrepreneur, 
Stanford Report, June 14, 2005 
2.1 Introduction 
In this chapter general background concerning the development of skin cancer and PDT 
treatment will be covered. The research focus will be made on the clinical importance of 
fluorescence diagnostics for studying the drug metabolism used in PDT treatment and the need 
for the development of a portable instrument which would enable in-vivo fluorescence imaging 
and quantities display by following a simple measurement protocol. The chapter will cover many 
aspects in the development of research instrumentation for clinical studies. Good clinical 
practice requirements for developing a prototype device and a number of fast prototyping 
techniques and development stages will be described. The chapter will culminate on a pre-
clinical testing of the device on the fluorescence from healthy volunteers and patients diagnosed 
with non-melanoma skin cancer (NMSC). 
Skin is the largest organ in human body. It regulates temperature when it is too cold or 
too hot, protects our body from injuries and infections and performs secretions functions. Skin 
consists of three layers – epidermis (upper layer), dermis (middle layer) and subcutaneous 
tissue (the lowest layer)1. The outermost part of epidermis is stratum corneum which consists of 
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corneocytes. Corneocytes are anucleated cells differentiated from nucleated keratinocytes 
present in deeper layers of epidermis. It was well established that the exposure to UV light 
results in DNA damage in keratinocytes and local immunosuppression which increases the risks 
of developing skin cancer2,3. By the recent reports only 65 % of melanoma cancers but as much 
as 90% of NMSC are associated with UV exposure4. That study also reports that sunscreen 
lotions do not reduce the risks of developing this cancer and chemoprotection is needed. Among 
the other factors responsible for promotion of the development of tumours except DNA damage 
is inflammation induced by UV exposure. Inflammation increases blood flow and vascular 
permeability which results in infiltrating leukocytes secreting a variety of proinflammatory 
signalling proteins which increase chances of tumour development4. It has already been 
established that melanoma skin cancer has genetic nature too. The genome of melanoma skin 
cancer was studied in one person and found to be able to repair cancer DNA sequences5. 
Another five-year study on 331 patients reported the discovery of four melanoma genetic 
subtypes6. There are some genomes which are associated with non-melanoma skin cancers, 
but the genetic nature of NMSC is still under investigation7. Other risk factors are 
immunosuppression in organ transplant patients which increases the chance of developing skin 
cancer to 65-250 times8 and environmental pollutants3. Skin cancer starts in the epidermis. 
When it proliferates on the surface and into deeper layers it can lead to metastasis and the 
spread of tumours to other organs. That is why skin cancer has to be treated in its early stages3. 
Non-melanoma skin cancer (NMSC) is one of the most common cancers in the world. It 
occurs with the highest rates in Australia and is less common in Africa9. In Australia in 2008 
there were 79,792 new cases of NMSC with 382 lethal outcomes; the growth rates doubled that 
year10. Incidence of NMSC is increasing worldwide; the UK has the highest rates in Europe9. The 
highest occurrence of NMSC in the UK is in the South West of England with the incidence of 121 
cases over 100 000 people per year9. In total in the UK there were 102,628 new cases for all 
NMSC in 201111. Due to a large number of NMSC cases every year, it is has become a 
substantial health problem to National Health Services worldwide. 
The most common NMSCs are basal cell carcinoma (BCC) and Bowen’s disease (BD). 
Actinic keratosis (AK) is a pre-malignant condition commonly occurring due to accumulation of 
sun damage. If left untreated AK can progress to squamous cell carcinoma (SCC)12. NMSC and 
dysplasia develop generally in fair skin mostly because of sun damage. Amongst the other risk 
factors there are radiation exposure, immune compromise, and human papillomavirus infections. 
NMSC and dysplasia differ by affecting various skin cells and layers. For instance, actinic 
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keratosis develops in epidermis and represents atypical keratinocytes. Basal cell carcinoma 
mostly affects follicular germinative cells – trichoblasts13.  
Amongst the treatment methods, topical Photodynamic therapy (PDT) has been widely 
used in dermatology for superficial NMSC and dysplasia with overall 70-90% clearance 
rates14,15,16. There are British and International Guidelines for the use of PDT in these conditions 
14,15. PDT can be used to treat 30 types of skin lesions17. The most common diagnoses treated 
by PDT are superficial BCC, BD, and AK1,2,16. Topical PDT is non-invasive, provides good 
tumour response, excellent healing and cosmetic outcome18. Topical PDT works by applying 
dermatological cream – pre-cursor of a photosensitizer and delivering excitation light afterwards. 
There are many studies to advance the photosensitizers, but this is beyond this thesis. The most 
clinically relevant advances in the drug development area are the developments of new 
upconversional particles which absorb NIR wavelength (980 nm) and re-emit in the visible range. 
Upconversional particles serve as a carrier and the photosensitizer is a cargo. The 
photosensitizer absorbs upconverted photons in the visible range; this leads to the conventional 
photodynamic reactions which are described in the next paragraph. The advantage of these 
drugs with the upconversion particles are that NIR light penetrates beyond 1 cm depth which 
would allow treating deeper cancers such as colon, lungs, breasts, stomach and others. A few 
studies reported good responses to PDT in mice studies; one of them used mesoporous silica 
nanoparticles with MC540 and ZnPc photosensitizers19. Silica nanoparticles have been 
successfully used for loading and transporting of drugs; without the drug silica nanoparticles 
have good biocompatibility and negligible phototoxic effect20. Another study reported similar 
concept: core–shell nanoconstructed particles with a titanium dioxide (TiO2) photosensitizer21. 
The study reports stable carriage of the photosensitizer to the tumours, good biocompatibility 
and reproducible PDT results. The most common photosensitizer for the conventional PDT is 
protoporphyrin IX (PpIX). 
When the dermatological creams are applied (Ameluze gel, 5-Aminolaevulinic acid ALA-
based or Metvix®, methylated ester MAL based) PpIX is metabolised via the haem biosynthetic 
pathway. Concentration of ALA and MAL in tissues depends on surface permeability22. PpIX 
metabolism in tumours is 15 times higher than in normal tissue23. PpIX is present in small 
concentrations in normal cells and is involved in synthesis of the heme molecule during normal 
metabolism. There are a few hypotheses for what is responsible for the increased PpIX 
metabolism in tumours. The first factor is attributed to reduced ferrochelatase activity or iron 
deficiency in abnormal cells. Enzyme ferrochelatase present in mitochondrion is responsible for 
catalysis of the insertion of the ferrous (form of iron) into PpIX. This catalytic reaction results in 
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the synthesis of PpIX into heme. Another factor can be the speed of reaction. Synthesis of PpIX 
into heame is relatively slow in normal cells. Abnormal cells tend to metabolise PpIX from 
endogenous precursors at much faster speeds than the conversion reaction of PpIX to heme24. 
And the last factor responsible for the increased PpIX metabolism in tumours could be that 
abnormal epidermis and stratum corneum could simply have better diffusion to the ALA and 
MAL pro-drugs25.  
Excitation of PpIX by light in the presence of molecular oxygen results in type II 
photodynamic reaction (photosensitization) during which the photosensitiser in a triplet state 
reacts first with molecular oxygen producing reactive oxygen. Photophysical processes involved 
in PDT are shown in Figure 2.1.  
 
Figure 2.1: Energy transition processes involved in Photodynamic treatment and 
diagnostics, photoabsorption and photoemission spectrums of PpIX 
PpIX has a few absorption peaks starting from 405 nm which is the most prominent, then a 
couple of green and an orange peaks at 505 nm, 540 nm and 576 nm and the last red one is 
633 nm. An absorption of light excites PpIX to a singlet state that can undergo intersystem 
crossing to a long-lived triplet state26,27. Triplet state of PpIX has much longer life time than 
singlet state and was reported to be 52 µs27. Triplet state of PpIX can be quenched by the 
ground state of molecular oxygen which is then excited to a singlet state. Singlet oxygen can 
decay back to the ground state via phosphorescence or luminescence. Phosphorescence 
measurement of singlet oxygen at 1275 nm showed that the rise time of singlet oxygen is 
dependent on the concentration of PpIX, it is faster for lower concentrations of PpIX26. This study 
also reported that the life time of signet oxygen decreases with the increase of PpIX 
concentration. Singlet oxygen and other reactive oxygen species (ROS) are cytotoxic and induce 
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oxidative stress to the proteins and lipid membranes of cells. This oxidative stress ultimately 
results in cell death28,29. Although, singlet oxygen can also extensively damage DNA (strand 
breaks and base modification) it seems to have a secondary role and is not involved in 
phototoxic effect to the cells18. 
Singlet oxygen is an ultimate factor which defines the response of the lesions30. Singlet 
oxygen is luminescent at 1270 nm life time equal to 500 to 2000 ns31. There are many 
background sources at this emission wavelength such as background scattering, photosensitizer 
fluorescence and phosphorescence32. Short luminescence life time and backgrounds make it 
challenging to accurately measure the luminescence and extract the concentration values of 
singlet oxygen during PDT treatment33. One method could be to use single-photon counting 
detectors34. In one of the reports such a detector was based on optical fibres. The luminescent 
signal was verified by narrow band spectral filtering and chemical quenching of the 
photosensitized used in the experiments. 35 Analysing the kinetics was reported to significantly 
increase accuracy in estimating singlet oxygen from the luminescence measurements31. Another 
method which can be used to study the formation of singlet oxygen in cells is luminescence 
microspectroscopy 36 
The other emissive process involved in PDT photophysical reactions is PpIX decay from 
a singlet excited state back to the ground state; this process is called fluorescence29,30. PpIX has 
emission peaks are at 633 nm and broader peak at 700 nm. Fluorescence life time is 1.2 ns and 
shorter in living cells compared to the solutions37. Another study reported a 19.2 ns PpIX 
fluorescence life time27. PpIX phosphorescence is another radiative decay process, but at a 
longer wavelength (840 nm) and with a longer lifetime26.  
PpIX fluorescence can be used as an indicator of PpIX concentration in tissue. PpIX 
fluorescence shows the concentration of accumulated PpIX, but and also can be used for 
calculating singlet oxygen by taking into account the fluence rate of excitation light and quantum 
yield of singlet oxygen. Measuring PpIX fluorescence is a much simpler technique to allow for 
calculation of singlet oxygen compared to challenging direct measurements of luminescence of 
singlet oxygen. Also PpIX fluorescence diagnostics can distinguish pre-clinical malignant 
changes in skin, and NMSC38,39,40. Another use of PpIX fluorescence diagnostics is the 
investigation of PpIX metabolism from the pro-drugs which is of high clinical importance29,39. 
The outcomes of PDT treatment are dependent on the combination of three key 
treatment factors: concentration of molecular oxygen in tissue, excitation light and PpIX 
distribution41. It has been reported that lower irradiances result in more efficient generation of 
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singlet oxygen because of better availability of molecular oxygen. For high irradiances the 
diffusion of oxygen from the vessels is lower than the concentration of excited PpIX42,43.  
Pain is among one of the strongest adverse effects of PDT. In some cases it is 
unbearable for the patients and the treatment has to be paused or terminated44. Pain seems to 
be correlated to the size of the lesion and erythema (skin redness as a response to the 
treatment) but be independent of the concentration of photosensitizer45. Mechanisms of PDT-
induced pain are unclear44,46,47. During one of the discussions with an expert in pain mechanisms 
an interesting hypothesis came up relating to one of the possible mechanisms of pain involved in 
PDT. Singlet oxygen may diffuse into heat receptors in skin. It then oxidises the receptors. This 
may induce painful sensations. Due to the fact that the depth of the heat receptors in skin varies 
between individuals this could explain different grades of experienced pain during PDT in 
different patients, and poor correlation between PpIX fluorescence and pain. Nonetheless PDT 
is painful, it is not recommended to interfere with reactivity of singlet oxygen for pain relief 
because it might have an adverse effect on the clinical outcome. Topical methods for pain relief 
can interfere with PDT efficacy because of their high pH, which interferes with the stability acidic 
ALA or MAL. Possible pain relief methods which do not have an adverse effect to clinical 
outcome include nerve blocks46. Pain can be reduced when a different light delivery is used; it 
was reported lower for pulsed light48. Also low irradiance light sources in addition to providing 
better clinical outcomes provide less painful PDT treatment17,49,50. One of the recent studies 
showed that reduced PpIX metabolism times increase the specificity of PpIX accumulation, 
reduce photo bleaching rates and reduce pain. This study reported on correlation between 
photobleaching and pain, and also between erythema and pain. The conclusion of this study 
was to shorten incubation times for PpIX and apply Pulse PDT51. Erythema (inflammation) after 
PDT can also be painful; the same group showed that administration of topical corticosteroid 
reduces the inflammation without compromising the response to PDT in a randomised study on 
AK52. 
As well as the pain factor, another problem is attributed to incomplete responses or 
recurrence of the lesions. The overall response rates to PDT are 70-90% depending on the type 
of the lesion53. A possible cause for recurrence or incomplete response may be insufficient PpIX 
metabolism in the lesions53,54,55. PpIX metabolism was studied by measuring PpIX fluorescence 
spectrum at one point by conventional non-time resolved spectrometers and analysing the peak 
fluorescence. PpIX metabolism reaches its plateau concentration after six hours of application of 
ALA (5-aminolevulinic acid) as a pro-drug with the full incubation period of 24 hours56. For MAL 
(methylester of 5-aminolevulinic acid) the plateau concentration in both BCC and AK lesions is 
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established after 13 hours of continuous application57. However, the time which is recommended 
for the creams to metabolise into PpIX before commencing PDT treatment is three hours14,15. 
Yet, there is insufficient information in the literature about PpIX metabolism at shorter periods of 
time56,57, 58. Detecting surface fluorescence is one of the best choices so far to study PpIX 
formation in the skin. There are studies which have reported development of optical 
spectrometers for various medical applications39,53,55,59,60. However, most of the systems are 
cumbersome and were not suitable for in-vivo time course imaging.  
In addition to exogenous PpIX fluorescence developed from the pro-drugs, endogenous 
auto-fluorescence can also be used to detect malignant changes in tissue. The development of 
the lesions entails structural changes of the malignant skin due to the change in production of 
collagen, elastin and keratin. The metabolism rates and the relative amount of NADH 
(nicotinamide adenine dinucleotide) and FAD (flavin adenine dinucleotide) which are responsible 
for energy production in cells are different in normal and malignant tissue61. Both NADH and 
FAD molecules are fluorophores which means that they can also be excited by light and result in 
fluorescence. Due to the fact that those fluorophores develop endogenously (without any pro-
drugs), the fluorescence from those molecules is called auto-fluorescence. Therefore, detecting 
the change in auto-fluorescence can indicate malignant changes in skin. There are reports in the 
literature which show that it is possible to distinguish both melanoma and non-melanoma 
cancers by measuring auto-fluorescence from the skin62. Another study shows that time-
resolved fluorescence spectroscopy gives 97.4% specificity in distinguishing melanoma 
cancer63. So in addition to PpIX fluorescence, auto-fluorescence is becoming a complementary 
optical diagnostics for skin cancer. 
The aim of this project was to develop a portable convenient device to use for clinical 
measurements fluorescence imaging and display system; gather fluorescence images from 
different types of NMSC and healthy skin; and in addition to develop flexible image analysis 
techniques to study the formation of fluorescence patterns in time for filling the gaps in 
knowledge about PpIX metabolism in healthy and diseased skin for potential improvement of 
PDT treatment protocols. In addition to PDT diagnostics, the same system with a different band 
pass filter matching the auto-fluorescence peak (NADH and FAD molecules) could also be 
suitable for detecting malignant changes in the skin for assisting with optical diagnosis of NMSC. 
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2.2 Methods 
The development of the fluorescence imaging device involved selection of the camera 
and the collection optics, design of the illuminator, the electronics, device control and user 
interface, and a casing for the device to provide convenient measurements in the clinical 
environment. The device had to meet Good Clinical Practice (GCP) requirements for a research 
device, and be assessed by the Instrumentation Department at the Ninewells hospital and 
Medical School in Dundee. 
2.2.1  Optical design software  
Zemax EE 2010 optical design software was used to virtually prototype the illuminator for 
the device. This is an industrial standard ray tracing software similar to LightTools, ASAP, FRED 
Photon Engineering, LightTrans VirtualLab, OSLO, etc. Zemax has its advantages and 
disadvantages compared to other optical software. It is widely used by optical engineers for both 
imaging and illumination applications. It has many optimisation operands for imaging optics. The 
software develops very rapidly and new tools appear to address current needs for optical design. 
The library of components, materials and coatings which contains measurements and data from 
the manufacturers is growing and it has good import and export capabilities. Yet, it is lacking 
flexibility, it handles illumination problems less well as imaging, and diffractive components are 
not modelled as well as in dedicated diffraction optics software such as LightTrans. In addition 
there is a relatively long learning curve.  
Zemax works in the following way. All of the optical surfaces of the components have to 
be defined, then rays are generated at the source, they are propagated through all components 
in the system until they exit from the system or are terminated by absorption or their energy is 
below the threshold. After ray tracing, there are numbers of detectors available which calculate 
desirable characteristics of the system - size of a beam waist, point spread function, irradiance, 
etc. Then optimisation operands can be used to automatically change combinations of different 
parameters - distances between the components, position, thicknesses of lenses, materials, etc. 
to achieve better performance – smaller aberrations, better focus, etc. There are two models 
available in Zemax – sequential which is typically used for imaging systems (a ray interacts with 
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optical surfaces in defined order) or non-sequential (a ray can intersect any optical surface 
multiple times in any order) for illumination optics The task for the modelling of the illuminator 
was to achieve even irradiance in the field of view of the camera for even excitation of PpIX. The 
first step for the design was to model an array of LEDs placed around the camera lens, larger in 
diameter that the field of view of the camera. The design would then be refined by adjusting the 
LEDs positions and introducing optics if needed to achieve uniform illuminations.  
2.2.2  Fast prototyping  
The camera system was developed using fast prototyping approaches which included 
electronics design using USB development modules - FTDI technology, graphical user interface 
and device control - Matlab, and 3D plastic printing technology for fabrication of custom made 
casings. In addition laser cutter was used to prepare holders for optical phantom test arrays. 
(a) Electronics design and device control 
After finalising the optical design, electronics design was developed in DipTrace 
software. It is a quality schematic capture and printed circuit board (PCB) design software that is 
used to create multi-layered printed boards for schematics and manufacturing. It has a big library 
of electronics components with schematic and physical models and allows automated and semi-
automated routing between the components. DipTrace provides export of the drawings into 
many fabrication and CAD exchange formats - drill and gerber for PCB cutting, coper layers 
etching and drilling mount holes.  
FTDI USB UM245R development module was used for power control of the illuminator 
and camera synchronisation with the illumination. A MEX file provided by the manufacturer was 
used to control UM245R from graphical user interface written in Matlab. The camera was 
controlled from the user interface using manufacturer’s Matlab drivers.  
The user interface was developed in Matlab GUIDE toolbox. GUIDE is a fast 
development environment which allows for the scripting of m-files and for working in a user 
development environment (GUI DE). It is similar to LabView which is the industrial standard 
software for instrument control, but in addition allows plugging in different data processing 
capabilities in the user interface without the need of installing two different software packages. In 
particular, display of images in calibrated axis, 3D surface plots, pixels values, 2D intensity cross 
sections, intensity integration, data export, etc. was implemented in the interface in addition to 
image acquisition and illumination control. 
2.2.3 Image analysis 
24 
 
(b) 3D CAD design and 3D plastic printing 
3D CAD Rhinoceros 4.0 software was used to design drawings for casing for the device 
and then the casing was printed using a RoboSavvy MakerBot® Replicator® desktop 3D printer. 
Rhino 4.0 is an industry-standard software similar to SolidWorks, Autodesk Inventor, etc. for 
designing complicated geometries, assembly and display of virtual prototypes and exporting the 
drawings for digital machinery fabrication, such as milling, drilling, printing, laser cutting, etc. In 
this work 3D CAD design was exported to stereolithography format and then imported by 
MakerBot Desktop software to set printer instructions. The printer uses MakerBot® polylactide 
(PLA) bio-thermoplastic fibre filament. A typical resolution which is achieved with the printer is 
0.2 mm. Caution is needed when orienting the drawing for the print - the heaviest part should be 
at the bottom. If the drawing does not have optimal orientation the design can deform during the 
print or the support structures built in the hollow parts can simply collapse. The support 
structures are removed after the print is complete. 
(c) CO2 laser cutting 
The last prototyping method used for the work in this chapter was CO2 laser cutting. It 
was used to fabricate special shape containers for optical phantoms. The laser cutter (CTR 
Lasers, the UK) contains an enclosed CO2 class 4 laser with 1024 nm emission wavelength and 
150 Watt power. Interlock system and full enclosure brings the system down in the laser safety 
classification to class 1. The laser cutter is suitable for cutting and engraving a wide range of 
materials, such as acrylic plastic – PMMA sheets, wood, paper and card, fabrics and thin metal 
sheet. The software provided with the laser cutter - LaserCut5.3 has limited drawing capabilities 
and is only suitable for simple jobs. Drawings for the cutting can be prepared in any other CAD 
software which allows exporting into AutoCAD DXF (Drawing Interchange, or Drawing 
Exchange) .dxf format. The drawings in this format can be imported into LaserCut5.3 which is 
used to define cutting and engraving parameters - laser power, cutting/engraving speed, etc. 
The resolution of the laser cutter is up to 0.1 mm which is limited by the deformation of the edge 
of the plastic during the cut. The quality of the edge after the cut is better for thinner sheets. It 
becomes more challenging to achieve fine cuts for thicker plastics, and optimal parameters 
should be experimentally defined, for instance for thicker plastics it is better to set the focus of 
the laser deeper in plastic rather than on the surface. For some jobs, multiple runs over the 
cutting area give cleaner cuts than higher laser power.  
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2.2.3  Image analysis  
The Image Acquisition64, Image Processing65 and Computer Vision66 Matlab Toolboxes 
were used for all stages of working with the images. The functions for the graphical user 
interface for image and data display included acquisition of the images, automatic saving with 
automatic generation of file names, digital filtering, background subtraction, calibration, 3D 
display, display of pixel values and 2D cross section. Additional routines were developed for 
semi-automated image processing and analysis - automatic motion and distortion compensation, 
cropping, sectioning and integration of regions of interest, image correlation and exporting the 
data.  
One of the most challenging steps in image processing was to align all of the time course 
fluorescence images in order to analyse the same area between time course measurements. 
Although a good procedure for the camera alignment to the imaging area was developed, there 
was still a 1-2 mm displacement between measurements. In addition, during the imaging of 
curved body surfaces such as fingers, edges of the hands and feet, displacement of the camera 
resulted in distortions due to imaging with slightly different angles. In order to centre, rotate and 
compensate for the distortions caused by imaging curved surfaces and camera misalignment 
between the images Random sample consensus (RANSAC) geometrical transformation was 
used. This transformation identifies pointers on two images which are reference points of 
common objects on the images. These pointers allow for calculating various transformation 
matrixes to manipulate the two images. In this chapter motion displacement and distortion was 
compensated.  
2.2.4 Preparation of phantoms for optical measurements 
A tissue simulating phantom is an object which mimics properties of tissue. For some 
measurements there is a need to simulate only optical properties in which case the mechanical 
properties can be different from skin. In some cases there are requirements to have both 
mechanical and optical properties simulating tissue properties. For optical testing of the 
fluorescence camera mimicking PpIX fluorescence and scattering of light were of interest. Solid 
PpIX fluorescent phantoms were fabricated from a silicone polymer following the protocol 
described in [67]. The base for the phantoms was room temperature vulcanised silicone polymer 
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which has a similar refractive index to skin. Alumina powder was added to mimic the scattering 
properties of the skin68 and PpIX was added to provide fluorescence. Two parts, A and B of 
RHODORSIL RTV 141 polymer were mixed in a 1:10 ratio, 4% of alumina scattering powder 
was added to the mixture, and Protoporphyrin IX P8293 - ≥95% from SIGMA-ALDRICH were 
dissolved in Methanol. A range of PpIX concentrations of 10, 20, 40, 80, 160, 320 and 640 nM in 
the phantoms was made for the test. PpIX solution was thoroughly mixed with the silicone 
polymer and alumina powder and left at room temperature to vulcanise. The phantoms normally 
vulcanise and the methanol evaporates after 72 hours.  
Absorption spectra of PpIX in methanol solution and solid phantoms were recorded with 
the Varian Cary 300 Bio UV-Vis spectrophotometer. The spectra of just the solvent or 
transparent silicone polymer base were recorded separately and subtracted. However, there 
was no absorption from the solvent or the polymer. 
The PpIX emission spectrum in methanol solution with alumina powder was measured 
using a Fluromax 2 fluorimeter. The excitation source of the fluorimeter is a xenon bulb. A 
monochromator selects the wavelength that is used for excitation. A scanning emission 
monochromator records the emission from the sample at different wavelengths using a 
photomultiplier tube. The emission properties of the phantoms were compared to a standard 
Coproporphyrin solution in HCl which is used as a surrogate test solution for fluorescence in the 
medical community. Also the phantoms were compared to PpIX fluorescence developed in the 
skin of healthy volunteers after application of PpIX precursor – Ameluz gel. 
2.2.5 Optical biopsy system for PpIX emission in vivo in clinical 
settings 
As a routine practice in the Photobiology Unit, Ninewells Hospital, Dundee PpIX 
fluorescence in in-vivo experiments is measured using an optical biopsy system (OBS)69,70,71,16. 
OBS consists of an excitation source – 405 nm laser diode and fibre-coupled spectrometer. It 
records an emission spectrum at one point on the sample. One of the examples of in-vivo 
experiments is measurements of PpIX fluorescence decay during PDT treatment to predict PpIX 
photobeaching and depth profile69,72,70. 
OBS was used to measure PpIX emission from the solid PpIX phantoms, Coproporphyrin 
standard solution and in-vivo from the skin of healthy volunteers after three hours of application 
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of Ameluz gel. Fluorescence measurements using the OBS and the camera were compared to 
identify the performance of the camera.  
2.3 Results 
The requirements for the device were the following. The device had to be able to image 
PpIX fluorescence with a field of view of a few square centimetres with submillimetre resolution, 
had flexible image processing capabilities, preferably was handheld, portable, lightweight, easy 
to use in clinical experiments on patients, was able to access different sites on the patient, 
complied with the Good Clinical Practice standards for medical device ISO 14155:2011 Clinical 
investigation of medical devices for human subjects73. It is desirable to have multiband detection, 
such as combined auto-fluorescence and PpIX measurements using blue/red excitations and 
red/NIR PpIX emission at 635 and 710 nm. Different bands of PpIX excitation and emission 
would provide information of PpIX accumulation at different depths in skin. Blue 405 nm light 
excites PpIX at the surface and 635 nm wavelength penetrates in deeper layers. Such a 
configuration was considered for the design of the device at the start. However, for the proof of 
concept to gather initial images, to establish clinical protocols and the relevance of the 
fluorescence time course imaging, and to identify image analysis and statistical analysis 
routines, it was decided to keep the design of the device and the protocol as simple as possible. 
So one excitation and one emission wavelength was chosen for the initial configuration of the 
device. The device had to fulfil the requirements in electrical safety, allergic reactions, energy 
output and infection control of the Instrumentation Department at Ninewells hospital and Medical 
School in Dundee.  
The flow chart of the development stages is shown in Figure 2.2. The camera for the 
system was chosen based on the resolution, sensitivity, power management and the cost. 
Lumenera LM075m had an appropriate sensor size of 640x480 pixels which provided 50 µm 
resolution with the field of view equal to 3.1 x 2.4 mm2 at 8.5 cm. There was a possibility to 
power the camera from a USB port of a battery driven laptop which reduced electrical safety 
risks. In addition it was small, fast and light weight. A lens with an adjustable focal length and 
aperture and a removable band pass filter with central wavelength (CWL) of 635±2 nm and full 
width at half maximum (FWHM) of 10±2 nm were selected for the collection optics.  
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Figure 2.2: Fluorescence camera development flow chart. 
The illuminator was developed on a custom made printed circuit board (PCB) with a low 
power 405 nm LED array, a separate 9 V battery power supply, and a USB control module. All 
components were assembled in a custom plastic casing. The casing of the camera provided a 
fixed distance to the imaging plane. The illumination was pulsed during the image acquisition via 
a custom user interface. This synchronisation was important to reduce the dose of excitation 
light to eliminate the possibility of PpIX photobleaching during the measurements. Also the 
pulsing regime improved signal to noise ratio by reducing the sensitivity to ambient light and the 
background. A special camera alignment procedure allowed referencing between time course 
images and the study area. In addition camera displacement and motion distortion 
compensation routines were written in Matlab Computer Vision Toolbox. The full specification 
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and the description of the device is available in the Appendix XIV: Capturing fluorescence – 
Fluorescence Imaging System Specifications v.1 09.10.2013.  
In order to meet electrical safety requirements the device was designed as fully battery 
driven. The casing for the device was made from an inert thermoplastic which meets the allergy 
reaction requirements. In order to address infection control the device was made “wipe clean” – 
the casing did not have dust traps and the standard operating procedure was written, [Appendix 
IV: Capturing fluorescence – Standard Operating Procedure (SOP)]; the device did not come in 
contact with the skin – a disposable laminated reference frame was prepared for each 
experiment. The frame can be fixed with a dermatological tape to the skin of each subject. This 
prevents the casing tube of the camera to come in the contact with the skin of the study 
subjects; the camera is placed on the laminated disposable frame. Optical power output – UV, 
UVA and blue light exposure limits were measured for the eye and skin safety assessment. The 
device can be used without any special precautions as long as it is not placed directly on the 
unprotected eye [Appendix XIV: Capturing fluorescence – Fluorescence Imaging System 
Specifications v.1 09.10.2013]. The device does not become hot during continuous 
measurements.  
The camera was tested on in-house made optical phantoms, standard fluorescent 
solutions and in-vivo on healthy volunteers The device received approval from the Head of the 
Instrumentation Department at Ninewells for application in a clinical research study. Two 
patients were recruited for preliminary data gathering, choice of appropriate camera settings and 
finalising the design of the clinical study which is described in the next chapter.  
2.3.1 Optical design 
To be of low power, compact and lightweight, the first design idea was to have a ring of 
LEDs around the lens of the camera, larger in diameter than the field of view of the camera. The 
LEDs were selected with a relatively large directional emission, in addition there was a diffusing 
coating on the inside walls of the illuminator tube. The datasheets for VAOL-5GUV0T4 LED with 
the optical power, dimensions, directional emission and the spectrum were imported to Zemax 
model. Then the coordinates of each LED in the illuminator were calculated and an array was 
created. The walls of the illuminator tube were set with 60 % diffusing coating. An irradiance 
detector was placed at the end of the illuminator tube with 50 µm pixel size. 1,000,000 rays were 
generated in the system which normally is a sufficient number to achieve a realistic distribution. 
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The irradiance at the detector is shown in Figure 2.3, (c). The end of the illuminator tube is at 
8.5 cm distance – which is the focal distance of the lens. The field of view of the camera is 
marked as ROI – the region of interest on the irradiance detector. The irradiance is uniform with 
non-uniformity less than 5% which is an acceptable variance for the illumination. For instance for 
the Aktilite CL16 which is one of the most common PDT treatment devices based on an array of 
635 nm LED the non-uniformity of the treated area of 4 x 6 cm2 at 8.5 cm distance was 
estimated to vary for up to 38%74. As a result of the modelling, the design was confirmed and no 
additional iterations were needed to optimise it. 
 
Figure 2.3: Optical design of the illuminator and an assembly of the fluorescence 
imaging device. a – bottom view at the illuminator tube and an array of LED and camera lens. 
The camera lens is in the middle (white small circle on the image). The LED array of 405 nm 
LED with dome lenses mounted around the opening for the lens on a doughnut shape printed 
circuit board (PCB). The camera casing tube shields ambient light during the measurement 
which allows conducting the experiments with dimmed lights on. b - Zemax design of the 
illuminator and raytracing simulations. c – an irradiance detector showing that the area at the 
region of interest (ROI) which corresponds to the field of view of the camera is uniformly 
illuminated. 
 31 
 
2.3.2 Electronics design 
After satisfactory results of optical modelling an electronic driving circuit and PCB board 
were designed in DipTrace. The LED array was made of VAOL-5GUV0T4 Ø5 mm (160 mcd, 3 
V, 20 mA) LEDs which were connected to an INFINEON BCR402W/SOT343 surface mount LED 
drive and a MMBF170L/SOT23 N-MOSFET switch. The switch was connected to a 9 V battery. 
The switch was turned on and off from a FTDI USB development module UM245R controlled 
from a laptop via a user interface written in Matlab. (Figure 2.4). It was a single layer PCB with 
LEDs mounted through holes and wired connection to the battery and the USB control unit. 
 
Figure 2.4: Printed circuit board (PCB) for the illuminator. The LEDs were placed around 
the opening to the camera lens. Each pair of LED is connected to an LED drive and resistor. 
There are +/- battery terminals and a terminal for the signal and ground wires of the FTDI USB 
development module. The signal pin #6 of FTDI USB module is connected to a MOSFET switch. 
The FTDI module reads the signals from a graphical user interface and then turns the switch. 
The other layers of the drawing of the PCB can be found in the Appendix XV: Capturing 
fluorescence – Printed Circuit Board PCB Design. These drawings were developed for PCB 
fabrication – board cutting, copper layer tracking and drilling mount holes 
. 
2.3.3 Opto-mechanical design and system integration 
After the assembly and testing of the illuminator, a 3D casing was designed in Rhino 4.0 
software to contain the PCB, the battery, the USB module, and the camera. It provided a wired 
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connection between all of the components and an access to an adjustable aperture and the 
focus of the lens. The dimensions are 12.5 cm by 13.5 cm; the weight is less than 100 g. The 
camera mount has fixation at the sides and does not cover the camera – it allows for heat 
dissipation in air which eliminates any possibility of overheating during continuous 
measurements. There are marks on the casing which allow aligning the camera to the study 
area. A 3D drawing of the casing and the camera assembly are shown in Figure 2.5.  
 
Figure 2.5: The fluorescence camera and the 3D CAD design of the casing. a - the 
assembly of the camera. A lens with an emission filter is connected to the camera via C-mount. 
The lens slides in from the top of the plastic casing and is fixed with four M3x0.5 screws from the 
sides. The casing contains the illuminator PCB, 9 V battery and the USB module. b – two parts 
of 3D drawings for the casing. It is printed using a RoboSavvy MakerBot® Replicator® desktop 
plastic printer. The illuminator’s PCB is sandwiched in the compartment between the two parts of 
the casing. Two parts of the casing are then fixed together with three M3x0.5 screws. There is a 
compartment for an off-the-shelf plastic casing for 9 V battery which is fixed with M3 screws, a 
compartment for the USB control module, camera mount and access to the lens. 
2.3.4  Optical power output and risk assessment 
After the prototyping of the device, the optical power output was measured using a 
Thorlabs PM100D power meter and was equal to 0.1 mW/cm2 at 8.5 cm distance – the end of 
the casing tube. The illumination was pulsed with the duration of the pulse less than 1 s 
depending on the exposure of the camera. The spectrum of the LED was measured using an 
Ocean Optics spectrometer, (Figure 2.6). 
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Figure 2.6: An emission spectrum of 405 nm VAOL-5GUV0T4 LEDs. The emission peak 
matches the absorption peak of PpIX. This spectrum was used for the calculation in the risk 
assessment for the UV, UVA and blue light exposure for the eye and the skin. 
The power of the illuminator is low and should not cause significant photobleaching of 
PpIX, therefore it should not affect the treatment if the measurements are taken on the day of 
routine PDT treatment. For instance, a typical irradiance of a conventional PDT lamp such as 
The Aktilite CL128 or Aktilite CL16 used for the treatment with 75 J/cm2 dose, 18 minutes 
duration should be 65 mW/cm2 (in fact it varies from 74 mW/cm2 to 49 mW/cm2)74, an ambulatory 
treatment device such as Ambulight PDT75 delivers 75 J/cm2 during 3 hours and has irradiance 
of 7 mW/cm2. 
The optical output has been evaluated for the eye and skin safety. The spectrum has UV-
A (340 – 399 nm) and the visible (400 – 700 nm) wavelengths. In order to evaluate the safety, 
the contribution of the UV-A and Vis wavelength was calculated and found to be equal to 32 % 
and 68 % of the spectral power correspondingly. A risk assessment for the eye and skin safety 
for three wavelength ranges UV, UVA and blue light was done using the International Standard / 
Safety of laser76 and the University of St Andrews local rules for lasers77 and approved by Prof 
Harry Moseley, the Head of Photobiology, Department of Medical Physics, Ninewells Hospital & 
Medical School, Dundee (Appendix XIV: Capturing fluorescence – Fluorescence Imaging 
System Specifications v.1 09.10.2013 / Appendix 2). The calculations for the maximum exposure 
time for the UV light are listed below. 
𝐸𝑒𝑓𝑓 = ∑ 𝐸𝜆𝑆(𝜆)𝛥𝜆
𝜆
 
𝐸𝑒𝑓𝑓– effective spectral irradiance, W/cm
2; 
𝑆(𝜆) – relative spectral effectiveness, does not have any units; 
𝐸𝜆 – spectral irradiance, W/cm
2; 
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𝑡𝑚𝑎𝑥, 𝑠 =  
𝐻𝑒𝑓𝑓,
𝐽
𝑚2
𝐸𝑒𝑓𝑓,
𝑊
𝑚2
 
𝑡𝑚𝑎𝑥, 𝑠 – maximum exposure time; 
𝐻𝑒𝑓𝑓 – exposure limit. 
For the UV the exposure limit is 𝐻𝑒𝑓𝑓  = 30 
𝐽
𝑚2
; 𝑆(𝜆) = 0.000064; Considering that a part 
of the LED spectrum is at 380 nm which is the most harmful in consideration for the eye and skin 
safety, this wavelength was selected for the evaluation of the maximum exposure for UV. The 
spectral irradiance is equal to the measured value for the UV part of the spectrum, 𝐸𝜆 =
0.32 
𝑚𝑊
𝑚2
. Than the effective spectral irradiance is equal to 𝐸𝑒𝑓𝑓 = 0.32 × 0.000064 =
 2.05 x 10−5,
𝑚𝑊
𝑚2
; the maximum exposure time is  
𝑡𝑚𝑎𝑥, 𝑠 =  
30 
𝐽
𝑚2
2.05 × 10−8,
𝑊
𝑚2
= 15 × 108𝑠 = 4 105ℎ ≫ 8 ℎ 
Maximum exposure limits will not be exceeded after 8 hours of continuous exposure to 
the UV light, therefore no special precautions are required. Similar calculations were done for 
the UV-A and the blue light. According to these calculations the eye exposure should not exceed 
53 minutes and the device should not be placed on the unprotected eye. 
2.3.5 User interface 
The system is fully integrated in the Matlab 2012b environment and configured for the 
Windows 7 64-bit operating system. The system requirements, installation and operation 
procedure is described Appendix XVII: Capturing fluorescence – The FluoImLu3 Software 
Installation and Operation Instructions.  
The graphical user interface (GUI) is shown in Figure 2.7. The GUI allows for fast clinical 
measurement (Record test and Record control buttons) – the illumination is pulsed when an 
image is recorded, a folder is automatically created when the first image is acquired, an 
automatic name for the folder is generated in a format of dd-mmm-yyyy, the following images on 
the same day are saved in that directory, automatic names are generated for the images in 
similar format of Test-dd-mmm-yyyy-ssmmhh.jpeg or Control-dd-mmm-yyyy- ssmmhh.jpeg. The 
record test button is designed to acquire a series of 3 images for averaging of background. 
Record control acquires only one image to minimise the exposure to UVA and blue light for 
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preventing photobleaching. A description and implementation of all the functions of the user 
interface are described in the Appendix XVII: Capturing fluorescence – The FluoImLu3 Software 
Installation and Operation Instructions. 
 
Figure 2.7: Graphical user interface (GUI) for the camera system. The Record Test and 
the Record Control buttons allow pulsing the illumination during the image acquisition (the first 
button acquires three images in a series for averaging purposes and the other button records 
only one image to minimise the exposure to the UV light). When the Record Test/Control button 
is pressed logical “1” is sent to the USB control module which opens the MOSFET transistor 
switch; an image is acquired and placed in a buffer memory, the flash is immediately turned off, 
the image is then automatically saved in a folder dd-mmm-yyyy with the name of dd-mmm-
yyyyy-ssmmhh.jpeg which is the date and time when the image was acquired. The settings for 
the camera and live preview are managed with the manufacturer’s software which is 
synchronised with the Matlab GUI. The other functionality of the GUI allows turning the 
illumination on and off (the LEDsOn and the LEDsOff buttons), record images without 
illumination (the Record image button) and various displays of the images and the data – 3D 
surface plot in calibrated axis - millimetres and normalised fluorescence intensity (the 3D Plot 
button), 2D intensity cross section (the Line Profile button), display of pixels value (the Image – 
Pixels button), display of not processed image on monochromatic full intensity scale (the Raw 
Plot button), export of the 2D cross section intensity values in excel format, etc. 
2.3.6 Time course imaging procedure  
In the first repeated time course measurements a marker pen was used to draw a 
contour on the skin to align the camera to the study area. However, the solvents in Ameluz gel 
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or Metvix® cream and the cleaning alcohol wipes compromised the reference contour. It was 
blurred or completely removed during the procedure of re-applying of the creams or cleaning the 
skin between the measurements. In order to have an identical reference in the time course 
images the following measurements procedure was developed. Previously described laminated 
alignment frame was firmly fixed with dermatological tape and stayed fixed during all time course 
measurements. There were marks on the outer edge of the reference frame corresponding to 
the alignment marks on the casing tube to position the camera. On the inner edge of the 
reference frame there was a bright orange fluorescent contour which was used as a reference 
for small displacements and distortion compensation in the software. (Figure 2.8).  
 
Figure 2.8: The handheld fluorescence camera is positioned on a patient’s Actinic 
Keratosis lesion.  
The camera displacement between the measurements was approximately 1-2 mm. 
These small displacements were compensated by the image processing using the reference 
fluorescent contour. The orange fluorescent contour appeared as a white saturated line on all 
the fluorescence images. The features in this contour were used for “Matching features” 
algorithms in RANSAC image transformation78 (Figure 2.9). This transformation detects inlier 
points on the fluorescent contour (small cyan triangles Figure 2.9) and on a reference image 
which is normally a background fluorescence image (red circles on the red line). Using these 
matching points RANSAC calculates a vector matrix and allows for various transforms. In this 
2.3.6 Time course imaging procedure 
37 
 
procedure the image was transformed to match the orientation, position and shape of the 
reference image. The transformed images were saved for the next processing stage.  
 
Figure 2.9: Two image processing steps RANSAC geometrical transformation and 
cropping out the fluorescent reference contour. In order to compensate camera displacement 
during time course imaging, a Matlab m-file was written which uses RANSAC geometrical 
transformation function available in Computer Vision Matlab Toolbox. This file searches for 
matching features on the fluorescent contour and creates a matrix of translation vectors to 
transform the time course fluorescent images to match the position and the shape of the 
reference image. This transformation rotates, centres and stretches any small distortions caused 
by imaging of curved body surfaces in time course experiments. Cyan and red lines are 
fluorescence contours on a background image (reference image for RANSAC) taken at 0 min of 
the time course measurements and a fluorescence image taken at 60 minutes. RANSAC 
matching features are shown as small red circles and cyan triangles. Images are transformed 
and saved for the next processing step automatically. After that coordinates of a top left pixel (a 
small white rectangle – Ref Corner) and area size (green dashed line) are chosen and passed 
into another m-file to crop out the fluorescent contour. The images are cropped and saved 
automatically. 
At the next processing stage cropping of images was applied. A reference corner was 
defined manually; the coordinate of the corner and the size of the cropping area were saved in 
the Matlab cropping m-file. Normally the image size is reduced from 680 x 480 pixels to 540 x 
380 pixels which is enough to crop out the fluorescence reference contour. The green dashed 
line of the figure shows the cropping area. Cropped images were saved for the next stage which 
is calculating integrated fluorescence. An area of interest can be selected and the coordinates 
are passed to the integrated intensity m-file. For the peak fluorescence time course an area with 
the highest fluorescence was chosen. Also the size of the area was passed to the file. This file 
reads all 18 fluorescence images and calculates the mean intensity over the area of interest and 
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automatically saves it into an excel file. Another function calculates correlation coefficient 
between images. The correlation analysis was meant to help identifying “fluorescence 
fingerprints” between different types of the lesions and look for the correlation of the 
fluorescence patterns to the lesion shape. The correlation coefficients were also saved to the 
excel file for further analysis. 
All of the image processing routines are described in Appendix XVIII: Capturing 
fluorescence – Image Processing and Analysis Algorithms. Each of the files is dedicated to one 
processing or analysis stage – compensating camera displacement during time course 
measurements (Matching features algorithms), automatic cropping of reference contour 
(Cropping images algorithm), image sectioning and integrated intensity calculations (Integrated 
intensity algorithm). 
2.3.7 System validation ex-vivo and in-vivo on skin of healthy 
volunteers 
The camera performance was tested on solid silicone PpIX scattering phantoms, 
Coproporphyrin solution in HCl, and PpIX fluorescence from a healthy volunteer after three 
hours from the application of topical Ameluz gel in an aluminium Finn® chamber for patch tests.  
A PMMA plastic sheet was used to prototype containers for the test array of the PpIX 
phantoms. An array of 2 cm diameter cavities which fits in the field of field of view of the camera 
were cut using the CTR laser cutter and glued on top of the base sheet. The phantom holder 
with the phantoms of different concentration of PpIX is shown on the left hand side of Figure 
2.10.  
Coproporphyrin was imaged in a standard 60 mm × 15 mm polystyrene Petri dish. In 
order to prevent reflections from top and bottom lids, the bottom lid of the Petri dish was 
engraved with the laser cutter and an opening was cut at the top lid; a piece of black beam 
blocking paper was glued on top of the upper lid to provide a reference (Figure 2.10). 
The absorption and emission spectra of PpIX in Methanol solution which was used for 
preparing PpIX phantoms were measured with a Varian Cary 300 Bio UV-Vis spectrophotometer 
and a Fluromax 2 fluorimeter, and are shown on the right side of Figure 2.11. Emission 
spectrums from PpIX phantoms, Coproporphyrin solution and PpIX fluorescence from a healthy 
volunteer were taken with the OBS system at the Photobiology unit, Ninewells hospital in 
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Dundee (Figure 2.11) and the results compared with the images taken with the camera (Figure 
2.10: c, d, e). 
 
Figure 2.10: Optical phantoms and camera validation. a - solid PpIX phantoms with a 
range of PpIX concentration 10, 20, 40, 80, and 160, 320 nMol/mg. b - Coproporphyrin solution 
in a Petri dish. The green dashed line shows the camera casing tube position. c, d, e – 
fluorescence images taken with the camera – PpIX phantom, PpIX fluorescence from a healthy 
volunteer after 3 hours of Ameluz gel application, and Coproporphyrin solution correspondingly. 
The camera has good specificity for PpIX emission and rejection to the other wavelength. 
 
Figure 2.11: Characteristics of optical phantoms and PpIX fluorescence in healthy skin to 
validate the camera performance. The graphs of the right show typical PpIX absorption and 
emission measured in methanol solution with Varian Cary 300 Bio UV-Vis spectrophotometer 
and Fluromax 2 fluorimeter. The graphs on the left show emission spectra from Coproporphyrin, 
PpIX solid silicone phantom with 80 nMol/mg concentration of PpIX and PpIX fluorescence in-
vivo developed in the skin of a healthy volunteer after three hours from Ameluz gel application 
taken in clinical settings with optical biopsy system (OBS). PpIX fluorescence from a healthy 
volunteer gives similar fluorescence intensity to the 80 nMol/mg PpIX solid phantom. The results 
indicate that the camera can distinguish all tested fluorescence substances. 
A solution of PpIX in methanol had an emission spectrum with the strongest emission 
peak at 633 nm and the second peak at 700 nm. Solid phantoms had similar emission except 
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the 700 nm peak is slightly elevated. Coproporphyrin had two peaks at 594 and 653 nm. PpIX 
fluorescence from the skin of a healthy volunteer after three hours from topical application of 
Ameluz gel had a peak at 635 nm which matched the transmission wavelength of the band pass 
filter in the camera. The camera system has strong selection for 635 nm PpIX emission and 
rejects the other wavelengths. That is why PpIX fluorescence from the healthy volunteer 
appeared brighter on the fluorescent images than PpIX phantom or Coproporphyrin standard 
solution.  
The current set up does not take into account melanin concentration therefore it is not 
possible in this procedure to compensate for the differences in the optical properties of skin 
between the individuals. Due to that we are not able to calculate real concentrations of PpIX 
from the data. However, the study was conducted in Scotland where most of the subjects have 
skin types I-III by Fitzpatrick scale1 which do not have drastic variations in melanin. This in 
principle should allow for comparison of relative PpIX fluorescence measurements across the 
subjects. 
2.3.8 Pre-clinical study data gathering 
After the approval of the device for the electrical, infection control, allergy reactions and 
optical power output safety assessment by the NHS Tayside Instrumentation Department, a 
clinical study proceeded. The study was conducted in compliance with Good Clinical Practice 
(GCP) laid down in The Medicines for Human Use (Clinical Trials) regulations 2006 No. 1928. 
There was no requirement for clinical trial authorisation (CTA) from the UK Medicines and 
Healthcare products Regulatory Agency (MHRA) as the device was approved internally for the 
study. 
Two patients were selected prior to finalising clinical study design. One patient P1 had a 
basal cell carcinoma lesion and was administered Metvix® PDT treatment. Routinely,  there are 
two treatment cycles for BCC diagnoses69. A lesion was prepared with a curette to remove any 
crust, then Metvix® cream was applied and covered with occlusive dressing for three hours. 
After three hours the cream was wiped off, Woods lamp was used to visually assess and score 
the fluorescence before the treatment commences. For both treatment cycles the procedures 
were the same. The treatments were performed one week apart69. The imaging was performed 
before the first and the second cycle PDT treatment. The fluorescence images from two 
measurements are shown in Figure 2.12. Figure 2.12 (a) shows 3D surface fluorescence from 
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the lesion before the first PDT treatment. The horizontal axes (x and y) are calibrated in mm; the 
vertical axis (z) shows fluorescence in arbitrary units. Fluorescence is normalised to the camera 
maxima. In Figure 2.12 (c) there is a reduction in fluorescence area as well as the intensity drop 
compared to Figure 2.12 (b). This shows the response of the tumour to the first treatment cycle.  
 
Figure 2.12: Fluorescence before the first and second PDT treatment cycles of P1 
patient with Basal Cell Carcinoma (BCC) after three hours of Metvix® application. a - 3D surface 
fluorescence calibrated in millimetres in x and y-direction; and on z-axis there is fluorescence 
intensity normalised on the camera maximum (on false colour scale). b – 2D plot of the 
fluorescence before the first PDT treatment. c – 2D fluorescence intensity before the second 
PDT treatment. 
As fluorescence greatly varies from subject to subject53, in order to confirm the settings 
for the camera (0.1 ms exposure, x1 gain for normal images without the filter, 16 ms exposure, 
x11 gain for fluorescence images at 60 fps with fully open aperture) second subject was 
recruited in the study. This patient P2 had multiple lesions: one BCC lesion and two AK. Metvix® 
PDT was administered for all three diagnoses. All three lesions were treated on the same day. 
Analogous to the previous measurents on P1, PpIX fluorescence from patient P2 was imaged 
after three hours of Metvix® application (Figure 2.13).  
 
Figure 2.13: PpIX fluorescence images taken with the camera from P2 patient after three 
hours of Metvix® application before PDT treatment. a –Actinic Keratosis (AK). b, c – BCC 
lesions. The images were taken to confirm the choice of the settings of the camera and finalised 
the design of the clinical study. 
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All of the fluorescence readings were clear which confirmed the choice for the settings for the 
camera and allowed to finalise the design for the clinical study which is described in the next 
chapter. 
2.4 Conclusion 
The developed instrument and the method introduce a few advantages in PpIX 
fluorescence imaging compared to existing devices. The illumination light in the device has low 
irradiance. In addition to this it is pulsed and synchronised with image acquisition. So the total 
light dose delivered during the measurements is orders of magnitude lower than PDT treatment 
dose. Because of this low dose the device was not expected to induce PpIX photobleaching or 
pain during the measurements. Another advantage of pulsed light was reduced sensitivity to 
ambient light and background noise.  
Developed measurement procedure and image processing algorithms enable good 
referencing of the fluorescent images to the study area, and enable analysing identical regions in  
time course images. This makes the device appealing for fluorescence time course imaging. 
Fluorescence time course imaging will provide spatial information on PpIX fluorescence. 
Different areas on the fluorescent images can be integrated for the time course analysis which is 
a more accurate method compared to the conventional one point measurement using optical 
fibre based spectroscopy techniques. 
The results during the camera validation demonstrated that it was suitable for monitoring 
and quantitative PpIX fluorescence display in clinical setting. The camera was selective to the 
635 nm peak wavelength in ex-vivo measurements on fluorescent solutions and PpIX phantoms, 
and in-vivo experiments on the skin of a healthy volunteer after three hours of ALA application, 
and PpIX fluorescence developed in AK and BCC tumours of two patients after three hours of 
Metvix® application. The fluorescence developed in the BCC tumour of the first patient (P1) was 
imaged before the first and the second PDT treatment cycle which were performed with an 
interval of one week. The fluorescence images from the first week and the second week showed 
how the tumour responded to the first PDT treatment. This was of interest and promoted 
finalising a clinical study which aimed to answering important questions about PpIX metabolises 
in different lesions using two different creams. 
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Chapter 3 
3 Fluorescence time course imaging: clinical study of 
Protoporphyrin IX formation in healthy and diseased 
skin 
We went down into the silent garden. Dawn is the 
time when nothing breathes, the hour of silence. 
Everything is transfixed, only the light moves. 
 
The task of the right eye is to peer into the 
telescope, while the left eye peers into the 
microscope. 
― Leonora Carrington (1917 – 2011), 
Surrealist artist 
3.1 Introduction 
The general background about PDT treatment covering the metabolic reactions involved 
in uptaking the pro-drug from the dermatological creams and converting it into PpIX 
photosensitizer, the photophysical processes related to the excitation of PpIX and resulting in 
phototoxic reactions were covered in the previous chapter. This chapter will focus on the clinical 
aspects relevant for PDT treatment, in particular the treatment procedures at the Photobiology 
unit (PBU), Ninewells Hospital; and PpIX fluorescence diagnostics. The study will discuss PpIX 
metabolism with respect to different creams, diagnoses, body sites, correlation to pain and 
tumours response. 
Topical PDT is an effective treatment of NMSC and dysplasia with excellent cosmetic 
outcome and healing1,2,3,4,5. PDT is administered for the treatment of superficial basal cell 
carcinoma (sBCC), Bowen’s disease (BD), and actinic keratosis (AK) in Europe, Asia, Australia, 
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South America1,2,3,6,7. In the US it is only used for treating AK which is a pre-malignant skin 
condition occurring due to chronic sun damage8. If left untreated AK can progress to squamous 
cell carcinoma (SCC)9. BD is carcinoma in situ, similar to AK it can progress to invasive SCC. 
BCC is the most common skin cancer. NMSC and dysplasia are often multiple with low risk. PDT 
is one of the best choices for large multiple superficial lesions, field carcinogenesis or dysplasia. 
It is also a good choice in cases where repeated treatments are needed3 often in 
immunosuppressed patients, including organ transplant recipients10.  
At the PBU PDT is administered for sBCC, nodular BCC, BD and AK. A typical procedure 
is shown in Figure 3.1. White light photographs were taken by a medical photographer before 
the treatment, and the lesions were prepared with a curette to remove all crust and help the 
creams to diffuse better in the skin. A thin layer of cream (5-aminolaevulinic acid (ALA), Ameluz 
or methyl aminolevulinate (MAL), Metvix®) was applied to the lesion and covered with 
TegadermTM film and Mepore™ occlusive dressing for three hours to metabolise into PpIX. The 
amount of the cream should be sufficient (between 0.01-0.09 ml) to cover the whole area of the 
lesion11. After three hours the dressing is removed, the surplus cream is cleaned up with a 
cotton wipe, PpIX fluorescence is visually accessed using a Wood’s lamp, and 635 nm centre 
wavelength PDT lamps are used for conventional treatment. The total treatment dose is 75 
J/cm2. In the other centres total dose varies between 37 and 150 J/cm2. Topically 65-75 mW/cm2 
irradiance is used12. The treatment lasts for approximately 19 minutes (the regime is chosen for 
each PDT lamp to deliver 75 J/cm2). After the treatment pain is assessed on the visual time 
scale from 0 points which corresponds to no pain to 10 points which is the worst pain one can 
imagine. Only in 16% of the cases the treatment is accompanied by severe pain and in some of 
the cases it has to be terminated or paused, cooling air is typically used for pain relief during the 
treatment13,14. However, there are reports in the literature that cooling air reduces the rate of 
sucessful outcomes15. It is not clear what causes the pain during the PDT16,17; there are 
controversial reports questioning whether PpIX concentration (fluorescence) has any correlation 
to the pain experienced8,18. 
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Figure 3.1: PDT procedure for treating a skin cancer at the Photobiology Unit, Ninewells 
Hospital (a - d – lesion’s preparation). a – the surface of the lesion is prepared by a curette. b –
Ameluz gel or Metvix® is applied with a wooden spatula at the surface of the lesion. c, d – 
Tegaderm™ film and Mepore™ occlusive dressing are covering the cream for three hours. e – a 
white light medical photograph. f – PpIX fluorescence visual assessment using a Wood’s lamp; 
g – PpIX fluorescence measurements using an optical biopsy system 19,20,21. h – Aktilite CL128 
lamp is used for the conventional PDT treatment. Typically, 75 mJ/cm2 total dose is delivered 
during 18-20 min with 65-75 mW/cm2 irradiance at 8.5 cm distance from the lamp. After the 
treatment pain is assessed on the visual pain score (from 0 to 10 points). 
Although topical PDT is an effective and widely used treatment, the response to the 
treatment could yet be improved. AK and sBCC have better response to the treatment, 94 % 
compared to 74 % for nodular BCC22. Morton et al (2007) in the Guidelines on the use of 
photodynamic therapy4 report the clearance rates. AK at 3 month follow up was cleared in 90% 
of the cases, sBCC at a 3 month follow up was cleared in 80-97%, BCC at 48 month was clear 
in 78% cases. A median clearance was 73% at a 6 months median follow-up (range 2–12) in 
382 lesions (BCC: n = 126, BD: n = 104, AK: n = 135, nodular BCC: n = 7) across 10 PDT 
centres in Scotland3. 26% of lesions require more than one cycle of PDT treatment3; routinely 
BCC diagnoses administered two cycles treatment separated one week apart. A possible 
explanation why BCC is more difficult to treat with PDT could be that PpIX metabolises better in 
superficial layers than in deeper layers23. BCC develops in basal cells which are deeper in the 
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skin than keratinocytes cells. AK develops in keratinocytes. PpIX distribution is one of the key 
treatment factors. Surface fluorescence is a powerful way of studying the formation of PpIX.  
There have been many studies on PpIX fluorescence for PDT24,25,18,23,26,27,22,8,28,29,30,31, 
however, there are still many gaps in our knowledge of how PDT works and conflicting reports 
on PpIX metabolism. One of the arguments is whether or not PpIX fluorescence can be useful 
for PDT diagnostics. In [29] 54 lesions (21 BCCs, 22 AK, and 11 seborrheic keratosis SK) were 
used in the study to establish if auto-fluorescence combined with PpIX assisted fluorescence 
can be used for optical detection of NMSC. ALA solution was applied to the lesions and the 
fluorescence was imaged at 15, 30, 45 and 60 min in a dark room. They found a noticeable 
difference between the autofluorescence in healthy and diseased skin; PpIX fluorescence 
increased the contrast at the lesion margins. In the following study [30] 8 BCC lesions on 
different anatomical sites were studied using MAL as PpIX precursor. PpIX fluorescence was 
imaged after 3 hours of MAL application before PDT treatment and immediately after for the first 
and the second PDT treatment which were separated one week apart. They found that the 
fluorescence was different at different anatomical sites of the lesions; it was higher on the lip of 
one subject compared to the eye lid on another subject. The fluorescence was higher before the 
second PDT session. In both studies relative fluorescence was measured by a portable 
fluorescence imaging camera integrated with a treatment light source. The dressing and the 
cream was removed between the images. But it is not clear what the procedure was to make 
sure that the identical area was analysed between the time course images. Our experience 
showed that marker pen is not a stable reference as it was dissolved in creams and blurred over 
the surface of the skin, or removed during the cleaning between the images. The fluorescence 
was integrated from the images using the values of red pixels. Again, it is not clear what area 
was integrated and if it was identical between the images. The illumination light was not 
synchronised with the image acquisition; and the irradiance was 50 mW/cm2 which is 
comparable with the treatment PDT lamps. The excitation wavelength of the device was 405 nm; 
PpIX absorption at this wavelength is more than 10 times higher that at 635 nm treatment 
wavelength. There was a high probability of PpIX photobleaching during the measurements. 
There are other reports which support the facts that PpIX fluorescence can be an 
indicator of pre-clinical changes in the tissue [27,24,32]. On the other hand there are 
contradictory studies which show that PpIX fluorescence does not correlate to PDT 
responses22,25 therefore can not be ultimately and solely used for PDT diagnostics or optical 
detection of skin cancer. In these studies fluorescence was not quantified, but visually analysed 
and correlated to the lesion response. 
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Another controversial point is the correlation of PpIX fluorescence and pain8,18; and the 
differences in PpIX time course formed from ALA and MAL precursors. There was one study 
which reported higher PpIX metabolism from ALA precursor than from MAL18. From previous 
experience at PBU there was no difference in ALA and MAL induced fluorescence after 3 hours 
from the application of the creams in BCC and BD11, the fluorescence was not significantly 
different in healthy skin after application of ALA precursor than MAL at 4 hours from the 
application of the creams, but it became higher for ALA precursor at longer metabolism times33. 
Typically PpIX concentration reaches plateau in 6 hours after the application of ALA precursor34 
and 13 hours after the application of MAL precursor35. The full time course for ALA precursor is 
24 h34 and 18 hours for MAL precursor35. It is worth noting that the specificity in PpIX metabolism 
in healthy and diseased skin decreases substantially with time. The most recent reports show 
that pulsing and shorter metabolism times increase specificity of PpIX accumulation in the 
malignant cells and reduce pain36. 
In order to address all the above open questions, this study aimed to gather fluorescent 
images from different diagnoses using two types of creams looking at specific fluorescence 
patterns and differences between the creams, to learn about PpIX time course at small time 
steps during the recommended three hours for PpIX metabolism before the treatment, gather 
information on fluorescence correlation to pain, and to investigate how the improved device and 
fluorescence diagnostics in general can be helpful in predicting the lesions’ response and the 
reccurence.  
3.2 Methods 
3.2.1 The Good Clinical Practice (GCP) regulations for a clinical study 
using a prototype device  
The University of St Andrews Teaching and Research Ethics Committee (UTREC) is 
responsible for evaluating ethical considerations for conducting any studies involving study 
biological materials or in-vivo measurements on healthy volunteers. The Medicines for Human 
Use (Clinical Trials) regulations 2006 No. 1928 for good clinical practice (GCP) stipulates the 
requirements for conducting any studies on healthy volunteers and patients. Among the most 
important requirements laid down in both regulations there are the following points. The 
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participants have to be informed at least one day before the study and be able to discuss the 
study, an informed written consent for taking part in the study has to be obtained before the 
study, the data handling has to be anonymous, only the members of the research team should 
be able to identify the participants, the data has to be stored on a computer in a special locked 
room, the participants should be able to withdraw from the study at any point without providing 
any reasons, the participation in the study should not have any impact on the treatment, clinical 
procedures have to be conducted only by trained clinical personnel, and health and safety 
regulations have to be met.  
In order to eliminate any possibility for the patients to feel uncomfortable giving a 
negative response or having concerns about the outcomes of the treatment in cases of negative 
response the recruitment procedure was designed in the following way. The patients’ referrals 
were screened by the Chief investigator. In case the diagnoses met the exclusion and the 
inclusion criteria the patients received an opt-in slip at the bottom of the Patient Information 
Sheets (PIS) together with their appointment letter for the PDT treatment. The opt-in slip asked 
them to respond by phone, mail or email in case they were interested in taking part in the study 
instead of being approached by a clinician. The patients did not need to take any actions if they 
were not interested in taking part in the study. These considerations did not concern the cohort 
of the healthy volunteers as they were recruited from the database of the Photobiology unit by 
the research coordinator.  
Both the patients and the healthy volunteers had a chance to discuss the study prior to 
their visit to the PBU with a member of the research team: the chief investigator, the research 
coordinator or the investigator, or with an independent person at Ninewells hospital with relevant 
expertise. On the day of the experiment they were briefed about the study and had a chance to 
ask any questions. There were no personal benefits for participating in the study and the 
experiment could be terminated at any point if it was uncomfortable. The patients were provided 
lunch and refreshments, and the volunteers were provided with a small compensation for their 
expense and inconvenience. All of the data was kept as confidential and the access to the 
identity of the participants was only available to the members of the research team. The 
participants agreed that their unidentifiable data could be used for scientific reports, journal 
papers, conferences and the thesis. 
The patients had their standard PDT treatment after the measurements. For the healthy 
volunteers the area on the skin used in the study was cleaned with alcohol wipes and covered 
with an occlusive dressing for 24 h to prevent photosensitivity. After that the volunteers would 
have completed the study. 
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The application in the Integrated Research Approval System IRAS has Project ID 
136393, and Tayside medical science Centre TACS R&D, REC Ref # 2013DS03. The 
application received approval by the East of Scotland Research Ethics Service EoSRES 
committee at the TACS, Ref # 13/ES/0151, and the UTREC commettee Ref No: PA10783.  
All of the required documents: the study protocol, patient (PIS) and volunteer information 
sheets, letter of invitation, travel expense forms, patient and volunteer consent forms, a letter of 
Sponsorship Insurance (Ref 2013DS03) can be found in the Appendix II- XIII: 
Appendix II: Capturing fluorescence – Protocol v.1 21.10.2013; 
Appendix III: Capturing fluorescence – Device assessment for clinical trials; 
Appendix IV: Capturing fluorescence – Standard Operating Procedure (SOP); 
Appendix V: Capturing fluorescence – Healthy Volunteer Participant Information Sheet 
PIS v.2 17.12.2013PIS; 
Appendix VI: Capturing fluorescence – Patients Participant Information Sheet PIS v.2 
17.12.2013; 
Appendix VII: Capturing fluorescence – Healthy Volunteer Consent Form 21.10.2013 V.1; 
Appendix VIII: Capturing fluorescence – Patient Consent Form 21.10.2013 V.1; 
Appendix IX: Capturing fluorescence – Patient Consent Form 21.10.2013 V.1; 
Appendix X: Capturing fluorescence – Participant Travel Expenses Form 2013 V.1; 
Appendix XI: Capturing fluorescence – Sponsor Letter Insurance Note 2013DS03; 
Appendix XII: Capturing fluorescence – East of Scotland Research Ethics Service 
EoSRES Favourable Opinion Letter; 
Appendix XIII: Capturing fluorescence – University of St Andrews Teaching and 
Research Ethics Committee UTREC Approval Letter 10.02.2014. 
 
3.2.2 Statistical data analysis  
In order to compare the results of PpIX time course between the groups – the diagnoses, 
the creams, etc. two-sample t-test with unequal variances was calculated in excel between 
different groups. P-values were analysed at each time step to identify the statistical significance 
between the groups. The groups are statistically significantly different if p-value > 0.05. 
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3.3 Results  
3.3.1 The set up 
The full experimental setup for clinical experiments is shown in the Figure 3.2. It fits on 
top of a small hospital trolley. The consumables for the study such as cotton wipes, the 
dressings and the creams are normally kept in a handy location on a small hospital tray. 
 
Figure 3.2: Fluorescence measurements setup. The camera was connected to a laptop 
via a USB cable and can move around the patient; two timers control the time step of the 
measurement, one was used to time the waiting and another the duration of the imaging 
procedure which is re-applying the cream and taking an image. The disposable reference frame 
is fixed at the study area after the lesion is curetted. The filter is fixed at the camera lens after 
normal images of the skin are taken. All of the disposables such as the creams, the spatulas, the 
dressings, a dermatological tape, gloves, and cotton wipes are placed in a carton hospital tray 
and are on the patient’s chair on this image. 
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3.3.2 Study design 
For the patient cohort, the study was designed to avoid an extra visit to the hospital and 
be compatible with the routine PDT treatment at the PBU (Figure 3.1). The fluorescence was 
imaged during the three hours of what is called “waiting” time, i.e. the time between the 
application of the cream and the start of the treatment. A clinical technician was present to apply 
the cream and prepare the lesions.  
The measurement procedure is shown in Figure 3.3. The measurements were taken at 
10 minute intervals. The healthy volunteers’ skin was cleaned with ethanol wipes, and left for a 
few minutes to dry. After that the reference frame was fixed and the study area was ready for the 
measurements. Patients’ lesions were photographed by a medical photographer then the lesions 
were prepared with a curette to remove all crust; the reference frame was fixed and the study 
area was ready for the measurements.  
The first iteration of the measurements was different from the rest of the measurements: 
a normal image under 405 nm illumination was taken with the camera in addition to white light 
medical photographs. Then the emission filter was inserted and the settings for the camera were 
changed to image the fluorescence. Background fluorescence was recorded. The cream was 
applied and covered with an occlusive dressing. The cream was removed before each 
fluorescence measurement, re-applied after an image was taken, and covered with the dressing 
again. The cream had to be removed due to Metvix® is being opaque. Regardless that Ameluz 
gel is transparent and did not affect the imaging, the procedure had to be consistent for the 
comparison. Re-application of the cream should not have made any difference as long as the 
quantity is in the range of 0.01-0.09 ml11. Two timers were used to control the time step. One 
was set to 9 minutes and another one for 1 minute. After the first application of the cream the 9 
minute timer was started. When it had lapsed, the one minute timer was started. During this 
minute the dressing was lifted up, the cream was removed with a wooden spatula, cleaned up 
with a cotton wipe, a fluorescence image taken, the same cream from the spatula was put back 
on (a small amount of fresh cream was added each time when the cream was used up during 
the measurements to keep the area covered), and the dressing was put back on. After the 
minute timer had lapsed (normally it was enough for the procedure), the 9 minute timer was 
started; and the measurements were repeated 18 times during the three hours. 
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Figure 3.3: The procedure for the fluorescence time course imaging. 
The size of the initial images were cropped from 640x480 pixels (3.1 mm x 2.4 mm). 
They were cropped to remove the fluorescent reference contour to 540x380 pixels which 
corresponded to 2.6 mm x 1.9 mm.  
3.3.3 Study population 
Healthy volunteers’ cohort, inclusion/exclusion criteria 
The study protocol included 10 healthy volunteers, a half of them were administered 
Metvix® and the other half Ameluz. However, one of the volunteers did not express much 
fluorescence and one extra volunteer was added to the Metvix group in order to have a better 
baseline. So in total there were 11 volunteers recruited for the study. A previous study at the 
PBU showed that PpIX fluorescence varies with the body site37,38. It was higher on the forearm, 
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lower on the lower leg and in between on the trunk. Considering this and the fact that the skin on 
the back is the most uniform, the middle back avoiding the paravertebral regions was the best 
choice for the base line and was imaged in all the volunteers.  
The inclusion criteria for the healthy volunteer cohort were: males and females 18 years 
old and over (age matched to patient cohort as far as is practicably possible) capable of giving 
informed consent and able to understand and adhere to protocol requirements. The exclusion 
criteria were: individuals who are not able to give informed consent, anyone with known allergy 
to Metvix or Ameluz and known to have a light sensitivity disorder. 
Patients’ cohort, inclusion/exclusion criteria 
There were 15 patients planned in the protocol: 5 patients diagnosed with AK and 
administered Ameluz PDT, 5 with AK and administered Metvix® PDT and 5 with biopsy 
confirmed BCC and administered Metvix® PDT. Due to the time scale of the project the study 
was terminated after 13 patients, meaning that two patients with AK and Ameluz PDT were 
lacking from the study population. 
Inclusion criteria for the patients cohort was males and females 18 years old and over 
presenting with superficial NMSC and dysplasia, capable of giving informed consent and able to 
understand and adhere to protocol requirements. The exclusion criteria were: patients who had 
had previous treatment within the last four months, unable to give informed consent and with 
known allergy to Metvix or Ameluz or with a light sensitivity disorder. 
Neither the body site nor the lesion size were specified. In cases when the size of the 
lesions were larger than the field of view of the camera, a small area was selected for the study 
and marked with a marker pen. The area outside was routinely prepared for PDT treatment and 
covered with an occlusive dressing. An opening in the dressing was cut out to leave the study 
area accessible. The reference frame was fixed on top of the dressing and the area was ready 
for the measurements (Figure 3.4).  
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Figure 3.4: measurements on large lesions. The area outside of the field of view of the 
camera was prepared and covered for the routine PDT treatment; a small area was left 
accessible for the study. 
3.3.4 PpIX fluorescence time course in healthy volunteers 
The fluorescence imaged in healthy volunteers was mostly uniform in 8 out of 10 cases. 
Two volunteers had a slightly spotted pattern, such as show in Figure 3.5.  
 
Figure 3.5: Fluorescence patterns on healthy skin and an integrated PpIX time course. 
a – a monochromatic image of the skin under 405 nm illumination taken with the camera. b – 
PpIX fluorescence image after 180 min of Ameluz gel application. Red rectangle shows a small 
area which was used in the comparison to the whole area of the image. c – an integrated PpIX 
fluorescence time course from the small area and the whole area normalised on the camera 
maximum. 
There was no obvious correlation between the fluorescence pattern and the skin in either visual 
assessment or calculations. The correlation coefficient between the image of the skin and the 
fluorescence image was below 0.3 for all the subjects. The fluorescence time course from a 
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small area on the images was almost identical to the time course calculated by integrating the 
fluorescence over the whole area of the images (Figure 3.5, c). 
The fluorescence time courses from six healthy volunteers in Metvix® group are shown 
in Figure 3.8. Background fluorescence was subtracted and the result normalised to the 
maximum pixel intensity of the camera (which was equal to 255). The time course varied 
between the individuals; the fluorescence continued to grow over the three hours of the 
measurement in all subjects. The fluorescence was averaged for the six subjects and is shown 
in Figure 3.8, (b).  
 
Figure 3.6: PpIX fluorescence time course in Metvix® healthy volunteers group. a – 
fluorescence for six individual subjects in the group. b – an average fluorescence time course 
for the group.  
The PpIX fluorescence time course for the Ameluz group is shown in Figure 3.7. The 
same dynamics were found for this group: the fluorescence continued to grow over three hours 
of the measurement time and varied among the individuals. 
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Figure 3.7: PpIX fluroescence time course in Ameluz healthy volunteers group. a – 
fluorescence for five individual subjects in the group. b – an average fluorescence time course 
for the group.  
The results from the two groups are shown in Figure 3.8. The two groups were 
analysed for statistical significance in order to establish if there was any difference between the 
creams. A two sample t-test with unequal variances was used to calculate the p-values for the 
groups. The p-values for six volunteers in Metvix® group V.S. five volunteers in Ameluz group at 
each time step were larger than 0.05, p-value (the average for the time course and at the last 
time step) was equal to 0.3. The extra volunteer did not change the statistical significance. P-
values for the group of 5 Metvix V.S. 5 Ameluz volunteers were similar: average p-value was 0.3 
> 0.05 and p-value at 180 min was 0.45 > 0.05. This shows that the groups were statistically 
insignificant, there was no obvious difference for the Ameluz gel or Metvix® cream. This was 
concurrent with the previous studies conducted at the PBU11,37,38.The previous studies [11,37,38] 
showed that there was no substantial difference in the fluorescence formed from ALA and MAL 
precursors at 4 hours after the application of the creams, but at longer times the fluorescence 
was substantially higher after the application of ALA precursor. 
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Figure 3.8: PpIX fluorescence time course in both (Ameluz and Metvix®) healthy 
volunteers groups. 
 
3.3.5 PpIX fluorescence patterns in different diagnoses 
The fluorescence patterns of the lesions were analysed with respect to the skin structure. 
The findings agree with the previous reports27,24,32,39,18 that in some patients the fluorescence 
develops over an area of the visible tumours forming a rim at the margins (Figure 3.9). 
Sometimes it spreads outside the visible tumour or develops in areas without any evidence of 
the diseased skin to the naked eye which may be an indication of early stages malignant 
changes. There findings support the studies showing that PpIX fluorescence is an effective 
method for detecting pre-clinical diseased skin and assisting with identifying tumours’ margins 
for the surgery27,24,32.  
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Figure 3.9: Biopsy confirmed BCC lesion of P010 patient administered Metvix® PDT. a 
– a white light image of the tumour taken by a medical photographer. b – a monochromatic 
image of the tumour taken by the camera under 405 nm illumination. A half of the image is 
overlapped with a semi-transparent fluorescence image on a false colour scale taken at 180 min 
from the application of the cream. It shows that the shape of the lesion is similar to the 
developed fluorescence pattern. Although, the fluorescence area is larger than the visible 
tumour; and there is a rim at the margins which may be an indicator of early stages 
malignancies. c, e – a monochromatic image and a false colour image of PpIX fluorescence at 
180 min from the application of the cream. The red dashed rectangle shows an area on the 
tumour with the highest PpIX metabolism. This area was used in the time course calculations of 
peak fluorescence. d – a false colour fluorescence image taken at 60 min from the application of 
the cream. The fluorescence starts to develop over the area within the visible tumour and then 
spreads to the area outwith the tumour. 
The fluorescence time course was analysed by integrating regions of interest (ROIs) 
which developed the strongest fluorescence. The red dashed line in Figure 3.9 (e) shows such 
a ROI. The size of the ROIs varied depending on the size of the uniform peak fluorescence 
region. The smallest ROI was 25 x 38 pixels for P004 subject and the largest was 73 x 86 pixels 
for P013. 
Another example was patient P005 who had two AK lesions treated with Metvix® PDT. 
The lesions were located on the same foot close to each other; they were similar in shape and 
size and threated on the same day. Lesion #1 developed almost twice as much PpIX 
fluorescence over the area corresponding to the lesion compared to only partial fluorescence at 
the lesion #4 (Figure 3.10). The intensity of the fluorescence was also lower in lesion #1. The 
fluorescence distribution in lesion #4 showed the formation of two halves which may suggest 
that there were two centres of the malignant growth which merged together in one lesion.  
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Figure 3.10: Two AK lesions of subject P005 subject who was administered Metvix® 
PDT. The lesions were located on the same foot; they were similar in shape and size and 
treated on the same day. However, the fluorescence from the left lesion (marked as #4 on the 
image) is almost twice as high and larger in area than the fluorescence from the lesion on the 
right, marked as #1 on the image. a, b – a monochromatic and a false colour fluorescence 
image of lesion #4 taken at 180 min after the application of the cream. c – a white light image 
taken by a medical photographer. d, e – a monochromatic and a false colour fluorescence 
image of lesion #1 taken at 180 min after the application of the cream. Although the fluorescence 
was much higher in one lesion than in the other the pain after the treatment was evaluated as 
the same. 
Surprisingly the pain experienced during PDT was the same for both lesions. Another 
interesting finding was that both lesions were clear at 3 month follow up. This supports the 
reports that PpIX fluorescence does not always correlate with PDT outcomes, the fluorescence 
can be poor yet there is a response to PDT or vice versa22,25.  
Fluorescence imaging becomes more challenging in the cases of crusted and eroded 
lesions, and when there is any bleeding after the curettage. Figure 3.11 shows the 
fluorescence of a crusted AK lesion treated with Ameluz gel which was bleeding after the 
preparation. Crust and blood blocked some of the fluorescence signal. However, it was still 
possible to select areas with a clear surface for the analysis. In this case the fluorescence 
spreads beyond the visible lesion (Figure 3.11, c) and it grows with different speeds over 
different regions (Figure 3.11, d). 
3.3.5 PpIX fluorescence patterns in different diagnoses 
66 
 
 
Figure 3.11: AK lesion of P011 subject administered Ameluz PDT. The surface of the 
lesion was crusted and there was some bleeding after the curettage. The crust, erosion and 
bleeding can block some of the fluorescence signal and make the imaging mode difficult. 
However, it was still possible to analyse the fluorescence in the clear surface around the crusted 
and bleeding part. a – a white light medical image of the lesion. b – a monochromatic image of 
the lesion taken with the camera under 405 nm illumination. The size of the images taken with 
the camera were cropped from 640x480 pixels (3.1 mm x 2.4 mm) to 540x380 pixels 
corresponding to 2.6 mm x 1.9 mm to remove the reference contour used for the alignment. c – 
a false colour fluorescence image taken with the camera at 180 min after the application of the 
gel. d – PpIX fluorescence time course was integrated over different regions on the image. The 
black line shows fluorescence integrated over the whole image, three different areas correspond 
to the areas on the fluorescent image (c).The fluorescence develops with different speeds over 
different areas. 
There was a case with a blurred fluorescence pattern in a BCC tumour treated with 
Metvix® PDT (Figure 3.12). The margins of the tumour were not clear and it developed a 
random spotted pattern which did not correlate to the lesion or the skin. Dense sebaceous 
glands on the neck could be one of the explanations of such patterns. Treating this tumour with 
PDT would be the best choice as surgery would be quite challenging.  
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Figure 3.12: Biopsy confirmed BCC tumour of P008 patient administered Metvix® PDT. 
a – a white light medical image of the tumour. b – a fluorescence image taken with a colour 
digital camera under Wood’s lamp. c – a monochromatic image of the tumour taken with the 
camera under 405 nm illumination. d – a monochromatic fluorescence images taken with the 
camera at 180 min after the application of the cream. The margins of the tumour are not very 
clear to the naked eye; the fluorescence has blurred random spotted pattern which may be 
caused by the activity of sebaceous glands which are quite dense on the neck. 
Fluorescence homogeneity was calculated in the ROIs and over the whole image at 180 
min from the application of the creams. The fluorescence value and pixel indices for local 
minimum and local maximum for ROI and global minimum and global maximum for the whole 
image were identified. In order to reduce numerical noise 5 pixel values were averaged at the 
minima and maximuma. The homogeneity was calculated as 1-({global, local} max- {global, 
local} min) / local_mean, %.  
On average for 12 patients the fluorescence of the lesion was homogeneous with more 
than 75 % homogeneity in the ROIs; and for one patient it was heterogeneous with homogeneity 
equal to 25 %. Over the whole image the fluorescence was heterogeneous with homogeneity 
less than 21 % on average for 12 patients which indicated the contrast between the peak 
fluorescence in ROI and the rest of the image including healthy parts of the skin in cases for 
well-defined fluorescence patterns; the fluorescence was 54 % homogeneous for one patient 
with poorly defined weak fluorescence. 
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3.3.6 PpIX fluorescence correlation to pain 
The possibility of correlation between PpIX fluorescence and pain was investigated by 
calculating correlation coefficient between the pain scores and the peak fluorescence measured 
at 180 min. The correlation coefficient was calculated in excel using the formula 
𝐶𝑜𝑟𝑟𝑒𝑙 (𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒, 𝑃𝑎𝑖𝑛) =
∑(𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒−𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ )·(𝑃𝑎𝑖𝑛−𝑃𝑎𝑖𝑛̅̅ ̅̅ ̅̅ ̅)
√[∑(𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒−𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ )2 ∑(𝑃𝑎𝑖𝑛−𝑃𝑎𝑖𝑛̅̅ ̅̅ ̅̅ ̅)2]
. The pain was scored 
by the visual pain score from 0 corresponding to no pain to 10 corresponding to the worst pain 
one could imagine. The patients were asked to score the pain which they experienced during the 
PDT treatment straight after the treatment. The patients’ data including the type of cream, lesion, 
body site, peak fluorescence at 180 min, pain scores, and lesion clearance at follow up is 
collected in Table 3.1.  
Figure 3.13 shows fluorescence correlation of fluorescence to pain. The data points on 
the figure represent two values for each patient: the peak fluorescence on the horizontal axis 
and to the pain experienced during the PDT treatment on the vertical axis. The graph shows 
random distribution of the data points suggesting that there was no obvious dependence 
between the fluorescence and the pain. 
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Table 3.1: Patients' data. The skin temperature was not measured during the 
experiment, but was estimated from IR thermograms of healthy skin taken from the literature; 
paragraph 3.4 explains how it was evaluated. 
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Figure 3.13: PpIX fluorescence correlation to pain 
There was a small negative correlation coefficient found which was equal to -0.24 (p-
value=0.0005). This means that the pain and fluorescence are statistically dependent (p-
value<0.001), but the correlation was too small and could be neglected. This agrees with the 
previous reports which did not see the correlation between the fluorescence and the pain18, 
including one study conducted at the PBU on PpIX fluorescence decay (photobleaching) during 
PDT treatment for BD and sBCC33. These findings contradict to the previous reports which 
showed positive correlation of PpIX fluorescence to pain and erythema40,8,36 
3.3.7 PpIX correlation to the creams and the diagnoses 
The fluorescence time course was calculated by integrating regions of interest with the 
same intensity (ROI) which developed the highest fluorescence. The background fluorescence 
was subtracted and the result normalised on the maximum pixel intensity of the camera.  
Figure 3.14 shows the results from the three groups AK Ameluz V.S. AK Metvix V.S. 
BCC Metvix. The results showed that the fluorescence continued to grow over three hours in all 
subjects. It varied between the diagnoses and the individuals. 
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Figure 3.14: PpIX fluorescence time course in three groups of patients 
The fluorescence was averaged for the three groups and the average fluorescence time 
course is shown in Figure 3.15. The difference in the time course between the groups was 
analysed by calculating the p-values which identifies statistical significance. P-values for all 
cases were larger than 0.05 at each time step (though in AK Ameluz group vs AK Metvix group 
after 130 min p-value was approaching 0.02). P-values were averaged for all time steps 
measurements; the statistical difference between the groups AK Ameluz group vs AK Metvix (p-
values=0.16), and AK Metvix group vs BCC Metvix (p-value=0.18) was insignificant. This agrees 
with the previous study at the PBU which showed no difference in the fluorescence developed 
from ALA or MAL precursors in sBCC and BD measured after three hours from the application of 
the creams, and during the treatment33. One study reported that fluorescence developed form 
ALA precursor was higher than from MAL precursor18. However, averaging peak fluorescence 
from an area is a more robust method compared to one point measurement. The results in 
Figure 3.11 demonstrate that the fluorescence can vary three times between three different 
regions. The distance between areas 1, 2, 3 on that image is less than 3 mm. So for one point 
measurement using a standard optical fibre with 2 mm diameter gives a high probability of 
inaccuracies. An integrated fluorescence in that image is much lower than the fluorescence at 
high intensity regions. So even by measuring the fluorescence over a few points and averaging 
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it, fluorescence imaging is superior to one point spectroscopic measurements as it gives control 
over the areas of interest. 
 
Figure 3.15: PpIX fluorescence time course in AK Ameluz V.S. AK Metvix® V.S. BCC 
Metvix® groups. The variation shows that there is no obvious difference between the three 
groups. 
This concludes that there was no obvious difference between the diagnoses or the 
creams. However, analysis of fluorescence with respect to the body sites shows that the 
fluorescence developed in the lesions on the head and the neck was much higher than the 
fluorescence on the lower leg (Figure 3.16). The fluorescence on the shoulders, the hands and 
the feet is in the middle.  
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Figure 3.16: PpIX fluorescence time course in three body sites groups of patients with 
AK and BCC: Head & neck V.S. Lower leg & feet V.S. Trunk & hands 
The fluorescence was averaged in these body sites groups (Figure 3.17). The error 
bars in the figure which correspond to the variation of the fluorescence in each group are already 
much smaller than the error bars in Figure 3.15, also the dependence is already obvious to the 
naked eye. Statistical calculations proof this observation. The groups Head & neck V.S. Lower 
leg & feet were statistically different (p-value=0.0003 << 0.05); so were the groups Head & neck 
V.S. Trunk & Hands (p-value=0.001<0.05). However, there is no statistical difference between 
the group Lower leg &feet V.S. Trunk & Hands (p-value>0.005). The  dependence concurs with 
the previous study conducted at PBU on the skin of healthy volunteers which discovered that the 
fluorescence on the forearm is higher than the fluorescence on the lower leg37,38. 
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Figure 3.17: PpIX fluorescence time course in Head & neck group V.S. Lower leg & feet 
V.S. Trunk & hands groups. The variation shows that the fluorescence is much higher in the 
group of Head & neck compared to the other two groups. 
3.3.8 Lesion clearance and correlation to the fluorescence 
The results of three month and one year follow ups for lesion clearance are shown in 
Table 3.1. P002 was lost to follow up. The correlation coefficient between PpIX fluorescence 
form the peak region and the clearance was not significant, -0.0285 (caution should be taken as 
the sampling population is small and the results should not be over interpreted). Although PpIX 
metabolism is one of the most important treatment factors and PpIX fluorescence helps to 
optimise treatment protocols, PpIX fluorescence did not correlate to PDT response in this study, 
similar to what was reported in the six year study on BCC treatment [22]. 
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3.4 Discussion 
3.4.1 PpIX fluorescence correlation to the skin temperature 
In order to explain the dependence of PpIX metabolism on the body site, the skin 
thickness could have been the reason, thicker skin could have had less cream diffusion than 
thinner skin; for instance PpIX fluorescence is higher when the surface of the skin stripped off 
with an adhesive tape before the application of the cream [37, 38]. However, the fluorescence is 
higher on the head and the neck compared to the lower leg, and the skin on the neck is thicker 
than lower leg41,42,43. So the skin thickness could not be the main reason for such fluorescence  
dependence.  
Another possible explanation was the temperature variation across the body. The 
temperature variation of the skin can be displayed with infrared imaging cameras44 
[http://www.rnhrd.nhs.uk/page/92]. It was shown that local perfusion and temperature of the 
lesions increases during PDT as a response to the treatment (but not because of thermal 
hearing induced by PDT lamps)45. Average lesional temperature in that study was 34.8±1.2 °C. 
Lesional temperature measurement was not included in the protocol of the fluorescence study 
described in this thesis. In order to evaluate the temperatures at the lesions sites, thermograms 
of healthy skin were collected from the literature44,46,47. Typical temperatures for the lesion sites 
were estimated from the thermograms. For better estimates the temperatures were averaged 
from a few thermograms where possible; also, considering that healthy individuals have 
symmetrical temperature distribution across the body48 the temperatures were taken from 
symmetric sites and averaged (Figure 3.18). 
Typical thermograms of the hands and the back are shown in Figure 3.18. The areas 
over the back and the trunk have similar temperatures to the hands. The areas of the hands 
show large temperature variations; there are many hot and cooler regions. The lesion of subject 
P001 was located over the thumb metacarpal section which is one of the hottest regions on the 
hands. The lesion of P012 was located over the middle of the outer palm (over the four fingers 
metacarpal bones) which has middle temperatures. And the lesion of P013 was located over the 
third metacarpophalangeal joint, the area over the four metacarpophalangeal joints is the coldest 
on the hands. P013 P001 and P012 were treated with Ameluz PDT and P013 was treated with 
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Metvix PDT. The fluorescence varied significantly in all three subjects with the highest in subject 
P001 and the lowest in subject P013 which correlated with the temperatures. 
 
Figure 3.18: Medical photographs of the patients’ hands and the thermograms. The 
arrows on the images indicate the location of the lesions. The arrows on the thermograms 
indicate typical temperatures of healthy skin at those locations. The fluorescence varied in all 
three subjects with the highest fluorescence in P001 and the lowest in P013. There are many 
small “hot” and “cold” areas, large and rapid variation of the temperature which could be 
responsible for the variation in the fluorescence time course. The thermogram was taken from a 
medical thermography course at the website of I.Ya. Horbachevsky Ternopil State Medical 
University, Ukraine48 
The head and the neck have the highest skin temperatures across the body typically 
reaching 35-37°C46,47, the lower leg and the cold areas of the feet and the hands have lower 
temperatures of 30-33°C. The estimated temperatures for all lesions are shown in (Table 3.1). 
PpIX fluroescence was found to depend on the skin temperatures (Figure 3.19). This 
hypothesis concurs with the reports that increased skin temperatures have higher PpIX 
metabolism rates49,50,51,52.  
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Figure 3.19: PpIX fluorescence time course and its correlation to the body site and the 
skin temperature. The temperatures at the lesions were evaluated from the thermograms of 
healthy skin found in the literature48,47,44,46. PpIX metabolism seems to be faster on the hotter 
areas such as the head and the neck compared to the lower leg which supports the findings that 
PpIX metabolism is higher for higher temperatures50,52,49.  
The correlation coefficient for these temperatures and the fluorescence at 180 min was 
0.93 (p-value = 2.7·10-18 << 0.005). This means that the temperature and fluorescence have very 
strong statistical dependence and very high positive correlation: the fluorescence increases 
when the temperature increases. The fluorescence at 180 min was averaged among the patients 
with the same temperatures. The histogram is shown in Figure 3.20.  
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Figure 3.20: PpIX fluorescence at 180 min in the patients with respect to the skin 
temperatures at the sites of the lesions. The error bars correspond to the range in fluorescence 
among patients for the corresponding temperatures. 
If the evaluated temperatures corresponded to the real temperature of patients’ lesion 
and this hypothesis that the skin temperature has such a significant influence on PpIX 
metabolism is true, then the temperature should be considered in the protocols.  
 
3.5 Conclusions 
A time course imaging method was developed and used in a small study on healthy 
volunteers and patients. The fluorescence continued to grow in both healthy volunteers and 
patients during the three hours following the application of the cream. Therefore waiting longer 
before starting the PDT treatment could improve PDT outcome, although care should be taken 
as the specificity of PpIX metabolism in healthy and diseased skin decreases with time36. 
There was no significant difference in the time courses between the creams (for both 
volunteers and patients) or among the diagnoses (p-values>0.05 for all groups). However, there 
was variation among the lesions, the patients and the volunteers; the PpIX fluorescence time 
course was found to be dependent on the body site (p-values<0.01 between the body sites 
groups). Temperature variation across the body was explored as one of the possible 
explanations. There is a positive correlation to temperature (correlation coefficient was 0.93, p-
value < 0.001): the fluorescence on the head and the neck was much higher than the lower leg 
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which coincides with the temperature variation. If this hypothesis is true then this finding could 
have significant impact on changing the treatment protocol – increasing the skin temperature by 
thermal dressing for improving PpIX metabolism, taking care when using cooling fans as pain 
management. After the reports that cooling fans reduce PDT outcomes2,15 in some PDT centres 
this pain relief method is not administered anymore. PBU at Ninewells hospital is one such 
centre.  The ambient temperature for daylight PDT should also be considered for administering 
PDT53,54. Also increasing skin temperature by simple thermal dressing could speed up PpIX 
metabolism and reduce the waiting time before commencing PDT treatment.  
There is conflicting evidence about PpIX fluorescence correlation to the pain experienced 
during the PDT treatment. No correlation was found in this study (correlation coefficient was -
0.24, p-value<0.01). 
The outcomes of this study should be treated with caution in order not to over-interpret 
the results in this small population; however, it is a first clinical attempt to undertake time course 
fluorescence imaging in measuring PpIX fluorescence. The findings address some of the gaps in 
understanding of PpIX metabolism in different lesions at different body sites, using different pro-
drugs. The results of the study demonstrate the effectiveness of the apparatus and the potential 
of time course imaging to advance our understanding of the biosynthesis PpIX and its effects on 
the treatment. This may lead on to further studies, with a view to optimisation of treatment 
regimes. 
In the subsequent studies it would be desirable to implement a multi-band imaging 
experiment in a time course study. Considering the availability and simplicity of fast prototyping 
equipment such as 3D printing it would be relatively easy to upgrade the current device by 
adding extra LEDs with different wavelengths in the illuminator PCB and a few different band 
pass filters which could be easily changed during the imaging. Wide filed thermal images of skin 
could be obtained with an additional thermal camera. It would be useful to include the following: 
white light colour imaging to study the development of erythema (skin reddening due to 
inflammation as a response to PDT); auto-fluoresce which could provide additional information 
on the malignant changes in the skin; excitation of PpIX in blue and red bands for extracting 
information about PpIX accumulation at different depth in skin; imaging two peaks of PpIX 
emission at 635 nm and 710 nm; and most importantly include infrared thermal imaging of skin 
temperature to investigate the hypothesis on body site temperatures on PpIX metabolism. It 
would be sufficient to do one measurement before and after PDT. Monitoring the change in skin 
temperature, erythema and PpIX fluorescence would be useful during and after PDT.  
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Chapter 4 
4 Towards improving ambulatory light sources for 
topical Photodynamic Therapy 
 
Old ideas can sometimes use new 
buildings. New ideas must use old buildings 
― Steven Johnson, 
Where Good Ideas Come From: The Natural History of Innovation, 2010 
4.1 Introduction 
Previous chapters covered general background of PDT treatment for NMSC. Chapter 3 
was dedicated to a clinical study of photosensitiser PpIX formation from the pro-drugs. PpIX 
concentration is one of the three key treatment factors. There are two other crucial parameters 
which are needed for a good clinical response. They are light delivery and molecular oxygen. So 
PDT dosimetry considers all three factors with respect to each1,2,3,4. This chapter will concentrate 
on the importance of low irradiance PDT light sources and diffusion of molecular oxygen to the 
lesions. It will then describe the development of an optical apparatus to design and test wearable 
light sources for future devices. The application of optical modelling will mostly concern 
optimisation of the uniformity of the light output from the devices and diffusion in skin as a helper 
to equalizing non-uniform irradiance. It will also compare an OLED treatment device to the 
current LED-based device. At the end, the chapter will raise a question about the significance of 
directional emission for potential improvements of light transmission in skin. 
Clinically relevant concentrations of singlet oxygen which induce oxidative stress and cell 
death can only be produced when the concentration of molecular oxygen is above a certain 
threshold. It is known that molecular oxygen diffuses to the lesions from subcutaneous vessels5. 
If tissue oxygenation is below the threshold any delivery of excitation light will no longer be 
efficient; it will only result in photobleaching of PpIX without the clinical effect6. In fact, an optimal 
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light source should deliver as much energy at a time as is needed to excite as much PpIX as 
there is molecular oxygen. In reality the irradiance should be just enough to excite as much PpIX 
as is needed to generate the treatment threshold amount of singlet oxygen. If the irradiance is 
too high with respect to the oxygen supply rate it would result in PpIX photobleaching instead of 
generating singlet oxygen7.  
The formation of singlet oxygen can be predicted by a dynamic microscopic model which 
takes into account oxygen supply rate, diffusion of oxyhaemoglobin and irradiance of light 
sources. In this model the specifics of the photosensitizer formation, the concentration and 
inhomogeneous distribution were not taken into account; the photosensitizer was assumed to be 
infinite and uniform in the model. In animal studies the photosensitizer was metabolised in the 
tumours after injections of the precursors. There was good agreement between the simulated 
and PDT induced necrotic diameter of the skin cancer in mice2,3,8. These studies also reported 
that the lowest irradiance which was equal to 15 mW/cm2 (the other irradiances were equal to 
50, 75 and 150 mW/cm2) resulted in much higher singlet oxygen production and better tumour 
response2,8. These findings play in favour of choosing low irradiance ambulatory PDT devices 
such as Ambulight PDT (7 mW/cm2)9 as a better alternative to the conventional PDT lamps with 
irradiance equal to 65-75 mW/cm2. 
Initial motivation for developing wearable PDT light sources was that it would reduce 
hospital load and improve quality of treatment by cutting down the time which patients spend in 
hospital by three hours. Also, there was an assumption that pain during conventional PDT 
treatment could be reduced at lower irradiances. Ambulatory PDT was first explored in a Proof 
and Concept project beginning in 2002 at the Photobiology Unit, Ninewells hospital, Dundee; the 
results were published in 200610.  
The proof of concept project led to prototypes of a new generation of ambulatory devices 
which consisted of a low-irradiance OLED with a 550–750 nm emission spectrum and a peak 
wavelength at 620 nm. They were potentially disposable, lightweight, with a 2 cm emitting area. 
A study was performed using the devices for the treatment of histologically confirmed BD in 8 
patients and sBCC in 4 patients with lesions smaller than 2 cm in diameter were administered 
aminolaevulinic acid for 4 hours and treated with a 45–60 J/cm2 light dose at irradiance equal to 
5 mW cm2. 60% of tumours were cured at a 12 month follow up. The rest of the tumours had 
peripheral margin failure which could have been caused by mismatch between the size of the 
treated area and the light emitting area. The patients were scored for pain during and 
immediately after the treatment using the numerical rating scale (NRS; 1–10); 100% of the 
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patients scored the pain as less than 211,12. In subsequent studies the light source was always 
larger than the lesion to avoid peripheral margin failure. 
Although OLEDs have very attractive features for PDT, a suitable OLED manufacturer 
was not available at the time of the next stage of development and so commercialisation has so 
far proceeded using inorganic LEDs, leading to Ambulight PDT (Figure 4.1) receiving a CE 
mark and has become a key choice for lesions under 2.4 cm in diameter in many countries.  
 
Figure 4.1: Ambulight PDT device. The emitting head has a diameter of 30 mm but the 
treated area can be up to 24 mm to prevent any marginal failure due to misalignment of the area 
or intensity drop at the edges. The battery pack shows information on the display about 
remaining time and the treatment mode. The pictures were taken from Ambulight PDT product 
information video. 
The device consists of an array of 42 LEDs emitting at 640 nm with a diffuser on a 
flexible substrate with a dermatological tape which is fixed to the lesion’s site. The area of the 
lesion is measured and an alignment contour is drawn with the help of a paper reference contour 
which comes with the Ambulight PDT device. The lesion is prepared with a curette, 
dermatological cream is applied and covered with a Tegaderm™ dressing film as for 
conventional PDT. After that the battery pack for the device is fixed on a belt on the patient or 
placed in a pocket, the light emitting head of the device is fixed with sticky plaster and the timer 
is activated. The patient is free to leave. The light will be automatically turned on after three 
hours; a 75 J/cm2 treatment dose at irradiance of 7 mW/cm2 will then be delivered over the 
following 3 hours. The patient then can remove and dispose of the device at home or place it in 
a casing and return it at the follow up visit in cases where rechargeable batteries are used 
(Figure 4.2). The responses to Ambulight PDT PDT in 53 patients with 61 lesion sBCC (n=30), 
BD (n=30), and AK (n=1) was 84%. 23 of these 53 patients received conventional PDT to 
separate lesions. The median pain score was compared between the conventional PDT and 
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Ambulatory PDT using a pain scale from 0 (no pain) to 10 (the worst pain one could imagine). 
The median pain score for Ambulight PDT was found to be 1 compared to 5 for conventional 
PDT13. 
 
Figure 4.2: Procedure for ambulatory treatment with Ambulight PDT. a – the size of the 
lesion is confirmed to fit in the treated area, the contours are marked with the help of a carton 
disposable card, the cream is applied, the lesion is covered with TegadermTM film dressing; after 
this the device was fixed with a self-adhesive tape. b – the device is fixed at the lesion and timer 
is activated. c – after 6 hours the treatment is complete (3 for metabolism of the cream, and 3 
for light delivery) the device can be removed and the battery pack disposed of or returned to the 
hospital at next visit. The pictures were taken from Ambulight PDT product information video. 
Although Ambulight PDT is already a big advance in PDT treatment, the response could 
be better still. One aim of this thesis was to explore the propagation of light from the current 
Ambulight PDT in the skin and identify ways to optimise the design. The uniformity of the 
irradiance, intensity drop at the edges, the significance of distribution of LED in the array and the 
diffusers were studied. This chapter will describe the modelling and measurement approaches 
for light propagation in tissue, including the brain and the skin for proof of concept studies and 
PDT device design and will conclude on the optimisation routes for future ambulatory devices. 
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4.1.1 Light propagation through the skin  
Light propagation in tissue is a statistical process. An incident ray of light which consists 
of a packet of photons can be randomly reflected, refracted, scattered, absorbed or propagated 
without any change at the interfaces or interaction points in tissue where there is a variation in 
optical properties (scattering at membranes, absorbing in heme and melanin molecules, etc.). 
How much and how far certain photons will penetrate in tissue is governed by wavelength-
dependent optical properties.  
(a) Absorption in tissue 
There are many chromophores in tissue which absorb light via different mechanisms. For 
instance porphyrin and pyrrole molecules, heme and melanin cells absorb by electronic 
transitions via p-orbitals, water absorbs via vibrational states14. Absorption is defined by the 
effective cross-section of absorbing chromophores 𝜎𝑎,  [𝑐𝑚
2]15: 
𝜎𝑎 = 𝑄𝑎𝐴, Eq. 4.1 
where  A, 𝑐𝑚2 is the geometrical area of the chromophore, and 𝑄𝑎 is the absorption efficiency. 
The absorption coefficient 𝜇𝑎 for the bulk tissue is then calculated as: 
𝜇𝑎 =  𝜌𝑎  𝜎𝑎  [𝑐𝑚
−1] Eq. 4.2 
where 𝜌𝑎 is the density of chromophores in units of cm
-3. 
Light transmission 𝑇 through tissue with thickness equal to 𝐿, [𝑐𝑚] is defined by: 
𝑇 = 𝑒−𝜇𝑎𝐿 Eq. 4.3 
Total absorption in the skin is a sum from contributions from all chromophores16: 
𝜇𝑎(𝜆) = 𝑙𝑜𝑔10 ∑ 𝐶𝑖𝜀𝑖
𝑖
, 𝑐𝑚−1 Eq. 4.4 
where 𝐶, [mol/L or M] is the concentration and 𝜀, [cm-1M-1] is the extinction coefficient. Blood and 
water are one of the strongest chromophores in skin and considering that they are present in 
high concentration, they will typically dictate the overall absorption16: 
𝜇𝑎(𝜆) = 𝑓𝐻𝑏[𝑆 𝜇𝑎
𝑜𝑥𝑦𝐻𝑏(𝜆) +  (1 − 𝑆 )𝜇𝑎
𝑑𝑒𝑜𝑥𝑦𝐻𝑏(𝜆)] + 𝑊𝜇𝑎
𝑤𝑎𝑡𝑒𝑟(𝜆),  [𝑐𝑚−1], Eq. 4.5 
𝑓𝐻𝑏 - fraction of blood or haemoglobin concentration with units of g/L. 
𝑆 – tissue oxygen saturation (oxygenation fraction), 
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𝜇𝑎
𝑜𝑥𝑦𝐻𝑏(𝜆),  𝑐𝑚−1
𝐿
𝑔
 and 𝜇𝑎
𝑑𝑒𝑜𝑥𝑦𝐻𝑏(𝜆),  𝑐𝑚−1
𝐿
𝑔
 - wavelength-dependent absorption 
coefficients of oxygenated haemoglobin and deoxygenated haemoglobin,  
𝑊 - water content, 
𝜇𝑎
𝑤𝑎𝑡𝑒𝑟(𝜆) ,  𝑐𝑚−1
𝐿
𝑔
 - absorption coefficients of water. 
The absorption spectra have been measured by many groups and reviewed by Steven 
Jacques (Figure 4.3).  
 
Figure 4.3: Absorption properties of biological tissue. The figure was taken from Oregon 
Medical Laser Centre (OMLC) website17 
The resulting absorption of skin consists of the contribution of many chromophores. Skin 
is layered; each layer contains different chromophores. The concentration of the chromophores 
and the thickness of the layers vary between the individuals, body site and the skin types. This 
makes it very challenging to measure and model real absorption in skin. 
(b) Scattering in tissue 
Scattering in tissue occurs due to fluctuation of refractive index 𝑛 which mostly takes 
place at the interface of membranes of mitochondria, nuclei and cells, myosin protein and 
collagen fibrils, macromolecular aggregates, lysosomes and vesicles. Lipids are some of the 
strongest scatterers; they play the most significant role in defining the refractive index and 
scattering properties of tissue18. Similar to how absorption was described, scattering is defined 
by the effective cross-section of the scatterers19:  
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𝜎𝑠 = 𝑄𝑠𝐴, Eq. 4.6 
where  𝐴, [𝑐𝑚2] is the geometrical area of the scattering particle, 𝑄𝑎 is the scattering efficiency. 
When the size of the scatterers is comparable to the wavelength of the photon the 
scattering is described by Mie theory. When the scatterer is much smaller than the wavelength it 
is described by Rayleigh theory. 
The scattering coefficient 𝜇𝑠 is: 
𝜇𝑠 =  𝜌𝑠 𝜎𝑠 Eq. 4.7 
where 𝜌𝑠 is the density of scattering particles. 
The probability of light scattering at certain angles in tissue can be approximated by the 
Henyey-Greenstein angular dependence function20: 
𝑃(𝑐𝑜𝑠 𝜃) =
1
4𝜋
1 − 𝑔2
(1 + 𝑔2 − 2 𝑐𝑜𝑠 𝜃)
3
2⁄
 
Eq. 4.8 
𝜃 – the angle of the scattered ray with respect to the specular ray, 
 𝑔 – anisotropy parameter defined by the media; it varies from “-1” to “1”. “-1” 
corresponds to total backward scattering, “0” to isotropic (Rayleigh) scattering and “+1” to 
forward scattering. For biological tissue typical values are 0.7-0.9 which means that the tissue 
strongly scatters light in a forward direction.  
The integral of the probability density function is equal to one: 
∬ 𝑃(𝑐𝑜𝑠 𝜃) 𝑠𝑖𝑛 𝜃 ԁ
2𝜋𝜋
00
𝜃ԁ𝜑 = 1 
Eq. 4.9 
In some of the modelling algorithms reduced scattering coefficient 𝜇𝑠
′  is used instead of 
the regular scattering coefficient μs. Reduced scattering coefficient is calculated from the 
scattering coefficient 𝜇𝑠 and the 𝑔 parameter as
19: 
𝜇𝑠
′ =  𝜇𝑠(1 − 𝑔) Eq. 4.10 
There are many reported values for optical properties of tissue; the most up to date 
collection can be found in the Handbook of Biophotonics by V. Tuchin21. However, there is a 
huge variation among the values from different groups especially for the scattering coefficients, 
for instance there is an order of magnitude variation of the reduced scattering coefficient for both 
the brain and the skin tissue16. In [16] Steven Jacques et al. developed fit models for 
approximating and extracting a wavelength dependent reduced scattering coefficient using 
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experimental data from seven different groups for different types of tissues. They also presented 
a number of values for fit parameters to their model together with some values for the optical 
properties and examples of fitting curves for a few types of tissue cultures, the rest of the optical 
properties can be taken, for instance, from the Handbook of Biophotonics by V. Tuchin [21]. The 
fit model for the reduced scattering coefficient is16:  
μ𝑠
′ (𝜆) = 𝑎 (
𝜆
500 𝑛𝑚
)
−𝑏
, 𝑐𝑚−1, 
Eq. 4.11 
where 𝑎 and 𝑏 are fit parameters, λ is the wavelength. Scattering coefficient is calculated: 
μ𝑠 =
μ𝑠
′
1 − 𝑔
, 𝑐𝑚−1 
Eq. 4.12 
Later in the chapter there will be measurements and simulations presented for the skin 
and the brain at 840 nm and 633 nm. Here there is an example of the calculations of the 
reduced scattering coefficient which will be used in the simulations for brain white matter at 840 
nm. The fit parameters and 𝑔 value were taken from the paper [16] 𝑎𝑏𝑟𝑎𝑖𝑛 = 40.8,  𝑏𝑏𝑟𝑎𝑖𝑛 = 3.089, 
𝑔𝑏𝑟𝑎𝑖𝑛 =  0.8. From Eq. 4.11: μs
′ brain(λ) = 40.8 (
840
500 nm
)
−3.089
= 8.216, cm−1. From Eq. 4.12: 
μ𝑠
𝑏𝑟𝑎𝑖𝑛 =
0.8216 𝑚𝑚−1
1−0.8
= 4.108 𝑚𝑚−1.  
Transmission through 𝐿, 𝑐𝑚 path length of tissue can be calculated as: 
𝑇 = 𝑒−𝜇𝑠𝐿 Eq. 4.13 
Scattering in tissue is approximated by the Henyey-Greeinstein probability density 
function. Fortunately, there are many reports from different groups on measurements and 
modelling for combinations of scattering coefficients and the 𝑔 value of the probability function 
for different tissue cultures. Unfortunately, there are big differences among the reports. This can 
be explained by the variation of optical properties between subjects for the same tissue culture. 
S. Jacques developed an approximation based on the data from 8 groups which allows for 
calculations of wavelength dependent scattering properties for many types of human tissue and 
gives a more accurate prediction. 
(c) Monte Carlo approach for modelling light propagation through tissue 
The gold standard for modelling light propagation in tissue is the Monte Carlo algorithm. 
It was first introduced by Nicolas Metropolis and Ulam in 1949 for solving a class of 
mathematical problems which occurs in natural sciences and deals with a class of particles22. 
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The Monte Carlo approach was pioneered to describe light propagation in tissue by B Wilson 
and G Adam in 198323. And since then the method has been improved and widely used to 
describe light propagation at many wavelengths in many biological tissues by the pioneers in the 
field B. Wilson24, S. Prahl25,26 and S. Jacques,27, and others 28,29,30.  
The Monte Carlo algorithm records the history of photon packets as they travel through 
the tissue. Once a parent packet is launched at a source at (𝑥, 𝑦, 𝑧) position with initial power 𝑃 it 
is moved for a step ∆𝑠 (or ∆𝑠′ =
1
µ𝑡 
=
1
µ𝑎+µ𝑠
′   in cases when reduced scattering coefficient is used 
in the simulations). At the end of each step the energy of the parent ray can be split into child 
rays, the rays can be reflected, scattered, absorbed or transmitted. The probability for each 
scattering or absorption events is defined by the scattering and the absorption coefficients. New 
coordinates (x′, y′, z′)of the ray are calculated:  
𝑥′ = 𝑥 + 𝑐𝑜𝑠𝜃𝑥∆𝑠, 𝑦
′ = 𝑦 + 𝑐𝑜𝑠𝜃𝑦∆𝑠, 𝑧
′ = 𝑧 + 𝑐𝑜𝑠𝜃𝑧∆𝑠, Eq. 4.14 
where 𝑐𝑜𝑠𝜃𝑥 , 𝑐𝑜𝑠𝜃𝑦, 𝑐𝑜𝑠𝜃𝑧 are directional cosines which define the angle for the child ray after the 
parent ray underwent reflection, refraction or scattering. If the ray is absorbed or terminated the 
parameters (position and absorbed energy) are recorded and stored in ray history files for the 
analysis after the simulation has been completed. The ray is propagated many times until it 
escapes from the tissue, is absorbed or has an energy which is below the simulation threshold. 
In theory when the number of simulated events approaches infinity, light distribution (reflection, 
transmission, scattering and absorption profiles) will approach true values26. However for real 
simulations 1,000,000 generated rays with reasonable threshold energies for terminating 
propagation of the rays with low energy can predict light distribution in tissue with sufficient 
accuracy29,30.  
Monte Carlo modelling has been used as a tool to predict light propagation in tissue for 
sensing applications and to calculate light doses for treatment applications. Also in a 
combination with diffuse reflectance measurements regression Monte Carlo modelling allows for 
extraction of optical properties. Using real values of optical properties allows for more accurate 
modelling of light transport in tissue. 
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4.1.1 Optical phantoms and measurements for studying light 
propagation in skin and tissue 
Tissue phantoms emulate optical properties of tissue. They are commonly used for 
measurements to test proof-of-principle concepts, develop devices and validate theoretical 
models. There are many choices for fabricating phantoms. The most common ones are made of 
silicone, gelatine, gel, Intralipid, and water matrixes with addition of scattering, absorbing and 
fluorescent particles31,32,33. 
There are a few liquid and gel phantoms. For instance, water with milk is the simplest 
liquid phantom with scattering similar to tissue. Intralipid is another liquid phantom which 
intrinsically has scattering properties close to tissue. It can be mixed with blood which will 
provide a very good match to absorption in tissue. Fluorescence can be added by mixing up 
fluorescence compounds with Intralipid. Such liquid fluorescence suspension was used to test 
and calibrate fluorescence measurements devices for PDT34. Water, gel and gelatine are other 
possibilities for fabricating liquid and gel phantoms. 
The most common solid phantoms are made of silicone polymer which has a rubber-like 
texture, it is flexible, and can be moulded in any shape to represent body parts and organs33. So 
in addition to optical properties, silicone can mimic the natural shape of the body; it also to some 
extent matches mechanical properties of skin.  
Silicone is almost transparent in visible and near IR, it has a refractive index similar to 
some layers of the skin and brain tissue. Absorption or fluorescence can be added by mixing 
absorptive inks, dyes, or blood cells. Fluorescence can be incorporated by dissolving fluorescent 
agents in ethanol, methanol or DMSO solutions and mixing it up with the silicone. The solutions 
evaporate from silicone under a fume hood and the phantom is vulcanised over 72 hours33. 
The most common additives to mimic scattering in silicone (and also in gel and gelatine) 
are TiO2 and Al2O3 powders. The prediction of the ultimate scattering properties of the phantom 
is made based on the size, shape and volume percentage of alumina (or TiO2) powder in the 
phantom. However, the powders vary in particle size and shapes from manufacturer to 
manufacturer. Also, when mixed to the silicone the particles can form sediment and form 
aggregates. The aggregates of the particles will have different scattering cross-sections 
compared to individually dispersed particles. The most common sources of discrepancy between 
the predicted ultimate scattering properties of the phantoms and the real vales are: the size and 
shape of the particles, the aggregates, non-uniformly distributed particles in the phantom, 
sedimentation of the particles during vulcanization and air bubbles33.  
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Reported values for the scattering coefficient of the silicone phantom with alumina 
powder was in a range from 2.37 𝑚𝑚−1  to 3.73 𝑚𝑚−1. In [33] a phantom with 4% of alumina 
with 2.5 µm particles was predicted to have 𝑛 = 1.4,  μ𝑠 = 2.46 𝑚𝑚
−1, g = 0.88 at 633 nm. Study 
[29] reported that for the phantom with 1% alumina powder with 4 µm particles size the predicted 
anisotropy parameter was g = 0.89, reduced scattering coefficient was  μ𝑠 = 0.41𝑚𝑚
−1 (from 
Eq. 4.12 scattering coefficient is μs =
0.41 mm−1
1−0.89
= 3.73  mm−1), refractive index was confirmed 
with the elipsometry measurements and was equal to 1.41. After the regression modelling using 
a custom Monte Carlo program written in C programming language and fitting to the diffuse 
reflectance measurements at 660 nm the scattering coefficient was adjusted to  μ𝑠 =
2.37 𝑚𝑚−129. The size, the shape and the aggregation of the particles was not studied in that 
work. 
Optical properties of the silicone phantoms are representative of the optical properties of 
tissues, such as skin and brain. For instance μ𝑠
𝑝ℎ𝑎𝑛𝑡𝑜𝑚 = 2.46 𝑚𝑚−1 [33] compared to μ𝑠
𝑏𝑟𝑎𝑖𝑛 =
4.108 𝑚𝑚−1. μ𝑠
𝑏𝑟𝑎𝑖𝑛 was calculated using Eq. 4.11 and Eq. 4.12 on page 91. The refractive index 
of silicone was also matched to tissue, it is equal to 1.4 for the phatnom33 compared to 1.35 for 
the brain, 1.5 for epidermis, 1.31 for dermis21. Scattering coefficients in skin vary from layer to 
layer, typical values for μ𝑠
𝑠𝑘𝑖𝑛 range from 10 to 53 𝑚𝑚−1[V. Tuchin21].  
Silicone phantoms have optical properties which are close to biological tissue, the 
phantoms can incorporate absorbing, scattering and fluorescent particles, it can be used for 
years, it is not toxic, easy to handle, it does not degrade, and scattering particles do not 
sediment after the phantom solidifies; the only caution needed is to keep it clean as the surface 
is very susceptible to dirt and is difficult to clean when contaminated. Rubber-like texture allows 
for fabricating phantoms of any shape and using it in various types of optical measurements. 
The phantom is a good choice for optical measurements for PDT and OCT devices. 
(a) Diffuse reflectance and transmission measurements 
Optical properties can be measured and extracted from the data using regression Monte 
Carlo modelling34,35. Diffuse reflectance measurements is one of the most common types for 
both in-vivo and ex-vivo data collection. In this case the source and the detector are placed on 
the same surface; diffuse backscattering is measured as a function of distance between the 
source and the detector. The most common set up is based on optical fibres: the source is 
coupled to one fibre and the backscattered light is out-coupled to the detector’s fibre35. The read 
out of such measurements can be quite demanding due to weak and noisy signals, but the 
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advantage is that it allows for measuring of backscattering at very small distances which are only 
limited by the thickness of the fibres; measurements at small steps are important to extract 
optical properties from the modelling. Another possibility is to use an LED and photodetectors 
without coupling them into optical fibres 29,30. The level of measured signals increases which 
allows simplifying the read-out. However, this set up is limited to the step sizes by the size of the 
detectors and the LED.  
Another type of measurement which can only be used on phantoms or in ex-vivo 
experiments on tissue is transmission measurement. Optical power is measured as a function of 
thicknesses of the tissue or phantom placed between the source and the detector. The 
advantage of this mode is that the signals can be much higher and simple meters can be used 
for readout; this may allow direct power comparison between measurements and the modelling 
(for weak signals the power is typically normalised). The diagram on Figure 4.4 demonstrates 
the concepts for both types of measurements.  
 
Figure 4.4: Optical processes in tissue and measurements of diffuse reflectance and 
light transmission. 
Absorption and scattering in tissue, especially in skin are the most challenging optical 
properties to measure and model. There are many layers with the variation in thickness and 
concentration of chromophores and light scatterers between the individuals.   
There are custom made optical probes which can measure optical properties34,35. They 
are normally calibrated on a number of in-house made phantoms with different concentration of 
scatterers, absorbers and fluorophores. Monte Carlo modelling is used to simulate diffuse 
backscattering for many combinations of the properties and look-up tables are generated. These 
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look-up tables contain modelled values of the diffuse backscattering at distances together with a 
combination of optical properties which were used for this simulation run. The measurements 
are compared with the simulated values and the combination of the properties is taken from the 
best fit. The same method can be applied to characterise optical phantoms. In this case Monte 
Carlo simulations are done for one set of predicted properties. By trial and error the initial set of 
properties are adjusted until the simulated results are in the best agreement with the 
measurements. 
4.2 Methods 
4.2.1 Choice of optical software for light transport in tissue 
During the first year of the PhD project Zemax optical software was evaluated for the 
ability to model light transport in tissue. A library extension (Tissue.dll) was compiled in Visual 
C++ programming language and added to Zemax. Tissue.dll extension contained an 
implementation of Henyey-Greenstein scattering approximation and a Monte Carlo roulette 
algorithm. The simulations of diffuse reflectance in tissue phantom in Zemax agreed well with 
the previous Monte Carlo simulations in a custom C program29,36; Zemax results also agreed 
well with the following diffuse reflectance measurements. However, software called FRED 
v.12.107.0/14.40.0 from Photon Engineering was found to be more suitable for light transport in 
tissue. In this chapter only the results obtained with FRED will be discussed.  
FRED software is a ray tracing suit optimised for non-sequential biomedical applications. 
It has an intrinsic Monte Carlo ray tracing algorithm and a model of Henyey – Greenstein 
scattering volume. These two capabilities can be activated for ray tracing in tissue. In addition 
there is a small library of optical properties of human tissues taken from V. Tuchin Handbook of 
Biophotonics21.  
A description of how a random generator is set for Henyey – Greenstein angular 
probability function (Eq. 4.8) is available in FRED help documentation37. The substitutions are 
made to solve the integral in Eq. 4.9: 𝑥 =  cos 𝜃, ԁ𝑥 =  − sin 𝜃 ԁ 𝜃, 𝑎 = 1 + 𝑔2, 𝑏 = −2𝑔. The 
integral is manipulated: 𝑟 =  
1−𝑔2
2
∫
ԁ𝑥
(𝑎+𝑏𝑥)
3
2
cos 𝜃
1
, where 𝑟 is a random number in the range 
between 0 and 1. The solution of the last equation: cos θ = t +
t
2
(1 − t2), t =  
2r−1+g
1+g(2r−1)
. New 
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coordinates for the ray in Eq. 4.14 are calculated using the directional sines and cosines. When 
new material is created to describe tissue this model can be selected from a drop down list of 
scattering volumes; wavelength dependent absorption, scattering and 𝑔 values can be entered 
in dialog windows. 
Simulations are multi-threaded which increases the speed. One simulation of light 
distribution in a cubic tissue model with 10 cm3 size would take from a few seconds to a few 
minutes (for power of a source equal to 1 W with 1,000,000 rays randomly generated at the 
source and cut off energies equal to half the energy of a photon). Simulations are slower for a 
larger number of rays, more complicated geometries of optical components and tissue, larger 
number of objects and optical surfaces in the system, higher scattering in tissue and lower or 
zero absorption. Still, for the most computation intense simulation performed to simulate light 
transport in fibrous muscle tissue containing 1457 optical surfaces, 400,000 rays generated at 
the source, the simulation of light propagation in 121 x 101 x 21 mm3 scattering volume with 53 
mm-1 scattering coefficient was less than an hour (this work will be described in the next 
chapter). FRED system units are millimetres and Watts. So all the values for scattering and 
absorption coefficients will be converted and discussed in mm-1. However, the irradiance will be 
discussed in mW/cm2 as this unit is used by the medical community. 
Creating, changing and debugging optical designs are easy in a user-friendly graphical 
interface. Different analysis and visualisation tools allow for more flexible optimisation of the 
devices. 
The possibility of running Monte Carlo ray tracing, the Henyey-Greenstein scattering 
model, the library of optical properties of tissue, many analysis and optimisation tools, a friendly 
user interface and fast multithreaded simulations made this software the best choice for 
modelling of light transport in tissue and developing of the optical device for bio-medical 
application. 
4.2.2 Fabrication of optical phantoms 
(a) Solid silicone phantoms 
The protocol for fabricating silicone phantoms was adapted from33. Two parts, A and B of 
RHODORSIL RTV 141 silicone were used in a 1:10 ratio, 4% of alumina powder was thoroughly 
mixed to the polymer and left at room temperature to vulcanise. The phantoms normally 
vulcanise and develop resin-like texture after 72 hours. They can be moulded in any shape and 
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easily come off the mould after the silicone vulcanisation. A simple rectangular-shape phantom 
was made for diffuse reflectance measurements. 
(b) Absorption properties of silicone pigments and dyes 
Various inks from Silc Pig® Silicone Pigments (Smooth-On, Macungie USA) and Cirius 
Urethane Resin Dye (ArtMolds, Summit, NJ USA) were mixed with the silicone to explore the 
absorption properties with the view to potentially mix different dyes and pigments in the phantom 
to match the complex absorption spectrum of the skin. In order to place the phantoms in an 
absorption spectrometer, 1 mm thick phantom layers were prepared in a sandwich-like container 
formed from 1 mm thick microscope glass slides. When silicone vulcanises it does not stick to 
any of the surfaces but forms quite a tight contact as it pushes out all the air trapped at the 
interface with the container. It is easy to use a spatula to lift up and peel off the phantom from 
the container, but in the case of small tight containers such as a regular glass cuvette taking the 
phantom out would become a challenge without damaging the cuvette. So cheap disposable 
glass slides were used as phantom holders in the film holder of an absorption spectrometer. Two 
1/4 pieces of the glass slide were placed as side walls and two full glass slides were used as top 
and bottom base of the container. A few drops of the silicone mixture were dropped in the middle 
of the semi-open cavity, and then the phantom was covered from the top with another slide. The 
Silicone is viscous enough to stay in the cavity and vulcanise on the slides almost without 
leaking out from the two open sides. Different colour phantoms in the glass semi-open 
containers are shown in Figure 4.5, a. A LAMBDA 950 UV/Vis/NIR spectrometer was used to 
measure the absorption spectrum. A broad range of wavelengths from 400 nm up to 2 µm was 
investigated for potential use in many applications, including PDT, OCT and other devices. A 
glass container with air and also one with pure silicone were measured for the baseline. The 
absorption spectra are shown in Figure 4.5, b. 
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Figure 4.5: Absorption in phantoms using of Silicone dyes. a –.phantoms with the dyes. 
b –.absorption spectrums. 
Considering that there are many chromophores in skin with complex spectra (Figure 
4.3) the task of imitating the ultimate absorption in skin is quite challenging. Necessary ink or 
dye or a combination of them can be selected to meet specific measurement requirements. 
However, for the purposes of the work in this chapter the ultimate phantoms did not have any 
absorbers.  
(c) Incorporating PpIX fluorescence in silicone phantoms 
Fluorescent phantoms mentioned in the previous chapter for testing the fluorescence 
imaging camera were made by incorporating fluorescent powder of PpIX in a similar way to that 
mentioned in [33]. Protoporphyrin IX P8293 - ≥95% from SIGMA-ALDRICH was dissolved in 
methanol. The methanol solution of PpIX was mixed with alumina powder to provide a more 
uniform suspension of alumina particles and PpIX fluorophores. This suspension was then 
thoroughly mixed to the silicone polymer. Methanol evaporated under a fume hood and the 
silicone vulcanised after three days. If kept in the dark the phantoms retain their fluorescence 
properties for months.  
(d) Gel synthetic silicate Laponite® RD phantoms  
Gel scattering phantoms for depth-dependent transmission measurements were made of 
a Laponite® RD38 aqueous suspension. The protocol for this phantom was developed by Dr 
Mario Giardini, former research fellow at the School of Medicine, the University of St Andrews. In 
addition to the optical properties this phantom mimics the mechanical properties of the brain 
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which enables various opto-mechanical manipulations in a brain-like medium. Laponite® RD is a 
synthetic layered silicate which is insoluble but hydrates and swells in water to give clear and 
colourless colloidal dispersions39. It stays in gel phase for as long as the water does not 
evaporate. 3% of Laponite® RD was mixed with water and 4% of alumina powder. Gel-like 
phantoms were thoroughly mixed in a plastic container and left overnight to swell and jellify. 
Before the measurement the phantoms were mixed up again to obtain a uniform gel structure. 
Optical properties of this phantom were dictated by all the components. Laponite® does not 
absorb in visible and near IR, so the only absorber in IR was water40. The refractive index of 
Laponite® RD powder is 1.54, in water suspensions it changes depending on the concentration 
Laponite® RD and ambient temperature41,42,43. Due to the fact that only 3% of the powder was 
added in the phantom, the refractive index of the ultimate phantom was only slightly increased to 
1.35 compared to 1.33 refractive index of water (this value was not confirmed by 
measurements). Scattering properties of the phantom were the same as in silicone phantoms 
with alumina powder33,29 as the same quantities were added. 
Two types of phantoms - gel and solid - enabled measurements to be conducted inside 
phantoms and on the surface. Gel Laponite® RD phantom had similar mechanical and optical 
properties of brain; solid silicone phantom had a flexible resin-like texture similar to the 
mechanical properties of skin and was close in optical properties. It was demonstrated that these 
phantoms could be mixed with any combination of absorbers or fluorophores depending on the 
requirements of the measurement.  
4.2.3 Diffuse reflectance and optical transmission measurements in 
tissue phantoms 
Two modes of measurements (diffuse reflectance and transmission) were used to 
validate optical modelling and adjust the predicted properties of the phantoms to the real values. 
The diffuse reflectance set up consisted of two optical probes: an IR LED source was coupled to 
one fibre and another fibre was out coupled into a silicon detector which was connected to a 
lock-in amplifier. The voltage signal was measured and converted to optical power taking into 
account the response of the detector and the detector’s gain at 50 Ohm load:  
𝑃, 𝑊 =
𝑉 [𝑉𝑜𝑙𝑡𝑠]
50 [𝑂ℎ𝑚] ∙ 𝐺𝑎𝑖𝑛 
∙ 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 [
𝑊
𝐴
]. Eq. 4.15 
The power was normalised on the maxima for the comparison with modelling.  
4.2 Methods 
101 
 
A transmission measurement set up was built and the data collected by Phen Toh, from 
the School of Medicine, the University of St Andrews under the supervision of Dr Mario Giardini. 
It was based on an IR LED and photodiodes without optical fibres. The LED was emitting light 
directly onto the gel phantom and a series of photodiodes detected the power transmitted though 
the phantom. The signal levels were sufficiently high, there was no need to use any advanced 
sensitive noise reduction equipment such a lock-in amplifier. This allowed use of a simple 
multimeter as a readout to perform a direct power comparison with the modelling. Short circuit 
currents from Phen Toh’ measurements were converted to optical power using the response of 
the photodetectors:  
𝑃, 𝑊 = 𝐼  [𝐴] ∙ 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 [ 
𝑊
𝐴
]. Eq. 4.16 
Both transmission and diffuse reflectance measurements can be used to study light 
transport in tissue and extract optical properties in regression modelling. If the distance 
resolution is important then the detector and the light source could be coupled to optical fibres, 
this however significantly reduces the intensity of the signal and would require a more expensive 
readout. Another option is to use simple LEDs and photodetectors which will allow for detecting 
strong signals and could enable the use of real power values for the modelling 
. 
4.3 Results 
4.3.1 FRED software validation with the work of previous groups on 
Monte Carlo modelling and diffuse reflectance measurements 
The results of the predecessors using Monte Carlo simulations written in C programming 
language and diffuse reflectance measurements on silicone scattering phantoms are available in 
[30, page 57]. [30] follows the work described in [29]. The only difference between [30] and [29] 
was that the volume part of alumina powder in the phantoms was increased from 1% to 4%. The 
initial properties of the phantoms were assumed to be the same as in [29]: 𝑛 = 1.41,  μ𝑠 =
2.37 𝑚𝑚−1, g = 0.89,  μ𝑎 = 0 𝑚𝑚
−1. The measurements set up consisted of a 5 mm in diameter 
IR LED SFH 487 with 880 nm central wavelength and series of 0,265 x 0,265 cm2 BPW34 
silicone photodiodes placed at 6, 10, 15, 20, 25, 30 mm centre to centre distances from the 
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source. Due to the sizes of the LED and the photodiodes the smallest distance which could be 
resolved at the first step was 6 mm. 
An optical model equivalent to the one in [30] was created in FRED. A light source had 
880 nm central wavelength. The actual power was not important as only the normalised power 
comparison was reported in that work; so the LED power was set to 1 W. The phantom had the 
same refractive index and scattering properties 𝑛 = 1.41,  μ𝑠 = 2.37 𝑚𝑚
−1, g = 0.89; however, 
considering the absorption measurements of pure silicone (Figure 4.5), an absorption 
coefficient equal to  μ𝑎 = 0.0072 𝑚𝑚
−1 was added in FRED model. 1,000,000 rays were 
generated at the source. Ray tracing cut off energies were 10-19 W which was a little bit less than 
half of the energy of a 880 nm photon: 𝐸𝑝ℎ𝑜𝑡𝑜𝑛 =
ℎ𝑐
𝜆
=  2.25 ∙ 10−19 𝐽. Diffuse reflectance signals 
were calculated at the photodetectors placed at 6, 10, 15, 20, 25, 30 mm centre to centre 
distances from the LED.  
 
Figure 4.6: Absorption spectrum of pure RTV silicone phantom. It is almost transparent 
in the visible range and starts absorbing in near IR; at 840-880 nm the absorption coefficient is 
0.0072. 
FRED simulations agreed well with the results in [30] (Figure 4.8). 
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Figure 4.7: FRED validation on Monte Carlo simulations and diffuse reflectance 
measurements on silicone phantoms with alumina powder. The values for the comparison were 
taken from [30, page 57]. 
FRED fit to the diffuse reflectance measurement of the predecessors was even better 
than their original Monte Carlo modelling possibly due to the fact that in the FRED model the real 
value for absorption in silicone was taken into account. This gave confidence in using FRED for 
the further studies of light transport in tissue. 
4.3.2 Fibre optics diffuse reflectance measurement set up to study 
light propagation in solid tissue phantoms 
After the validation of FRED, the optical measurements apparatus was developed. The 
measurement set up was built using a SFH4740 IR LED with 860 nm central wavelength which 
was coupled in 1 mm in diameter core optical fibre with 2 mm in diameter cladding. Signals were 
collected by the same type of fibre and coupled to a PDA36A silicon photodetector which was 
then connected to a lock-in amplifier (Figure 4.8, a). Output power from the source fibre was 59 
µW. In order to have a distance reference between the source and the signal fibre a fibre spacer 
was cut from 6 mm thick PMMA plastic sheet using a CO2 laser cutter (CTR Lasers, UK) 
described in in chapter 2. An array of 2 mm in diameter (plus a small tolerance) holes at 2 mm 
centre to centre distances provided a 2 mm step between the source and the signal fibres. A 
sheet of beam blocking paper was placed between the phantom and the fibre spacer to prevent 
any feedback on the interface between PMMA plastic and the phantom. The detector was set to 
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70 dB mode at 50 Ohm load which corresponded to 2.38 MV/A detector’s gain. The response of 
the photodetector was 0.65 A/W. The integration time of the lock-in amplifier was 1 s. Voltage 
measurements were taken at 3, 7; 11; 15; 19; 23; 27 mm. Optical power was calculated from the 
voltage, the photodetector’s gain and the response using Eq. 4.15. The power was normalised at 
the maxima. The results can be found in Appendix XIX.  
The optical model was equivalent to the measurement set up: the source with 1 mm in 
diameter emission area and the detectors with 1 mm in diameter sensitive area were placed at 
3, 7; 11; 15; 19; 23; 27 mm centre to centre distances. The light divergence from the source and 
acceptance angle of the detectors was set to ±12.7° which was due to 0.22 NA of the optical 
fibres. The LED spectrum and the directional emission were imported from the manufacturers’ 
datasheets. The source and the detector fibre had a 1 µm gap from the phantom. The model is 
shown in Figure 4.8, b, c.  
 
Figure 4.8: Measurements and modelling of diffuse reflectance in scattering tissue 
phantom. a – measurements set up. Two optical fibres (one source fibre coupled to LED on 
aluminium heat sink and signal fibre coupled to a photodetector) were placed in the holes of the 
plastic fibre holder for distance reference. A sheet of black beam blocking paper was fixed with a 
duct tape to the fibre spacer and then it was placed on top of the phantom. b –.modelling of light 
scattering in the phantom, c – the arrangements of the source and the detectors in the model 
which corresponded to the arrangements in the measurement set up. 
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The initial properties of the phantom and ray tracing properties were set the same as in 
the validation tests described above. The simulation for the initial properties of the phantom did 
not have a very good fit to the measurements. This could be explained by the fact that the 
properties of alumina powder were not measured in this work - the scattering coefficient used 
was based on previous reports. The aggregation state, sedimentation and bubbles could be the 
other possible reason for the discrepancies. In order to adjust the initial scattering coefficient in 
the phantom to the real value, regression modelling was done and the best fit was found to be 
for the value equal to μ𝑠
𝑝ℎ𝑎𝑛𝑡𝑜𝑚 = 4.1 𝑚𝑚−1 (Figure 4.9).  
 
Figure 4.9: Light propagation in silicone phantoms. The powers are normalised on 
maxima. The scattering coefficient was adjusted after regression modelling from 2.37 mm-1 
predicted value to 4.1 mm-1 real value in the phantom.  
Fabricated and measured silicone phantoms, fibre optics set up and FRED modelling 
completed the development of the optical apparatus for design and testing of devices for PDT 
and other applications.  
4.3.3 Measurements in gel phantoms and FRED Monte Carlo 
modelling to study optical power transmission in brain 
FRED modelling was used to explore the possibility of powering a small portable robot 
implanted in a brain phantom from a solar panel using an IR LED. In addition to optimising the 
design of the solar panel, the aim of the modelling was to perform direct power comparisons with 
the measurements. The measurements were done by Toh Pheng Shiew under supervision of 
Mario Giardini and the description of the project can be found in the Bachelor of Science 
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(Honours) in Medicine thesis, 2013, candidate number 1002338. The measurements set up 
consisted of an SFH4740 LED, Laponite® RD gel scattering phantom and two types of solar 
panels made in-house. The solar panels were moved through the phantom; the optical power 
transmitted from the LED was detected with the solar panels. The panel was connected to a 
variable load and a multimeter. The aim of this measurement was to find an optimal load which 
for which the robot could generate maximum power from the LED. The project report38 describes 
the voltage measurements as a function of variable load and the calculations of the peak power. 
However, this method brings extra inaccuracies in power measurements, so for the aim of the 
simulations a direct short circuit current was provided and this can be found in Appendix XX. The 
power was calculated from this current and the response of the photodiodes using Eq. 4.16. 
The first solar panel consisted of six silicone BPW34 photodiodes with the response 
equal to 0.48 A/W and another one was made of four silicone SLSD-71N300 photodiodes with 
the response equal to 0.55 A/W (Figure 4.10). The solar panels were made on a rigid probe 
which was then immersed in the Laponite® RD gel phantom and moved with a 5-20 mm depth 
step. The depth step was measured with a calliper as a distance between the front panel of the 
probe and the front wall of the aluminium heat sink where the LED was fixed. 
 
Figure 4.10: Solar panels and measurement set up for power transmission in brain 
phantom. a – BPW x6 solar panel probe. b – SLSD x4 solar panel probe. c – depth 
dependence measurements in gel phantom. (The photographs were kindly provided by Toh 
Pheng Shiew, graduate of the School of Medicine, the University of St Andrews). 
The optical model of the setup is shown in Figure 4.11. . The LED power was set to 
0.685 W (the same power was used for the short circuit current measurements). The LED 
emission spectrum and directional diagram were imported from the datasheets.  
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Figure 4.11: FRED model of IR light transmission in scattering brain phantom 
The arrangements and the properties of the solar panels corresponded to the fabricated 
solar panels in the experiment. Six silicon BPW34 photodetectors were placed in two rows, three 
detectors in each. The spacing between the edges of the detectors in a row was 1.2 mm, the 
spacing between the edges of the top and bottom rows was 2.4 mm. The radiant sensitive area 
of each BPW34 photodiode was 2.74 mm x 2.74 mm = 7.5 mm2, and 45 mm2 for the whole solar 
panel.  
The second panel was made of one row of four silicon SLSD-71N300 photodiodes with a 
radiant sensitive area equal to 10.16 mm x 5.08 mm = 51.61 mm2 per one photodiode and 
206.45 mm2 per whole solar panel. The detectors were placed as close as possible - with 0.2 
mm spacing between the edges. From the datasheet for both photodiodes BPW34 and SLSD-
71N300 the acceptance angle was equal to 60°.  
The consideration for the optical properties of Laponite ® RD phantom were described in 
paragraph 4.2.2: 𝑛 = 1.35,  μ𝑠 = 4.1 𝑚𝑚
−1, g = 0.89,  μ𝑎 = 0.0039 𝑚𝑚
−1. 
1,000,000 rays were simulated at the source and propagated with the same ray tracing 
properties as in the previous simulations. Irradiance and total power at each photodetector was 
calculated using an irradiance detector from the analysis tools. The resulting power was 
summed from all the detectors and compared with the measurements (Figure 4.12), Appendix 
XX. 
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Figure 4.12: Absolute power comparison in brain phantom transmitted from an IR LED 
and measured by two solar panels BPW x6 and SLSD x4. The power on the right graph was 
normalised on the maxima. 
For the initial set of optical properties there was an acceptable agreement between the 
measurements and the modelling. There is a small discrepancy, but it is still a good fit 
considering all the sources of possible inaccuracies which could have introduced a much bigger 
mismatch. Such sources could be possible aggregation or sedimentation of alumina particles 
with time, formation of air bubbles in the phantoms, especially during the movements of the 
probe in the gel; the model did not take into account optical properties of the 1.57 mm thick walls 
of the plastic container where the phantom was kept or slight tilt. 
The simulations of the irradiance distribution at each photodiode in BPW x6 and SLSD x4 
solar panels submerged in brain phantom at 5 mm depth are shown in Figure 4.12 and Figure 
4.14. The results showed that the arrangement of photodiodes in SLSD x4 panel was more 
effective than in BPW x6. Regardless of strong diffusing properties of the phantom the 
transmission of optical power is still directional even at large distances. If the LED and solar 
panel are cantered with respect to each other then most of the power will be detected in the 
central region of the panel. Big gaps in the centre of BPW x6 result in missing most of the 
transmitted power and collecting it only at the edges. SLSD x4 has very good coverage of the 
central area. The edge detectors contribute seven times less in collecting optical power than the 
middle detectors. The design of the panel could be improved by reducing the area and removing 
the edge detectors without significant loss in the efficiency. 
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Figure 4.13: BPW x6 solar panel in brain phantom irradiated by SFH4740 IR LED. a – 
light propagation. b –irradiance on the detectors 5 mm deep in phantom. c – total power at each 
detector. Central detectors detect much more power indicating that the arrangements of the 
photodetectors with the respect to the light source is very important regardless of the light 
diffusion in the phantom. 
 
Figure 4.14: SLSD x4 solar panel in brain phantom irradiated by SFH4740 IR LED. a – 
light propagation. b –irradiance on the detectors 5 mm deep in phantom. c – total power at each 
detector. The design is very efficient in collecting optical power by well covered central area. 
Two edge photodetectors collect much less power and could be removed from the design 
reducing the size. 
These results gave the confidence in the capabilities of the software to model absolute 
powers and real optical components for light transport applications. Regression tests from the 
previous paragraph and direct power measurements in this paragraph established scattering 
properties in phantoms for 4% alumina powder.  
The modelling also helped to better understand the most efficient placement of the 
photodiodes in the solar panels for wireless power collection in the brain for the potential 
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application in implanted robots. Big gaps in the first solar panel BPWx6 particularly playing the 
role in the centre resulted in poor power collection; the second solar panel SLSDx4 had good 
coverage of the central area and was much more efficient. The size of the SLSDx4 panel could 
be reduced without adverse effects to the efficiency. One monolithic photodiode and 
coordination between positioning of the LED and the panel would be an optimal approach for 
this application.  
The solar panel SLSD x4 detected approximately 2% of the transmitted power in 30 mm 
brain phantom. For the current LED with the wireless charging power equal to 0.685 W the 
SLSD x4 solar panel was able to generate 12.6 mW.  
One of the examples of miniature robots of high importance to this project was reported 
in [44], where a robot was able to perform in vivo natural orifice surgery. The robot was powered 
through wires but the group was aiming for developing wireless powering. However, there was 
no information about the power consumption for the robot available. Another work which reports 
power consumption of a miniature robot was published in [45]. The robot was able to move with 
the speed equal to 40 mm/s and was controlled by IR signals. It had dimensions equal to 20 mm 
x 8 mm x 15 mm and was powered from a battery. The power consumption was equal to 6 mW. 
So by detecting 12.6 mW with the SLSD x4 solar panel from the wireless IR power transmitter 
the SFH4740 LED at 30 mm in depth of the brain phantom it would be possible to wirelessly 
power this robot deeper than 30 mm in the phantom. 
4.3.4 Modelling of Ambulight PDT device and an investigation of ways 
for potential improvements in the design 
Declaration of Interests 
Ambulight PDT is an ambulatory device for PDT developed and commercialised by 
Ambicare Health Ltd. a spin-out company of the University of St Andrews. The supervisor of this 
research project is one of the founders of Ambicare Health Ltd and one of the inventors of 
Ambulight PDT.  
 
This section aimed to address the following questions: 
 how uniform was the output illumination in the current device; 
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 would it be possible to reduce the number of LEDs in the array without significant 
loss of the optical output or having adverse effects on the uniformity of the light 
field; 
 how much diffusion in skin could help to equalise non-uniformities of the 
illumination;  
 could the skin itself provide enough diffusion to allow the diffusers to be 
completely removed from the design;  
 investigate the potential of OLED light sources for future Ambulight PDT devices. 
(a) Geometrical arrangements 
The optical model of Ambulight PDT corresponded as closely as possible to the real 
device. The current device has an emission area with the diameter equal to 30 mm and consists 
of an array of 42 Kingbright Hyper Red KPD-3224SEC-J3 LEDs with 640 nm central wavelength 
built on a hybrid flexible printed circuit board (PCB) and two paper-based diffusers. The PCB 
and the diffusers are placed in a semi-flexible plastic-resin casing. The coordinates of the LEDs 
in the array can be found in Appendix XXI; the arrangements are shown in Figure 4.15 in the 
optical model and in Figure 4.16 (a) in real device.  
 
Figure 4.15: Optical model of Ambulight PDT. The numbers and the coordinates of the 
LEDs in the array correspond to the schematics of Ambulight PDT device; the heights of the 
optical planes on z-axis were selected as close as possible to the real values (however, the 
device is flexible so the values should be treated with caution). 
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(b) LED properties 
Each LED has a 1.2 mm in diameter dome-shaped microlens and ±10° emission 
divergence. The spectrum and the directional emission were imported to FRED from the 
datasheet. The optical output in the datasheet was given in photometric units and had to be 
converted to radiometric quantities which were required to characterise light sources in FRED. 
The calculations are as follows46. 
𝑃𝑜𝑤𝑒𝑟 = 𝐼𝑟𝑟𝑎𝑑𝑖𝑎𝑛𝑐𝑒 ∙ 𝐴𝑟𝑒𝑎 
𝐴𝑟𝑒𝑎 =  𝜋 ∙ 𝑟2, 𝑚𝑚2  
𝐼𝑟𝑟𝑎𝑑𝑖𝑎𝑛𝑐𝑒 =
𝐿𝑢𝑚𝑖𝑛𝑎𝑛𝑐𝑒 ∙ 𝑆𝑜𝑙𝑖𝑑 𝑎𝑛𝑔𝑙𝑒
𝐸𝑦𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 ∙ 𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡
 
𝑆𝑜𝑙𝑖𝑑 𝑎𝑛𝑔𝑙𝑒 =  𝜋 ∙ 2 ∙ (1 − cos (
𝜋 ∙ 20°
180°
)) = 0.378 
𝐸𝑦𝑒 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 (𝑎𝑡 640 𝑛𝑚) = 0.185 47 
𝑀𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 = 638.002 
𝑙𝑚
𝑊
 
𝐵𝑟𝑖𝑔ℎ𝑡𝑛𝑒𝑠𝑠 (𝑎𝑡 20 𝑚𝐴) = 1 𝑐𝑑 (from the datasheet) 
𝐿𝑢𝑚𝑖𝑛𝑎𝑛𝑐𝑒 =  
𝐵𝑟𝑖𝑔ℎ𝑡𝑛𝑒𝑠𝑠
𝐴𝑟𝑒𝑎
=  
1 𝑐𝑑
𝜋 ∙ 0.00062𝑚𝑚2
= 884642,6044 
𝑐𝑑
𝑚2
 
𝐼𝑟𝑟𝑎𝑑𝑖𝑎𝑛𝑐𝑒 =
884642,6044 ∙ 0.378
0.185 ∙ 638.002
= 2835,751771
𝑊
𝑚2
 
𝑃𝑜𝑤𝑒𝑟 =  2835,751771  
𝑊
𝑚2
 ∙  𝜋 ∙ 0.00062𝑚𝑚2 = 3.2 𝑚𝑊 
(c) Ray tracing properties 
There were 22,500 rays from each LED, the total number of rays for 42 LEDs was 
945,000. Power apodization was according to the directional diagram. Average energy for each 
parent ray was 3.2 ∙ 10−3 𝑊/22500 = 1.42 ∙ 10−7 𝑊. The energy of the 640 nm red photon was 
3.1 ∙ 10−19 𝐽. So one ray consisted of 4.5 ∙ 1011 photons. Cut off energy for the ray tracing was 
3 ∙ 10−19 𝑊 which is less than the energy of one photon. One simulation run with these ray 
tracing parameters took about 30 seconds. 
(d) Diffusers’ properties and power output 
To guide the modelling, light emission from Ambulight PDT with and without diffusers 
was imaged with a colour digital camera and a monochromatic Lumenera 075 CCD camera with 
635±10 nm band pass filter (Figure 4.16). The diffusers in the device were placed with a very 
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small gap between them at 2 mm distance from the LEDs’ optical plane (Figure 4.15)..  
 
Figure 4.16: Ambulight PDT emission. a – an image of LED array without diffusers 
taken with a digital colour camera b, c – monochromatic images of the emission through one 
and two diffusers correspondingly. The images were taken with a CCD camera and red band 
pass filter. 
In the model the diffusers were set to diffuse 80 % of the light with Lambertian profile and had 
40% reflection. The distance from the second diffuser to the skin was 3 mm. According to the 
specification of Ambulight PDT the irradiance output at the surface of the skin is equal to 7 
mW/cm2. 
(e) Skin model 
The Skin model consisted of two layers: epidermis and dermis. Layers which follow after 
dermis are not treated with PDT and were not considered in the model. Typical thickness of 
epidermis varies from 50 µm to 1.5 mm, the thickness of dermis can be from 0.3 to 3 mm48. The 
thickness of epidermis was set to 200 µm in the model. The thickness of dermis was set to 4 mm 
for modelling purposes, but the results were analysed only up to 2 mm as PDT is only 
recommended for superficial lesions. 
Scattering coefficients for epidermis and dermis were calculated for 633 nm using Eq. 
4.11 and Eq. 4.12. The fit parameters were taken from [16]. For epidermis 𝑎𝑒𝑝𝑖 = 68.7, 𝑏𝑒𝑝𝑖 =
1.161, 𝑔𝑒𝑝𝑖 =  0.79, 𝑛𝑒𝑝𝑖 =  1.5, μ𝑎
𝑒𝑝𝑖 =  0.43 𝑚𝑚−1 and for the dermis 𝑎𝑑𝑒𝑟𝑚 = 45.3,  𝑏𝑑𝑒𝑟𝑚 =
1.292, 𝑔𝑑𝑒𝑟𝑚 =  0.75, 𝑛𝑑𝑒𝑟𝑚 =  1.31, μ𝑎
𝑑𝑒𝑟𝑚 =  0.27 𝑚𝑚−1 (𝑎𝑡 633 𝑛𝑚). Values for 𝑛, 𝑔, μ𝑎 were 
taken from V. Tuchin Handbook of Biophotonics21. Resulting scattering coefficients were found 
to be μ𝑠
𝑒𝑝𝑖 = 25.011 𝑚𝑚−1, μ𝑠
𝑑𝑒𝑟𝑚 = 16.7 𝑚𝑚−1 (633 𝑛𝑚).  
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(f) Detectors and data analysis 
An irradiance and a power flux detectors in the model were used to analyse the 
transmitted light. A 30 mm in diameter 2D irradiance detector had pixel resolution equal to 300 
µm x 300 µm. The power flux detector had the same diameter, but with higher voxels resolution, 
equal to 50 µm x 50 µm x 50 µm. The model of Ambulight PDT with the skin is shown in Figure 
4.17.  
 
Figure 4.17: Optical model of Ambulight PDT with skin. a – simulations of light 
propagation in skin from one LED (red rays) through the diffuser (blue rays). b – light influx at 
the power flux detector at 100 µm cross-section in epidermis. 
(g) Test simulations 
The test run of the simulations was done for calculating the irradiance at 1 µm from the 
LED (Figure 4.18). Average irradiance at each LED was equal to 0.0029 𝑊/𝑚𝑚2 and is shown 
on the cross-section of the irradiance simulations (Figure 4.18, b). Power was calculated from 
an emitting area of one LED with the diameter equal to 1.2 mm: P =  0.0029 𝑊/𝑚𝑚2  ∙
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((
1.2
2
)
2
∙ 3.14 mm2)  =  3.2 mW which corresponded to 3.2 mW defined at the start of the 
simulations. 
 
Figure 4.18: Simulations test. a – simulated irradiance at 1 µm distance from the LEDs’ 
array plane. b – 2D cross-section of the irradiance simulation at the centre of the third row from 
the top of the LEDs array.  
Output irradiance at the optical plane of the skin (epidermis layer) was 7.3  mW/cm2 
which corresponded to the specification of the Ambulight PDT device.  
(h) Uniformity of the illumination from Ambulight PDT and optimising the diffusers 
According to the modelling after the diffuser the minimum irradiance was 6 mW/cm2 and 
average was 7.3 mW/cm2 (Figure 4.19). If non-uniformity is estimated as 
 𝑛𝑜𝑛_𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =
𝑎𝑣𝑒𝑟𝑎𝑔𝑒 − 𝑚𝑖𝑛𝑖𝑚𝑢𝑚 
𝑎𝑣𝑒𝑟𝑎𝑔𝑒
 ∙ 100% 
Eq. 4.17 
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output irradiance of Ambulight PDT is 18 % non-uniform which is better than in conventional 
PDT lamps with non-uniformity up to 38 %49. 
 
Figure 4.19:Detector at 5 mm from the source after two diffusers in air. a – irradiance 
distribution. b, c – 1D irradiance cross sections along x- and y-axis correspondingly. 
However, considering that the gap between two diffusers is very small the contribution 
from the second diffuser at this small distance may be much less significant than increasing the 
distance to the skin. Irradiance was simulated at 7 mm distance for one diffuser. The results 
demonstrated improvements in irradiance even with one diffuser (Figure 4.20). 
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Figure 4.20: Optimisation of the position and number of diffusers in Ambuligth PDT. If 
the diffuser is placed 2 mm more from the skin, the diffusion is more uniform even with one 
diffuser. a – irradiance distribution. b, c – 1D irradiance cross section along x- and y-axis 
correspondingly. 
(i) Optimisation of number of LEDs 
In order to find the optimal number of LEDs and the best configuration in the array, LEDs 
were taken out one by one from different locations in different combinations and the change in 
the output irradiance and the uniformity of the illumination was analysed. The positions of the 
LEDs in the array are shown in Figure 4.15. Figure 4.21 shows two irradiance plots for two 
cases. The left plot shows an irradiance when four LEDs were removed from the central 
locations from the positions numbers were #25, #27, #23, and #24. The right plot shows 
irradiance for the case when four different LEDs were removed from the edge locations from the 
positions #9, #13, #4, and #16. The irradiance formed non-uniform spots in both cases which 
demonstrated that removing central and edges LEDs would result in adverse effects to the 
design. However, taking out LEDs from the position #2 and #21 did not introduce any non-
4.3 Results 
118 
 
iformity. At the furthest edges LEDs #23 and #24 did not change the uniformity either. So it was 
safe to remove LEDs from the positions #2, #21, #23 and #24. 
 
Figure 4.21: The effect of removing a few LEDs from Ambulight array. The numbers on 
the images followed by # correspond to the positions of LEDs (Figure 4.15) which were taken 
out from the array. The most dramatic effect was observed from taking out edge LEDs. 
Illumination at the edges could play a role in marginal tumour response failure, so regardless 
that the emission area is larger than the treated area, illumination at the edges should stay as 
uniform as possible.  
Figure 4.22 shows the drop of average and minimum irradiance as a function of 
reduced number of LEDs. Average irradiance was integrated over the area of 30 mm in the 
diameter of the irradiance detector. The distance from the LED array to the detector was 5 mm. 
There was a diffuser placed at 2 mm distance from the LED array. Minimum irradiance was 
calculated from the pixel(s) at the detector with minimal incident power and integrated over the 
area of the pixels. The dots on the graph correspond to the calculated output irradiance from the 
Ambulight model at the detector for the scenario when one LED from the position #1 was 
removed, then for the case when one LED from the position #2 was removed, and so on. The 
results showed that the average irradiance was not affected by removing up to four LEDs, hower 
there were large drops in the minimal irradiance. As it was demonstrated in Figure 4.12, some 
of the locations have a more pronounced contribution to the uniformity than the other. So care 
should be taken when changing the distribution of LED in the array.  
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Figure 4.22: Optimisation of number and position of LEDs in Ambulight PDT array. The 
numbers in the boxes correspond to the # of LEDs which were taken out of the array. 
The irradiance distribution, average and minimal values could help in making a decision 
about changing the number of LEDs and to identify the least significant LEDs in the array. 
Average irradiance was still above 7mW/cm2 for more than 38 LED in the array which means 
that four LED could be safely removed from the current design. 
(j) Can the design of Ambulight PDT benefit from light diffusion in the skin? 
The aim of the work in this paragraph was to investigate how much natural diffusing 
process in skin can equalize non-uniform illumination delivered from treatment light sources. If it 
was discovered that at shallow thicknesses of skin equal to 100-200 µm the skin can 
compensate large fluctuations in the illumination field, it would enable simplifying the 
requirement for the uniformity of the illumination field in the treatment light sources. The 
modelling in this paragraph aimed to investigate whether a 100-200 µm or 1 mm thick layers of 
the skin could diffuse the light enough to enable removing the diffusers from the current model of 
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Ambulight PDT. This simplification of the design would make the device cheaper and the 
fabrication processes easier. The approaches taken to study the diffusion in skin was by 
modelling light distribution form the Ambulight LED array without the diffusers on the surface of 
the skin, and in depth of the skin. Two cases were studied with thicknesses of the skin relevant 
for PDT treatment. The first case was focused to investigate the diffusion at 100 µm depth in 
epidermis which is the depth relevant to AK where malignant keratinocytes proliferate. The other 
case was to study the diffusion at 1 mm depth in skin which consisted of two layers, a 200 µm 
thick layer of epidermis and an 800 µm thick layer of dermis layers. The emission from the LED 
array was modelled in air first at distances equal to 5 mm from the LEDs (the distance to the 
surface of the skin), at 5.1 mm from the LEDs (the distance when a layer of 100 µm thick 
epidermis would be added to the model), and at 6 mm from the LEDs (the distance when a layer 
of 1 mm thick skin would be added in the model). Then the skin was added in the model and the 
simulations of light distribution were repeated for the previous distances, but now with the skin. 
The diffusion in skin was evaluated by calculating the emission spot size from the LED in air and 
the change in the spot size introduced by adding the skin in the model. The uniformity of the 
illumination was evaluated by the percentage difference between the minimal and average 
irradiance. The ultimate result of the modelling was to estimate the improvements of the 
uniformity of the illumination of the treatment light sources by adding the skin in the model. 
In this paragraph the first case with a 100 µm thick epidermis layer will be investigated. 
First the irradiance at 5 mm and 5.1 mm from the LED array was simulated in air and the 
emission spot size from one LED was calculated. The irradiance simulations at 5 mm distance 
from the LED array in air is show in Figure 4.23. The spot size of one LED at this distance was 
found to be 3 mm. It is interesting to note that the emission spot size diverged from 1.2 mm at 
zero distance (Figure 4.18) to 3 mm at 5 mm distance. This may be useful to keep in mind 
when designing the light sources, at sufficient distances to the skin the divergence from the LED 
light sources may eliminate the need to introduce any diffusive components.  
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Figure 4.23: Irradiance at 5 mm distance from the Ambulight LED array in air. a – 
irradiance distribution. b – 1D irradiance cross section along x-axis at the third row of LED form 
the top 
Then the irradiance was simulated at 5.1 mm distance in air and is shown in Figure 4.24. The 
emission spot size from one LED did not increase much compared to the previous simulations 
(Figure 4.23). The spot size was found to be approximately 3.12±10 mm. So additional 100 µm 
distance from the LED array in air expands the spot for only 0.12±10 mm. 
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Figure 4.24: Irradiance at 5.1 mm distance from the Ambulight LED array in air. a – 
irradiance distribution. b – 1D irradiance cross section along x-axis at the third row of LED form 
the top 
Then the skin was added to the model. Light propagation was simulated from the LED through 5 
mm air and a 100 µm thick layer of epidermis. The detector was placed at 5.1 mm distance and 
the irradiance simulations are shown in Figure 4.25. The emission spot size of one LED 
increased to 3.25±10 mm compared to 3.12±10 mm emission spot size the LED in air at this 
distance (Figure 4.24). So 100 µm of epidermis can only compensate non-uniformities in the 
illumination field by 4%. 
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Figure 4.25: Irradiance at 5.1 mm distance from the Ambulight LED array in 100 µm of 
epidermis. a – irradiance distribution. b – 1D irradiance cross section along x-axis at the third 
row of LED form the top 
Even light distribution at larger thicknesses is more clinically relevant though as the 
intensity of light is very high at the surface and small depths, so even lower intensity at the 
minimum of non-uniform spots will be enough to achieve clinical effect.  
The second case studied the irradiance uniformity at 1 mm in depth of skin which 
consisted of a 200 µm thick layer of epidermis and an 800 µm thick layer of dermis. Similarly to 
the previous case, the irradiance was simulated in air at 6 mm and the skin was added to the 
models; the irradiance was simulated at 6 mm distance with light propagation through 1 mm of 
the skin. The irradiance at 6 mm distance from the LED array in air is shown in Figure 4.26. 
The emission spot size from one LED at this distance was found to be 3.5 mm 
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Figure 4.26: Irradiance at 6 mm distance from the Ambulight LED array in air. a – 
irradiance distribution. b – 1D irradiance cross section along x-axis at the third row of LED form 
the top 
Then the skin was added to the model. The irradiance was simulated at 6 mm distance from the 
LED array, which means that the light propagated though a 200 µm thick layer of epidermis and 
an 800 µm thick layer of dermis. The irradiance distribution at 1 mm depth in the skin is shown in 
Figure 4.27. The emission spot size from one LED was found to be 10 mm. This means that 1 
mm of skin expanded the emission spot size from 3.5 mm at this distance in air (Figure 4.26) to 
10 mm. The expansion of the spot size was 𝛥𝑠𝑝𝑜𝑡𝑠𝑖𝑧𝑒 =
𝑠𝑝𝑜𝑡𝑠𝑖𝑧𝑒2−𝑠𝑝𝑜𝑡𝑠𝑖𝑧𝑒1
𝑠𝑝𝑜𝑡𝑠𝑖𝑧𝑒2
∙ 100% =
10−3.5
10
∙
100% = 65%.  
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Figure 4.27: Irradiance at 6 mm distance from the Ambulight LED array in 1 mm of the 
skin which consisted of a 200 µm thick layer of epidermis and followed by a 800 µm thick layer 
of dermis. a – irradiance distribution. b – 1D irradiance cross section along x-axis at the third 
row of LED form the top (@Y=6 mm).  
This demonstrates that the skin can substantially reduce non-uniformities but if non-
uniform areas are far away from each other, the field will still remain highly non-uniform. For the 
current 4 mm centre to centre average distance between the LEDs with 3.5 mm emission spot 
size this diffusion is not sufficient to equalise the field.  
The following simulations aimed to investigate how much the skin could compensate 
smaller non-uniformities. A few extra LEDs were added to the second row of the Ambulight LED 
array; the LEDs became denser in this row. The the LEDs in this row were placed at 2 mm 
distance from centre to centre with 0.8 mm separation between the edges of the LEDs. The 
irradiance simulation in the air is shown in Figure 4.28. The emission spot size from eacn LED 
in the second row overlapped decreasing the fluctuation of the emission. Non-uniformity of 
illumination in this row was calculated as a percentage difference between the minimal and 
average irradiance at the irradiance cross-section of the second row (Figure 4.28, (b)) and was 
found to be 𝑛𝑜𝑛_𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =
0.8−0.6
0.8
 ∙ 100% = 25 %. 25 % non-uniform illumination is already 
within an acceptable non-uniformity range (non-uniformity from the conventional PDT lamps is 
up to 38 %49). 
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Figure 4.28: Irradiance at 6 mm distance from the modified Ambulight LED array in air 
(the LEDs in the second row were placed denser). 
Then the skin was added to the model and the irradiance was simulated at 6 mm 
distance from the LEDs while light was propagated through 200 µm thick layer of epidermis and 
800 µm thick layer of dermis. The irradiance simulations are shown in Figure 4.29. The non-
uniformity was calculated in the same way as in the previous paragraph 𝑛𝑜𝑛_𝑢𝑛𝑖𝑓𝑜𝑟𝑚𝑖𝑡𝑦 =
0.52−0.45
0.52
 ∙ 100% = 15 % This means that the non-uniformity was reduced from 25 % in air 
(Figure 4.28) to 15 % in 1 mm of skin at the same distance.  
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Figure 4.29: Irradiance at 6 mm distance from the modified Ambulight LED array (the 
LEDs in the second row were placed denser) in 1 mm of the skin which consisted of a 200 µm 
thick layer of epidermis and followed by an 800 µm thick layer of dermis. a – irradiance 
distribution. b – 1D irradiance cross section along x-axis at the second row of the LEDs form the 
top. 
A small separation between the LEDs over 6 mm distance resulted in 25 % non-uniform 
illumination which is already better compared to the conventional PDT lamps. Light diffusion 
though a 1 mm thick layer of skin compensated this non-uniform illumination by 10 % bringing 
the ultimate non-uniformity down to only 15 %. Thin layers of skin such as a 100 µm thick layer 
of epidermis diffuses non-uniform illumination but can only compensate 4 % of non-uniformities. 
Diffusion in skin on its own is not sufficient to compensate large fluctuations in the illumination 
field and will not allow for removing the diffusers from Ambulight PDT devices. However, the 
design of the device can benefit from the divergence of the emission from each LED in the array 
if they are placed at sufficient distances and close to each other.  
(k) Potential of OLED light sources for a new generation of Ambulight PDT devices 
OLEDs are very promising candidates for future Ambulight PDT devices. They are thin, 
will not require complex PCB and clever design with the diffusers. The technology readiness is 
already at a substantial level to deliver stable devices in mass production. A test OLED device 
from a potential supplier was measured and characterised for potential application in Ambulight 
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PDT. The power measurements and directional emission can be found in Appendix XXII. The 
emission is very close to Lambertian. The emission spectrum is quite broad, half width at half 
maximum (HWHM) is from 590 nm to 675 nm with peak wavelength at 612 nm which would be 
perfectly suited for application in PDT treatment (in the guidance for PDT the spectrum of the 
light sources should be within 570-670 nm7,9,51). At 370 mA driving current the irradiance was 
11.7 mW/cm2 which, if necessary, leaves enough room to compensate for the irradiance to take 
into account the spectral difference in this OLED compared to Kingbright Hyper Red. Kingbright 
Hyper Red is better centred to PpIX absorption so in order to keep the same treatment protocol 
as in the current Ambulight PDT irradiance in the test OLED would have to be higher; however, 
the decision upon treatment protocols and the irradiance levels is always a call for biomedical 
physics experts. 
The test OLED model was created in FRED based on the measured spectrum, power 
and directional emission from the test devices. The irradiance at the surface of the skin is shown 
in Figure 4.30. It is very uniform in the central area; the intensity drops down beyond the circle 
with a diameter equal to 16 mm towards the edges of the LED because of Lambertian emission. 
So the size of the treated area should be compensated to take into account the intensity 
distribution.  
 
Figure 4.30: Simulations of OLED irradiance at the surface of the skin as an alternative 
light source for next generation of Ambulight PDT devices. 
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4.4 Discussion 
4.4.1 Can treatment devices benefit from forward scattering in skin 
and structured illumination? 
One interesting observation was made during the simulations and that is that the 
probability of rays backscattering and escaping from the skin is much higher for large incidence 
angles (Figure 4.31). Conversely if the incidence angles are normal to the skin the rays are 
much more likely to propagate further in the skin. This is obvious due to the forward-scattering 
nature of the skin. The question is how much more light is it possible to deliver when the 
incidence is structured to normal incidence. Our group achieved less than 15° directional 
emission from OLED devices by introducing gratings which make the emission close to laser-
like52. The investigation of the potential of such structured OLED devices will be described in the 
next chapter.  
 
Figure 4.31: Modelling of light propagation through layered skin. White circles indicate 
rays which penetrate very small distances and quickly backscatter from the skin. White dashed 
line highlights the region of smaller incidence angles; in this region there is less backscattering 
and more forward scattering which suggests that the structuring of light sources could favour 
better light penetration for PDT treatment 
. 
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4.5 Conclusions 
The optical apparatus developed in this chapter enabled modelling and measuring of light 
transport and optical properties of tissue phantoms. The modelling approach based on 
commercial software allowed for flexibility in manipulating different parameters of optical 
systems to improve the design and learn about light transport in different tissue types. In addition 
to similar optical properties, two types of phantom gel and solid had textures close to brain and 
skin which enabled testing the proof of concept devices. This modelling approach was used to 
optimise current ambulatory devices Ambulight PDT. Although Ambulight PDT already has good 
uniformity, the design could be more efficient. The modelling demonstrated that natural diffusion 
processes in the skin do not fully compensate non-uniform illumination from an LED array such 
as in the Ambulight PDT device. For instance, if the distance between non-uniform illumination 
spots is smaller than the size of the spots, then at 1 mm depth in skin the diffusion of light can 
lead to smoothing the non-uniform illumination for only 10-15 %. Therefore it is necessary to 
keep at least one diffuser after the LED array. Though, it is possible to improve the illumination 
field of the device by removing one diffuser from the current device (there are two in the current 
model) and increase the spacer distance between the diffuser and the LED array. .  
Another improvement would be to shorten the distance between the LEDs  to 2 mm from 
the current 4 mm which will result in 25% non-uniformity without any diffusers; 1 mm of skin will 
compensate it to 15%. In this design the diffuser could be removed from the device, but it will 
then be necessary to double the number of LEDs which on the other hand could be operated at 
lower current keeping the battery consumption at the same level. This would be an alternative 
solution for the design if the cost of placing the diffusers were larger than the cost of increasing 
the number of LEDs in the device – an unlikely scenario. 
Up to four LEDs can be removed from the array without a significant change to the 
average irradiance, and then the irradiance drops down below 7 mW/cm2. Care should be taken 
about the position, as by removing LEDs form the least dense areas or from the edges (#4, #9, 
#13, #16, #25, #27) there was a dramatic drop in minimum irradiance. So LEDs in the array 
should remain evenly spaced with taking care of good coverage at the edges. Drop of the 
intensities at the edges when LEDs are removed from these locations can be particularly 
dangerous as there is a possibility of misalignment of the device with respect to the treated area; 
this could lead to poor tumour response at the margins. 
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The test OLEDs were tested for potential application in future ambulatory devices and an 
optical model was developed based on the measured characteristics. According to the 
modelling, the OLED had less than 5 % non-uniformity of the illumination. However, due to 
Lambertian emission the size of the OLED has to be substantially bigger than the treated area 
as the intensity rapidly drops towards the edges. For instance for an area equal to 2 cm in 
diameter the OLED has to be at least 3.5 cm in diameter. However, being thin and flexible they 
would allow treatment of areas with large curvatures. This in addition to excellent light output 
makes them good candidates for light sources for Ambulatory PDT. 
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Chapter 5 
5 The potential of structured light sources for PDT 
There is strong shadow where there is much 
light. 
― Johann Wolfgang von Goethe, 
Götz von Berlichingen, Act I (1773) 
5.1 Introduction 
The three previous chapters covered the background of PDT treatment, investigated the 
metabolism of the drug and the development of low irradiance wearable light sources. Currently 
most non-laser based PDT light sources have a wide angle emission, close to Lambertian. Much 
attention was drawn to pulsing light, using coherent light or multiple wavelengths. This chapter 
presents a theoretical and an experimental investigation on how structured emission could 
improve light transmission in skin. It will explore the hypothesis that natural forward scattering 
processes in skin could provide better light transmission from collimated light sources compared 
to the wide emitting angles light sources.  
5.1.1 Current attempts to structure light for optimising light 
penetration in devices for PDT 
There have been many attempts to improve PDT outcomes by optimising light delivery. It 
is clear that red light penetrates deeper than blue which is preferential for treating deeper 
lesions; blue light is only used for treating superficial lesions such as AK1. Also it was 
established that different irradiances play a role in tumour response; lower irradiances give a 
better outcome2,3. The situation is less clear about coherence and pulsed regimes.  
There is a report which suggests that when coherent laser light penetrates through tissue 
it does not completely lose its coherence as would be expected in highly scattering tissue; the 
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coherence is weakened but still present4. After a few millimetres in tissue coherent light forms 
speckles which supposedly improves biological responses to the treatment light4. In cell studies 
for PDT there is a report which shows that non-coherent compared to coherent light sources 
resulted in better phototoxic effect in L9 cells cultures with a photosensitizer5. Also there is a 
clinical repot which did not show any difference in PDT treatment outcomes using coherent 
compared to non-coherent light sources6.  
The situation is similar for pulsed light. Some reports show evidence that a pulsed regime 
is  less painful and results in complete lesion response7. But others report that continuous wave 
light sources give better outcomes8. There is a report which suggests that sequential pulses of 
blue and red wavelength give the best outcome9.  
The previous chapter gave a hint that structuring the emission could be beneficial for 
improving the penetration of the treatment light and set a scene to investigate the potential 
improvements of light propagation from directional light sources compared to broad Lambertian 
emitters. Forward scattering in skin suggests that if light is incident at normal angles it will 
penetrate further. Conversely there should be a bigger chance of light backscattering from the 
skin if the angle of incidence is large. It was demonstrated in our group that it is possible to 
achieve a narrow directional surface emission from OLEDs light sources10 which means that the 
incident angles from such light sources can be very small, less than 15°. If the hypothesis that 
directionality could provide substantial improvement in light propagation in skin is true, it will 
make directional OLEDs excellent candidates for a new generation of structured light sources for 
PDT treatment.  
The hypothesis was first evaluated by modelling and this was followed an experimental 
investigation. Although phantoms have representative properties of tissue and are commonly 
used to test devices, they do not fully mimic the complex layered structure of skin. In order to 
demonstrate clinically significant differences in the performance of one light source compared to 
the other, the results have to be obtained from real skin samples. One of the possible options 
which were considered for the experiment was chicken skin; however it is too thin, at 
approximately 0.5 mm, and would not allow for depth-dependent measurements. Porcine skin is 
thick enough for the measurements and is the closest analogue to human skin.  
Pig skin has been commonly used by pharmaceutical, biomedical and aesthetics 
communities. Goettingen mini pig skin was used in a drug study for pre-clinical assessment of 
Ameluz gel11. Another drug study used pig skin to demonstrate improvements in PpIX formation 
by applying a microneedle array for better penetration of ALA-precursor12. Pig skin was used for 
optical clearing for tattoo removal13, for sun screen lotion studies14, for measuring a change in 
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temperature induced by IR radiation for wound healing15,16, and for wireless power transmission 
of millimetre wavelength17. So measurement results on porcine skin have credibility in the 
medical and bio-engineering community. That is why it was identified as a good candidate for 
the measurements.  
For the purpose of modelling and measurements in this chapter, the data on optical 
properties and transmission of porcine skin were investigated in the literature. A small list of 
optical properties of porcine skin is reported by S. Chung et al (2011)18. Results on optical 
measurements in porcine skin were only available from few groups where they used different 
skin (piglet and pigs), different wavelength ranges and set ups. The results varied between 
groups: and the groups even reported big variations in the properties within their own 
measurements.  
Du et al19 measured optical properties in the range of 700 nm to 1500 nm using an 
integrating sphere for diffuse reflectance; a spatial filtering set up for measuring collimated 
transmittance; and reverse Monte Carlo calculations to extract the measured optical properties. 
They also studied the cellular change by microscopy imaging when the samples were stored at 
room temperature and in ice buckets. There was moderate change in optical properties stored at 
room temperatures compared to stable measurements when the samples were stored in ice 
buckets over 30 hours. They explain the change of optical properties due to cellular rupture and 
loss of water. The same results are reported by S. Firdous et al (2005)20. Scattering and 
absorption coefficients were lower for dry samples. 
Beek et al21 measured optical properties of piglet skin in the range from 630 to 1064 nm. 
They used two integrating spheres with the sample in between the spheres, one integrating 
sphere measured diffuse reflectance and the other transmittance at 630, 632.8, 790, 850 and 
1064 nm. An inverse adding–doubling algorithm was used for extracting properties from the 
measurements. They report reproducible, but hugely different results when different skin 
samples or slightly different lasers were used (argon dye pumped laser at 630 nm compared to 
HeNe laser at 632.8 nm). 
In this chapter optical properties were taken for porcine skin from Ma et al22 as they 
reported the data for the most appealing wavelength for PDT, 633 nm and adult pigs’ skin. They 
used an integrating sphere for measuring diffuse reflectance and collimated transmittance; and 
inverse Monte Carlo calculations. For the study in this chapter there was no interest in 
measuring absolute power transmission or reflectance of pork skin, neither was there intention to 
study optical properties (although regression Monte Carlo modelling was used to adjust the initial 
properties closer to the real values). 
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This chapter was aiming to model and build an experiment to investigate whether there 
was a difference between light transmission of directional light sources and wide angle light 
sources through the skin which could be useful to the medical community. 
5.2 Methods 
5.2.1 Optical modelling  
The same modelling approach was used as described in the previous chapter. The 
model was developed in FRED software and the optical properties of pork skin were taken from 
the literature. 
5.2.2 Fabrication of organic films 
Organic films were fabricated by Dr Ashu Bansal and Dr Guohua Xie. . Two identical 
organic films were fabricated on 25 mm x 25 mm glass substrates. One of the films had 5 
gratings of 3 mm x 3 mm size. The gratings provided directional emission. The other film was 
made of the same emitting material but on a substrate without the gratings. Gratings were 
nanoimprinted on the substrates by UV-Nanoimprint lithography (UV-NIL) process. The Super 
Yellow polymer was spin-coated from a Chlorobenzene solution on both substrates, with and 
without the gratings. The solution concentration was 7.5 mg/ml. The spin-coating speed was 
2000 rpm. The thicknesses of the films was 100 nm. 
UV-Nanoimprint lithography (UV-NIL)23 is used to nanopatterned films using a 
perfluoropolyether soft stamp. The soft stamps (MD700 (Solvay)) were cast on silicon master 
gratings (patterned by e-beam lithography and reactive ion etching), and hardened by ultraviolet 
curing. Before transferring a thick layer of perfluoropolyether(PFPE)-urethane dimethacrylate 
(Fluorolink MD700) as a compliant material onto a clean and bare silicon substrate, an adhesive 
layer (3-Trimethoxysilyl)propyl acrylate (Sigma-Aldrich) was spin-coated directly onto the glass 
substrate after oxygen plasma treatment. Another layer of MD700 was spin-coated on the glass 
substrate after UV exposure for 220 seconds. Through the second UV exposure, the 1D grating 
patterns with a period of 350 nm on a Si master were transferred onto this glass substrate 
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(daughter stamp) by adding some droplets of perfluoroalkylpolyether (Fluorolink MD500) mixed 
with 1-2% of the photo initiator DURACOUR (Sigma-Aldrich).  
The daughter stamp was used as a mould for replicating the grating structures onto a 
photoresist (Micro Resist Technology UVCur06) which was spin-coated atop another bare glass 
substrate with an additional adhesion promoter (Micro Resist Technology mr-APS1). The UV 
nanoimprint lithography (UV-NIL) processes were performed using an EVG®620 automated 
mask alignment system. 
The films had a broad emission spectrum with from 520 to 700 nm24. The directional 
emission from the films was measured by an in-house built set up for angular dependent 
measurement. The film was fixed in a holder and an optical fibre connected to a photodetector 
was moved with an angle step to measure the angular emission. Full width at half maximum 
(FWHM) of the directional emission of the film with the grating was found to be less than 15°, the 
same as was reported for the directional OLED devices10. The film without the grating had 
Lambertian emission. The films were stable; there was no drop in the intensity during the 
experiment. 
5.2.3 Porcine skin samples preparation  
Fresh pork skin was kindly provided by Minick of St Andrews butchers shop. Dehaired by 
hot the water method25 skin samples were collected post-mortem. The skin had to stay fresh as 
freezing ruptures the cells, the content leaks out and this results in change to optical properties. 
Unfortunately, the only option to dissect the skin was by using a surgical scalpel and trying to 
achieve dissections as uniform as possible.  
A special protocol was developed to dissect the skin and protect it from drying. Fresh 
skin tissue was collected from the butchers shop early in the morning. The samples were 
prepared and the measurements taken during 8-10 hours on the same day There was no 
storage protocol followed. The samples were disposed of after the experiment. The skin was 
handled at the ambient temperature of an optical laboratory at the Department. The skin was 
kept covered all the time in clean kitchen film between the manipulations. The skin was 
dissected in 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5 mm layers parallel to the skin surface (to keep the 
layered structure). The thickness of the skin was measured by placing the skin dissections 
between the legs of a digital calliper and sliding the calliper along the sample without introducing 
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any pressure or stretch. An averaging protocol for the transmission measurements was used to 
compensate for any non-uniformities in the skin and tolerances of the dissections. 
It is a known fact that skin has variation in optical properties among subjects, including 
which side of the animal is chosen, in-vivo or ex-vivo samples; also any skin processing such as 
dehairing or exposing postmortem skin samples to air changes the skin properties. In order to 
keep the variation to a minimum, small slices of the skin of the same animal from the same side 
of the animal were dissected for one experiment.  
In order to provide stable measurements the change in optical properties during the time 
of the experiment was studied. The samples were exposed to air for a short period of time for 
one measurement (less than a minute) and covered in kitchen film between the measurements; 
even with this protocol the optical properties were changing as the skin was drying out.  
A special protocol was developed to protect dissected porcine skin samples from drying 
and losing thier optical properties. The skin was placed in AQUASONIC® 100 ultrasound gel 
which is used for medical ultrasound scans. After one dissection had been finished it was 
covered with the gel and sandwiched in two standard 1 mm thick microscope glass slides 
(Figure 5.1). Care was taken to avoid formation of air bubbles. Nonetheless, any present 
bubbles were visible on the camera during the imaging of light transmission; and this area was 
avoided.  
 
Figure 5.1: Skin samples in hydrogel 
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5.2.4 Image analysis 
The transmission images were analysed in Matlab. It was used to outline the emission 
profiles of the light sources and use their contours for the integration of the intensity in the 
transmission measurements; and perform any other manipulations with the data such as 
averaging, removing autofluorescence background and normalising the transmission. 
5.3 Results 
5.3.1 Theoretical investigation: how much can directional emission 
improve light propagation in skin? 
The optical model for simulating depth dependent light transmission of structured 
illumination though porcine skin is shown in Figure 5.2. It was very straightforward and 
consisted of a surface emitting light source, a layer of porcine skin and an irradiance detector. 
The optical properties of porcine skin were taken from the Handbook of Biomedical optics 
(Edited by David A. Boas, 2011), p. 78, Tabl. 5.1 “Optical Properties of Human and animal skin 
and subcutaneous tissue measured in vivo and in vitro”18, from the group of Ma et. all, the 
original work was published in [22]. They were as follows: 𝑛 = 1.35,  µ𝑠 = 5.8 𝑚𝑚
−1, g =
0.72,  µ𝑎 = 0.07 𝑚𝑚
−1 for 633 nm wavelength. The thicknesses of the skin were 1.0, 1.5, 2.0, 2.5 
mm which are the most relevant thicknesses for PDT treatment.  
The light source had properties equivalent to the intended properties of the light emitting 
organic films and lasers. However, the simulations were performed for one wavelength and 
perfectly collimated light. The consideration for the wavelength included the consideration for the 
emission spectrum of the organic films, the laser, the availability of reported optical properties of 
porcine skin and the relevance to PDT treatment. The emission spectrum of the organic 
semiconductor films was wide from 530 to 700 nm. The intended laser was a HeNe laser with a 
spectral line at 632.8 nm. The reported optical properties of the porcine skin were measured at 
633 nm. This wavelength is the most relevant for PDT treatment and was chosen for the 
modelling. In addition there were other choices for light sources at this wavelength or very close 
to it.  
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Figure 5.2: Modelling of light transmission trough porcine skin 
One of the light sources had collimated emission and another one had Lambertian 
emission. The surface of the skin in the optical model was perfectly flat. The other parameters 
for both of them were identical. The light sources were 3 mm in diameter and were placed at a 
small gap equal to 1 µm from the skin for the purpose of modelling and the power was set to 1 
W (the results were normalised so the actual power was not important for this simulation). The 
transmitted power was measured at an irradiance detector with the diameter equal to 2 mm. The 
detector was smaller than the light source to avoid arguable results at the edges; only the central 
area was used for the comparison where the intensity profile of the two light sources does not 
change much but only the directionality of emission is different. The results were normalised to 
the input power at the front side of the skin sample (Figure 5.3).  
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Figure 5.3: Simulation results of light transmission in porcine skin from directional and 
Lambertian emittance light sources. 
The results of the modelling showed more than 10 % improvement in light transmission 
for 633 nm wavelength through the porcine skin from the directional light sources. This gave the 
motivation to proceed with the measurements. 
5.3.2 In-vitro transmission measurements of structured light from 
organic light emitting films through porcine skin 
The first experimental set up was built to study the transmission of light emitted by the 
organic films. The emission from one of the organic films was structured by the grating to 
provide narrow angle emission. The other film was made of the same active material but without 
the gratings. The films were encapsulated to prevent degradation in air. The films were pumped 
using a 393 nm Picoquant laser with a stripe laser profile driven by a PDL800 laser driver. The 
beam was expanded using a defocusing lens to provide a larger beam spot for the excitation; 
the larger study area would give better accuracy during the image analysis. The pump beam 
was spatially filtered through an aperture to pump only the area corresponding to the size of the 
grating. The area outside of the grating was also emissive. The active material was spin-coated 
on the whole substrate. The gratings were fabricated only on five small 3x3 mm patches on the 
substrate. So the whole substrate was emissive, but only those five areas with the gratings had 
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directional emission, the rest of the area had Lambertian emission. The pumping of this area 
(the area outside of the gratings with Lambertian emission) was avoided to prevent wide angle 
emission from the area outside the grating adding up to the directional emission from the area 
with the grating. That would reduce the directionality of the emission from the films with the 
gratings and potentially would make the expected improvements in transmission less 
distinguishable. A monochromatic Lumenera LM075 CCD camera with a wide angle TV lens and 
adjustable focal length was used for the measurements. The emission from the films was 
imaged before and after each experiment to ensure that the films did not degrade. A 530 nm 
long pass filter was used to cut off the excitation and was placed before the camera lens. The 
measurement set up is shown on Figure 5.4.  
 
Figure 5.4: Measurements set up using organic films. The camera with a M118FM08 
lens with an adjustable aperture and a focal length was on one optical axis with the filter, the 
sample plane and the organic film. The laser path was incident under a small angle on the 
organic films to avoid the lens of the camera. The excitation angle for the organic films was not 
critical in this experiment. The laser profile was diagnosed once when the camera was placed on 
one axis with the laser and then for the rest of the measurements the camera was moved to the 
axis of the films. The distance between the organic film and the camera lens was approximately 
40 mm; the length of the camera lens was 27 mm. The diameter of the optics used in the set up 
was 25 mm; the viewing angle of the lens was 50.8 x 38.6°; the lens aperture was set to 1.4. 
Defocusing lens in the laser path was used to expand the beam to excite the whole area of the 
grating in the directional organic light emitting film. The aperture in the laser path was used to 
match the size of the pump beam to the size of the grating. 
The laser profile and the calibration of the pixel size of the camera are shown in Figure 
5.5. 
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Figure 5.5: An image of the pump laser beam profile at the sample plane with fully open 
aperture. The long pass filter was removed from the set up and the camera was placed on one 
optical axis with the laser path. The camera was moved back to the sample plane axis and the 
ruler at the sample plane was imaged to calibrate the size of the pixel at the working distance. 
The organic light emitting films were placed after the aperture. The skin samples were 
put in contact with the organic films. In the first experiment when the skin was exposed to air, the 
skin was placed directly on the glass substrate of the film. The skin was greasy and sticky which 
formed a good contact with the film substrate; there was no need to use any additional fixation. 
The films were encapsulated so the active layer stayed protected from any contamination. The 
skin samples were covered in kitchen film between the measurements; one measurement took 
up to one minute.  
In all measurements the skin which consists of epidermis as the top layer and dermis as 
the bottom was oriented such that the epidermis was facing the light source and the dermis was 
facing the detector, as would be the case during PDT.  
Due to the fact that the UV and blue light excite autofluorescence in skin which has a 
broad spectrum in the green part and that could have had an effect on the red transmission 
measurements, the first measurement was an autofluorescence measurement. The film was 
replaced by an empty glass slide and the autofluorescence signal was imaged at six positions on 
each sample. After each position the sample was randomly shifted for a few millimetres in x-y 
directions. The ultimate result was averaged. This allowed for compensating any non-
uniformities in skin. The autofluorescence signal was compensated in the transmission 
measurements for each thickness of the skin samples. 
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After the autofluorescence measurements the organic film was placed in the set up and 
the camera was then focused to image the film’s emission to normalise the transmission 
measurements. The intensity on the transmission images was analysed in Matlab. A circular 
area with 2 mm diameter (which is less than the size of the 3 mm x 3 mm grating) was selected 
for the analysis. The circle was positioned in Matlab Image Processing Toolbox to fit in the 
middle of the grating. The central position of the circle was defined and saved in a Matlab file for 
further image analysis. The film was fixed at the same spot during the experiment, so the same 
pixel coordinates of the circle were used for all images. The intensity was integrated over the 
area of the circle.  
Then the skin was fixed at the film substrate and transmission measurements were taken 
in the same fashion as autofluorescence measurements: for six random positions on the skin 
sample and the results were averaged.  
Autofluorescence was subtracted from the transmission images; the result was 
normalised on the film emission.  
As the experiment was conducted in air, the change in optical properties was monitored 
over 3.5 hours. Thinner samples were losing water quicker and the transmission was increasing 
more rapidly. The change in optical properties for a 1 mm thick skin sample is shown in Figure 
5.6. The transmission increased up to 6%. The previous reports also observed increased 
transmission when the skin was drying out18,20.  
 
Figure 5.6: Change in optical properties of porcine skin when it is exposed to air 
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During the second experiment when the skin was placed in gel and was sandwiched in 
between the microscope glass slides, the sample glass slide was put in contact with the organic 
film. In order to keep the organic film fixed at the same position during the whole experiment and 
place the sample in contact with the film, a tiny amount of the ultrasonic gel was put at the 
surface of the film. The gel kept the sample glass slide sticking to the organic film. The same 
measurement protocol and image analysis were applied:  
 autofluorescence was imaged first for the six positions on the skin,  
 the film was placed in the set up 
 the emission profile of the film was imaged,  
 the transmission measurements for six positions on the skin were taken 
 the emission of the film was imaged to monitor stability of the film 
 the film was replaced by the other one,  
 the emission of this film was imaged  
 the transmission measurements for six positions on the skin were taken.  
 the emission from this film was imaged for stability purposes 
 a contour (the circle with 2 mm diameter) was selected to match the centre of the 
grating, the coordinates of the centre pixel were saved in a Matlab file for the 
analysis of all images 
 the intensity was integrated over this contour in all images 
 the results were averaged for 6 positions of one sample thickness 
 autofluorescence was subtracted from the measurements 
 the ultimate transmission was normalised on the films’ emission profile 
An example of the images: the emission profiles of the films and the transmission 
measurements through 0.5 mm skin are shown in Figure 5.7. 
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Figure 5.7: Light transmission through porcine skin on false colour scale from wide 
emitting angle and directional emittance organic films 
The simulations were repeated for the defined thicknesses of the dissected skin, the 
emission spectrum and the 15° FWHM angular emission of the Super Yellow polymer films. The 
simulations are shown in Figure 5.8. Super Yellow polymer has a peak emission wavelength at 
580 nm. For this wavelength, the angular range and this porcine skin model the expected 
improvement was up to 6 % (porcine skin properties were 𝑛 = 1.35,  µ𝑠 = 5.8 𝑚𝑚
−1, g =
0.72,  µ𝑎 = 0.07 𝑚𝑚
−1 22). Human skin has more forward scattering than the porcine skin, so it 
was expected that the directional light sources would have a more pronounced effect on the 
improvement in the light transmission.  
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Figure 5.8: Expected light transmission through porcine skin from directional and 
Lambertian organic light emitting films 
Both the measurements and the simulations are shown in Figure 5.9. 
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Figure 5.9: Simulations and measurements of light transmission in porcine skin from 
wide angle and directional light sources 
These results did not show that directionality can improve light penetration in skin. 
Regression modelling attempted to adjust optical properties of the skin to have a better fit to the 
measurements. The initial properties of the skin gave better agreement at small depths. At larger 
depths increased forward scattering and reduced absorption were in better agreement. This 
could be explained by the fact that the skin is layered; porcine skin has a substantial amount of 
fatty tissue in deeper layers which is less absorptive and more scattering. At 1.5-2 mm there 
seemed to be a different angle in the measured transmission curve, in the skin samples with the 
thickness starting from 1.5 mm the amount of adipose fat increased substantially. So a better 
theoretical fit for less scattering and more absorption at shallow layers, and a better fit for more 
scattering and less absorption at deeper layers could be explained and modelled by layered 
tissue with different properties and thicknesses. However, the fact that the measurement 
demonstrated better transmission for Lambertian light sources in contrast to the modelling could 
not be explained by the discrepancies in real and initial optical properties or layered structure of 
the skin.  
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One of the potential explanations of why the measurement did not show the improved 
transmission from the directional light sources as predicted by the modelling was that the 
emission from the organic films was not perfectly collimated; 15° divergence and a not very 
uniform emission profile could result in a very small discrimination between the transmission 
from the directional and Lambertian films. So a new experiment was planned using a collimated 
and a diffused laser beam. 
5.3.3 Transmission of diffused and collimated HeNe laser light 
through porcine skin 
The measurement set up is shown in Figure 5.10. A HeNe laser (0.5-0.1 mW, model 
05-LLR-811) beam was expanded and spatially filtered to have a uniform large beam spot 
necessary for the image analysis. The input beam was too intense to control with the exposure 
of the camera, so a set of neutral density (ND) filters was used, the settings of the camera 
remained the same during the experiment. The skin sample was placed after the aperture. The 
sample glass slides were gently placed in the sample holder to avoid introducing any excess 
pressure to deform the sample. A paper diffuser was placed at the exit of the aperture to diffuse 
the collimated beam. The same camera was used for the measurements. 
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Figure 5.10: Transmission measurements set up using HeNe laser to study collimated 
and diffused laser light propagation through pork skin. Two lenses were used to expand the 
beam spot and an aperture was used to spatially filter the beam. ND filters were placed before 
the first lens if needed. A diffuser was placed at the aperture.  
The laser profiles (diffused and collimated) were imaged at the microscope glass slides 
sandwiched with a drop of ultrasound gel and placed at the sample holder. The quality of the 
incident beam was improved compared to the emission spot from the organic films (Figure 
5.11, Figure 5.12). 
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Figure 5.11: The CCD camera’s field of view: HeNe laser profile. The area which was 
used for integration of the transmission in all images is marked with a small red circle. It 
corresponds to 30 x 30 pixels area and in calibrated coordinates it has diameter equal to Ø1.28 
mm. The position and the size of this circle remained the same for all images and so was the 
beam spot during the measurements. The combination of ND filters used to obtain this image 
was OD3.0 and OD1.5 
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Figure 5.12: Laser profile zoomed, ND filters OD3 OD1.5 
The measurement protocol and image analysis was the same as for the measurements 
on the organic films, except there was no need to compensate autofluorescence as it is only 
excited at shorter wavelength. The examples of the images: the collimated and diffused laser 
profiles and the transmission through 1 mm of porcine skin are shown in Figure 5.13.  
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Figure 5.13: Light transmission of collimated and diffused light thought porcine skin 
using HeNe laser 
The intensity profiles are shown in Figure 5.14. The collimated beam is 30 pixels in 
diameter. This area corresponds to a circle with 1.28 mm diameter and was used to analyse the 
transmission images. The beam was diffused to more than 200 pixels after the diffuser which 
was six times larger than the collimated beam. 
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Figure 5.14: Intensity cross sections of HeNe collimated and diffused laser beams and 
its transmission through 1 mm of porcine skin. The diffuser was placed at the exit of the 
aperture, ND filters between the laser and the first beam expansion lens. 
The transmission measurements were averaged and normalised by dividing by the laser 
profiles (Figure 5.15).  
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Figure 5.15: Light transmission through porcine skin from diffused and collimated HeNe 
laser 
For this experiment a different animal was used and new samples were dissected. 
Similar to the transmission measurements using the organic film there was a region where the 
transmission curve changed the angle. In the previous measurement this transition region was at 
1.5-2 mm depth, in this measurement this region was at 1-2 mm thicknesses. After 2 mm 
adipose tissue started to appear which had different optical properties. However, even with the 
improved experimental settings such as much better collimation of the beam and uniform laser 
profile, the results of the measurements again showed higher transmission for the diffused light. 
5.4 Discussion 
One of the possible explanations of the disagreement between the theoretical modelling 
and the measurements could be the fact that the roughness of the skin was not measured or 
taken into account in the modelling. The size of stratified ridges of the epidermal thickening is in 
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a range of 50 – 200 µm which proliferate over many layers26. This can form compartments which 
can play a role in light coupling. 
One group reported a big change in the calculations of optical properties when 
roughness is taken into account22. They used a confocal laser scanning microscope (LSM 510, 
Zeiss) to obtain confocal images of the samples sandwiched between microscope glass slides 
and obtained surface roughness from statistical analysis of the profile lines.  
They demonstrated that the g value, the scattering and the absorption coefficient were 
lower for the models where roughness of the skin was taken into account. The difference in 
some cases was more than two times. For instance, g value is equal to 0.4 for the rough skin 
and 0.8 for the flat skin. This means that in the case with rough skin there is much less forward 
scattering. This on its own would not explain why Lambertian light sources gave better 
transmission compared to collimated light, but demonstrates that rough porcine skin loses 
directionality in the scattering. A possible explanation why Lambertian emitters showed improved 
transmission could be that the roughness of the skin was also responsible for coupling 
mechanisms of light; light coming at large incidence angles could have been trapped by the 
rough surface and have less reflection compared to normal incidence.. 
The research in this chapter demonstrated that pig skin may not be a good choice for 
optical investigation as a surrogate representative of human skin. As it turned out, the roughness 
of the skin changes the optical properties; the roughness of pig skin is very different from human 
skin, so is the rest of the anatomical structure. Also there are many controversial points in the 
developed measurement approach such as changing optical properties in the time course of the 
experiment, non-uniformities of the skin due to dissecting, and when the skin samples are 
obtained from a regular butcher shop, the skin comes treated with hot water which changes the 
optical properties of the skin. The best way to improve the experiment attempted by this chapter 
would be to use a well-studied Intralipid phantom mixed with real blood such as was described 
by Kanick et al.27 Kanick et al used this mixture with different concentrations of blood and PpIX 
to perform diffuse reflectance and fluorescence measurements. The measurements results were 
matched to Monte Carlo modelling of light transmission in those phantoms to generate look-up 
tables of optical properties of skin and the concentrations of PpIX. These looks-up tables were 
used to extract optical properties and PpIX concentration from the measurements using the 
optical probes reported in that paper. Intralipid with blood is a well-studied skin phantom with the 
most representative scattering and absorption properties. It could be used for the same 
transmission measurements with a CCD camera, with standard photodiodes or spectroscopes 
using diffused and collimated laser light, and directional and wide emitting angles OLEDs. Such 
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a standard phantom would eliminate any possibilities of uncertainty related to measurements in 
pig skin samples.  
However, the structural properties of layered human skin would still be missing from the 
experiment, so would be the dynamic processes related to oxygen diffusion and PpIX 
metabolism in skin. Therefore the ultimate resolution in order to confirm the effect of structuring 
directional emission for PDT light sources would be a randomised controlled double-blind clinical 
trial with two identical OLED devices, but with directional and wide angle emission. The results 
from the previous chapter suggested that the area of OLED has to be substantially larger (3.5 
cm for 2 cm treatment area in diameter) to compensate for the drop in the intensity due to 
Lambertian emission. So this should be taken into account in the consideration of the sizes of 
the treated area and the devices. Considering that there have been a few successful clinical 
trials of using OLED devices for ambulatory PDT28,29,30,31 which led to commercialisation of 
inorganic version of such ambulatory devices (Ambulight PDT), a new trial comparing two 
OLEDs would follow already established protocols. If the intensity, wavelength and treatment 
time remained the same for both OLED devices, directional OLED would not be expected to 
cause any reduction in the efficacy of PDT, but an improvement. 
5.5 Conclusions 
The developed optical apparatus and modelling approach can distinguish presence of 
layers in skin tissue by detecting the change in the angle of the transmission curves. This 
change is due to different optical properties in a new layer. Monte Carlo regression modelling 
showed that it is possible to extract the properties of each layer by fitting the transmission 
modelling to the measured curve for each depth. 
Unfortunately by the transmission measurements on porcine skin we did not observe the 
expected 10 % improvements for the directional light sources which were predicted by the 
modelling. During the investigation of the possible causes which could have prevented 
measuring the improved transmission in porcine skin, it was discovered that there are too many 
assumptions about the properties of porcine skin. All of the reported results on the extraction of 
optical properties differ hugely. One of the most important findings was that taking roughness 
into account could change all optical properties, reducing the directionality of the scattering to be 
almost insignificant. This along with the fact that the structure of porcine skin is different from 
human skin leads to the conclusion that the absolute evidence which could demonstrate the 
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difference between the two light sources (directional and Lambertian) would be a randomised 
clinical study on patients using the same light sources but with the only difference being in the 
directionality of the emission. 
. 
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Chapter 6 
6 A wearable optoelectronic sensor for muscle 
contraction  
Any sufficiently advanced technology is 
indistinguishable from magic. 
― Sir Arthur Charles Clarke (1917 – 2008), 
British science fiction writer 
6.1 Introduction 
This chapter will describe how light interaction with tissue was employed for developing a 
flexible organic optoelectronic sensor suitable for continuous monitoring of tissue conditions. 
Anisotropic scattering of light by muscle was used for optical sensing of muscle activity. The 
potential of the sensor to drive active prosthetic devices with improved functionality by reading 
optical signals from muscle was demonstrated by actuating a robotic arm. Optoelectronic 
sensors can also be applied for continuous monitoring of other biological changes in the body 
and point of care diagnostics for risk groups of patients. The sensor was developed by Dr A. 
Bansal, Dr M. Giardini and Mr S. Hou. My contribution was to perform optical modelling of the 
device. The implementation of optical modelling of the muscle contraction sensor is the concern 
of this chapter. 
Continuous monitoring of health condition is particularly important for rehabilitation in 
groups of patients with chronic conditions or risk groups such as elderly people living alone. 
Monitoring of gradual changes in the mobility of the elderly can be done with the help of 
telemedicine1. The other risk group is patients with diabetes where chronic monitoring of blood 
pressure could reducing the risks of microvascular disease2. Measuring of the blood pressure 
and the pulse in real time is an important task; new technology is being developed which could 
be combined with current advances in telemedicine. There was a report on the development of a 
6.1 Introduction 
163 
 
wearable and highly sensitive sensor with gold nanowires3. Gathering information continuously 
about different physiological factors is highly relevant for rehabilitation4. 
Another growing field where real time continuous sensing is of great importance, is 
human-machine interactions. There are reports of flexible and stretchable sensors which can 
mimic skin functions5. These types of sensors were named epidermal electronics and combined 
two important parameters: the mechanical properties of skin and ability to measure all 
biologically relevant signals such as surface electromyography sEMG signals from the muscle, 
temperature, pressure, strain, etc.6,7. This area is currently most appealing for the real time 
gaming industry, however, it has potential for other applications.  
Organic optoelectronics has just begun to be applied for treatment, sensing, and 
manipulations of biological activity8,9,10. It introduces many advantages for wearable sensors 
such as simple fabrication technology by spin-coating from solutions, and it is potentially cheap. 
The devices can be made flexible to conform to body shapes, they can be incorporated on a 
wearable bandage, and are low weight11,12. The devices can be made on plastic13. From the 
recent advances, the emission of OLEDs can be structured to make laser-like surface emitters 
which open new opportunities14. In addition to the above advantages, organic electronics can 
bring benefits such as being non-toxic; also it does not degrade in the biological soup and can 
be implanted for neuronal photoactivation15 or in-vivo recording of brain activities16. Also organic 
optoelectronics is not sensitive to electromagnetic noise. 
The concept of wearable light sources such as OLEDs for ambulatory PDT treatment17 
was exploited further and resulted in implementation of the wearable organic flexible 
optoelectronic muscle contraction sensor18,19. The principles of how anisotropic scattering of 
muscle can be used to detect optical changes during muscle contraction and distinguish the 
degree and the type of the contraction was published in [20] using inorganic LED and 
photodiodes. This work was developed further: the light sources and the photodetectors were 
made of organic materials with tuneable properties of flexible substrates. The sensor was placed 
on a wearable bandage and was used to actuate a robotic arm18,19. This chapter will describe 
how optical modelling was used to understand the optical design of the sensor and get better 
insights into light interaction with anisotropic muscle in combinations with layered skin and fatty 
tissue.  
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6.1.1 Current prosthetic device based on reading electrical signals 
from the muscles 
The most common sensors used to detect muscle activity are based on measuring 
surface electromyography (sEMG) signals. Those are electrical signals are sent by the brain to 
the nerves to contract or relax the muscles. They are measured with surface electrodes21. 
However, this sensing technique introduces the need to insert electrodes in tissue which require 
simple and safe, but nevertheless surgical, intervention; the electrodes degrade due to the 
immune response and over time require replacement. Another issue is that sEMG is not able to 
distinguish the two types of muscle contraction (isotonic and isometric22) which are responsible 
for different functionality (flexion/extension and resisting or maintaining pressure). Distinguishing 
both types is important for the development of a prosthetic device able to mimic natural gaits, 
and other movements which require resisting or withstanding pressure. There have been a few 
attempts to distinguish the two types of contraction using sEMG but they have not been very 
successful so far. 
One of the studies attempted to analyse EMG tension and the frequency spectrum of 
some masticatory muscles at rest, during isotonic and isometric contractions23. It showed that 
the frequency spectrum is different for the two types of contractions. Another study applied 
adaptive mixture independent component analysis (AMICA) to analyse electro-cortical EEG 
signals in the lower limb of healthy volunteers and achieved 69-87% accuracy in distinguishing 
the two types of contractions24.  
Another approach in adding functionality to the prosthetic device which requires 
distinguishing the two types of contraction was by analysing the dynamics of drive energy 
consumption in the prosthetic device. It introduced some improvements in mimicking natural 
gaits when using active prosthetic devices by introducing more advanced models of mechanical 
motions25. 
We have demonstrated that optoelectronic sensors can successfully detect the two types 
of contraction and they can be used to drive a robotic arm to mimic the natural motion of limbs 
using the two types of contraction18,19. Another big advantage of this technology is that optical 
sensing does not require inserting electrodes and eliminates all the problems with degradation of 
electrodes and the need to replace them over time. The sensor is thin, lightweight and flexible so 
it can match the body shape which makes it a good candidate for an improved prosthetic device. 
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6.1.2 Anatomical structure of muscle, physiological and optical 
changes during muscle contractions  
Muscle consists of fibres, the structure of the fibres is shown in Figure 6.1. The first-
order fibres are threads of two proteins actin and myosin. They are bundled together in 
myofibrils which are second-order fibres. Myofibrils are finally bundled in the final third order 
fibres which are responsible for the physiological function of skeletal muscle – relaxation, flexion, 
extension and maintaining constant force. The length of third order muscle fibres is 10-12 cm 
and the diameter is 2-4 mm22.  
 
Figure 6.1: Structure of a third order skeletal muscle fibre26 
When muscle contracts actin protein slides along myosin protein making the fibres 
shorter and thicker. The volume of the fibre remains the same during the contraction27,28 (Figure 
6.2). Myosin is optically anisotropic29. Therefore the fibrous structure of muscle and anisotropic 
myosin protein are responsible for transverse and longitudinal anisotropy of light propagation in 
muscle.  
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Figure 6.2: Light scattering in muscles principles (figure credit: Dr Ashu Bansal) 
Light travelling parallel to muscle fibres is scattered differently from light travelling 
perpendicular to the fibres. This anisotropy can be detected by a surface-mounted light source 
and detectors positioned along and perpendicular to muscle fibre20,18,19 (Figure 6.2). 
Physiological change during muscle contraction results in changing the fibres aspect ratio; the 
fibres become shorter and thicker. It means that for contracted muscle there will be more light 
scattering perpendicular to the fibres compared to the amount of light scattered in this direction 
for relaxed muscle. Also, when muscle contracts it changes the oxygenation and blood 
saturation which affects light absorption. So by measuring the difference in light scattering along 
and across the muscle it is possible to tell the degree and the type of the contraction20,18,19. 
The challenges which come to play with optical detection of muscle activity are the effect 
of skin and adipose fatty tissue which cover the muscle. Both of the tissues are very diffusive 
which blurs the difference in the scattering in two directions. So the questions for the modelling 
in this chapter were: 
 how far it is possible to penetrate in tissue and probe the muscle activity? 
 what were the optimal thickness of the skin and fatty tissue where the signal from 
the muscle could still be resolved? 
 what was the optimal distance between the source and the detector in order to 
achieve the best discrimination in detecting the two different directional 
scatterings from muscle? 
The biggest achievement in this chapter was implementation of a 3D anisotropic 
scattering model of muscle in the commercial optical software by manipulating the geometrical 
shape of existing Henyey-Greenstein 1D anisotropic scattering model. This allowed for 
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optimising the performance of the sensor and learning about the effects of the skin and fatty 
tissue on the detected signal from the muscle. 
 
6.2 Methods 
6.2.1 Optical design software 
The same FRED optical design software was used as in the previous chapters. However, 
it only allows modelling of one dimensional anisotropy of light scattering in tissue by the standard 
Henyey-Greenstein approximation. This dimension is in-depth of the tissue (muscle). In order to 
model anisotropic scattering in two other directions – transverse (across the muscle fibres) and 
longitudinal (along the muscle fibres) some manipulations with the geometry and the Henyey-
Greenstein scattering model were done. Special geometrical arrangements of scattering fibres 
were implemented which corresponded to the anatomical structure of and biophysical processes 
in muscle.  
Optical properties of tissue were taken from30,31. The same approach as in the previous 
chapters was taken for approximating the scattering coefficients of the muscle, the adipose 
tissue and the skin for the wavelength range of interest31 (Eq. 4.11,Eq. 4.12). 
6.3 Results 
6.3.1 Wearable sensor for detecting muscle contraction 
The schematic of the sensor is shown in Figure 6.3. An OLED and four organic 
photodiodes (OPDs) were placed on a wearable bandage. Two OPDs were placed parallel to 
the muscle fibres and other two were placed perpendicular to the muscle fibres. 
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Figure 6.3: Schematics of the wearable bandage for muscle contraction sensing. 
The implementation of fully flexible sensor (on a flexible substrate with flexible 
electrodes, the OLED and the OPDs) is shown in Figure 6.4, (a). The sensor was put on a 
bandage with Velcro® straps wrapped around bicep muscle and connected to the robotic arm 
and is shown in Figure 6.4, (b). The signals from bicep and deltoid muscle of a healthy 
volunteer were measured by the sensor in real time and used to mimic the motion by the robot 
arm. This demonstrates the potential of the sensor to read the signals which would come from 
partial limbs of disabled people to drive a prosthetic device. 
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Figure 6.4: Sensor implementation. a – a fully organic flexible muscle contraction 
sensor (figure credit: Shuoben Hou). b – the sensor on a wearable bandage demonstrating the 
possibility to actuate a robotic arm using signals from the muscle in real time. 
The sensor was fabricated and applied to drive a robotic arm by Shouben Hou under the 
supervision of Dr Mario Giardini, Dr Ashu Bansal, and Prof Ifor Samuel. Full description of the 
fabrication technology, the implementation of the electronics circuits and the manipulation of the 
robotic arm can be found in the MS thesis of Shouben Hou32 and in [18, 19]. One pair of the 
detectors was placed along the muscle fibres (parallel pair) and another pair was placed across 
the muscle fibres (transverse pair). The signals from the two detectors in each pair were added. 
The two pairs were connected to a differential amplifier. The difference between the parallel and 
transverse pair was substrate. This difference was amplified; the signal was measured by an 
oscilloscope or was used to control the robotic arm. The robotic arm had two degrees of motion: 
flexion/extension, and rotation which corresponded to two different types of contractions 
(isotonic and isometric). The measured voltages from the sensor were sent to the robot. The 
amplitude of the motion of the robotic arm was calibrated using a relaxed muscle and a fully 
contracted muscle of a volunteer. The robot fully mimicked the motion of the arm of the volunteer 
in real time [the video can be found in the supplementary information in [33]. 
6.3.2 Optical model of the sensor  
The final optical model of the sensor corresponds to the above implementation of the 
sensor. The arrangements of the components are shown in Figure 6.5. A 3 mm x 3 mm OLED 
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was placed in the middle. The output optical power was equal to 0.27 mW, and the irradiance 
was 3 mW/cm2. The OLED was made of Super Yellow polymer with a low pass filter. The 
emission spectrum of the SY was from 530 nm to 700 nm with the peak wavelength at 580 nm34. 
There was a 580 nm long pass filter to cut off shorter wavelengths which did not penetrate at 
long distances in muscle. Shorter wavelengths would only scatter in the skin not reaching the 
muscle which would introduce noise in the measurements. The spectrum in the model 
corresponded to the spectrum of the SY polymer taking into account the transmission of the low 
pass filter. In the ultimate design four 6 mm x 6 mm OPD detectors were placed at a 20 mm 
centre-to-centre distance from the OLED. The OLED and the photodetectors were positioned at 
a small (1 µm distance is needed between two optical surfaces to prevent them overlapping and 
causing computing errors) distance above the skin for the modelling purposes. The power at the 
detectors was simulated for 5, 10, 15, 20 mm distances between the OLED and the detectors to 
find the optimal configuration. The results of the modelling will be shown in the next section after 
the discussion on the implementation of optical models of the tissue. 
 
Figure 6.5: Geometrical arrangements of the components in the sensor 
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6.3.3 Optical models of skin, adipose fatty tissue and 1D anisotropic 
scattering muscle 
Although muscle is anisotropic in all three dimensions, the initial model was simplified 
and did not take into account longitudinal and transverse anisotropy. The scattering in the 
muscle was modelled by the same Henyey-Greenstein approximation as in the skin or the 
adipose tissue. It was anisotropic only in the z-direction (in depth). This simplified model was 
created to evaluate how deep the signal can penetrate and how far the detector can be placed 
from the source. The skin and the adipose tissue were added to the model to evaluate how 
much it affects light distribution and signals coming from the muscle. 
Optical properties of bulk muscle were only available for two wavelength35. The scattering 
coefficient at 515 nm was 53 mm-1, and for 1024 nm it was 21.5 nm. The approximation of the 
scattering coefficient averaged over the emission spectrum of the OLED with the filter (580 nm 
to 700 nm) was calculated using Eq. 4.11 and Eq. 4.12. An example of the calculations for 580 
nm is the following. 𝑎𝑚𝑢𝑠𝑐𝑙𝑒 = 13.0,  𝑏𝑚𝑢𝑠𝑐𝑙𝑒 = 0.926, 𝑔𝑚𝑢𝑠𝑐𝑙𝑒 =  0.96. The fitting parameters were 
taken from [31]. Eq. 4.11: µs
′ muscle(λ),  𝑐𝑚−1 = 13.0 (
580 nm
500 nm
)
−0.926
= 11.3307 cm−1. Eq. 4.12: 
µ𝑠
𝑚𝑢𝑠𝑐𝑙𝑒(580 𝑛𝑚) =
11.3307 𝑚𝑚−1
1−0.96
= 28.3267 𝑚𝑚−1. The refractive index and the absorption 
coefficient were taken from [35] and were equal to 𝑛𝑚𝑢𝑠𝑐𝑙𝑒 = 1.37, µ𝑎
𝑚𝑢𝑠𝑐𝑙𝑒 = 1 𝑚𝑚−1.  
The same calculations were done for the skin and the subcutaneous adipose tissue. The 
fitting parameters for the adipose fatty tissue were: 𝑎𝑎𝑑𝑖𝑝 = 15.4,  𝑏𝑎𝑑𝑖𝑝 = 0.68, 𝑔𝑎𝑑𝑖𝑝 =  0.9, 
𝑛𝑎𝑑𝑖𝑝 =  1.3, µ𝑎
𝑎𝑑𝑖𝑝 =  0.26 𝑚𝑚−1, from Eq. 4.11 and Eq. 4.12 the scattering coefficient was 
µ𝑠
𝑎𝑑𝑖𝑝(580 𝑛𝑚) = 13.92 𝑚𝑚−1.  
It is known that optical properties of skin differ hugely, so there were 5 different fitting 
parameters in the range of: 𝑎𝑠𝑘𝑖𝑛 = 29.7 … 48.9,  𝑏𝑠𝑘𝑖𝑛 = 0.75 … 2.453, 𝑔𝑠𝑘𝑖𝑛 =  0.5 … 0.82. The 
values from Jacques, 1996 measurements (row #2, pageR4131) were taken for the simulations: 
𝑎𝑠𝑘𝑖𝑛 = 47.8,  𝑏𝑠𝑘𝑖𝑛 = 2.453, 𝑔 = 0.8. Ultimate scattering coefficients were found to 
be µ𝑠
𝑠𝑘𝑖𝑛 (580 𝑛𝑚). = 16.6 𝑚𝑚−1. Values for 𝑛, 𝑔, µ𝑎 were taken from V. Tuchin Handbook of 
Biophotonics35, and were equal to 𝑛𝑠𝑘𝑖𝑛 =  1.31, µ𝑎
𝑠𝑘𝑖𝑛(633 𝑛𝑚) =  0.27 𝑚𝑚−1.  
First, light propagation was modelled for individual layers of skin and adipose fatty tissue 
with the thicknesses equal to 2 mm each. The muscle was 30 mm (as by initial prediction the 
light at this wavelength would not penetrate deeper than this). The light propagation in all three 
layers is shown in Figure 6.6. Due to a very small absorption, and the largest mean free path 
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(𝑚𝑓𝑝 =
1
µ𝑠
 or 𝑚𝑓𝑝′ =
1
µ𝑠
′
36) the fat diffuses light more than the other tissue. This diffusion will have 
an adverse effect on the detection of the difference in directional scattering from the muscle. It 
will become challenging to detect the signal through large amounts of fat. Similar modelling 
results were reported in [37]. This showed that strongly scattering adipose tissue impedes with 
the detection of the oxygenation of the muscles (in terms of both sensitivity and sampling). In 
cases with thick adipose tissue it was possible to detect oxygen change in muscle when the light 
source and the detector were placed far away from each other. In this case at 20 mm the light 
interacted with the muscle at very shallow layers, but still it was possible to detect it.  
 
Figure 6.6: Light propagation from the OLED made from Super Yellow polymer in 
individual layers of 2 mm thick skin, 2 mm thick adipose fatty tissue and 30 mm thick muscle. 
A distance of 20 mm between the source and the detector was taken for the initial 
simulations for the muscle contraction sensor. The model consisted of 2 mm thick layer of skin 
and 30 mm thick layer of muscle. The OLED and the detector were placed at a small gap from 
the surface of the skin. The model is shown in Figure 6.7.  
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Figure 6.7: Light propagation from Super Yellow polymer in two-layered tissue model. 2 
mm of skin and 30 mm of muscle 
The maximal separation between the source and the detector at which there was still 
some light backscattered from the muscle and reaching the detectors was 20 mm. For SY 
emission spectrum the penetration depth was a little bit more than 20 mm. 
When a thick, 5 mm layer of fatty tissue is added to the model (Figure 6.8), the light is 
diffused much more. The light penetrates only to a very small depth in the muscle. The overall 
penetration depth is reduced to 12 mm through all layers; the light penetrates through the 2 mm 
thick layer of skin, the 5 mm thick layer of fat, and only 3-5 mm thick layer of muscle. The light 
interacts with deeper layers of muscle in the centre (approx. 5 mm). These results agree with the 
findings in [37] that at 20 mm there was still some signal reaching the detector, but only from 
very shallow layers.  
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Figure 6.8: Three-layered tissue model: 2 mm skin, 5 mm fat and 30 mm muscle. The 
light from SY polymer is diffused hugely through the fat, it only penetrates at 5 mm depth in 
muscle. 
This simplified model of layered tissue allowed for studying the penetration depth, 
selecting the separation between the source and the detector and estimating the maximum 
thickness of the fatty tissue at which optical detection of muscle activity was still possible. 
However, in order to find the optimal configuration for the sensor to discriminate between the two 
directional backscatterings from the muscle, it was necessary to be able to model anisotropic 
scattering along and across the muscle fibres. 
6.3.4 Optical model of 3D anisotropic muscle and the performance of 
the sensor 
Modelling of anisotropy of light scattering in muscle in two other directions, which were 
not considered by the simplified model, was implemented by creating the same geometrical 
arrangements of the scattering fibres as in the anatomical structure of muscle. The scattering 
was only modelled inside the fibres, the space in between the fibres was not scattering in the 
model. The integrated scattering in the ultimate muscle model resulted in more scattering events 
along the muscle fibres than across.  
 175 
 
The model consisted of an array of 2 mm in diameter and 10 cm long scattering fibres. 
There were 480 fibres which formed 8 layers with 60 fibres in each layer. The fibres were placed 
next to each other (at 1 µm gap). The size of this array was 120.059 𝑚𝑚 × 100 𝑚𝑚 ×
16.006 𝑚𝑚. The small micrometre precisions in the dimensions of the muscle array (59 µm x 0 
µm x 6 µm) corresponded to the accumulated 1 µm distances between the 60 fibres next to each 
other in one layer and the 7 fibre layers stacked one on top of the other. The size of the muscle 
model corresponded to the anatomical dimensions of a bicep muscle; the size of one fibre 
corresponded to an average size of human skeletal muscle fibres22,29. The array was placed in a 
box with the same refraction and absorption as in the muscle fibres, except there was no 
scattering in that box. The size of the box was slightly bigger to accommodate the muscle array: 
121 𝑚𝑚 × 101 𝑚𝑚 × 17 𝑚𝑚.  
The scattering in the final version of the muscle model (the box and the fibres) had to 
correspond to the reported scattering coefficients for muscle tissue. So scattering in the fibres 
was increased to compensate for the non-scattering volume of the box. The volume of the box 
was 𝑉𝑏𝑜𝑥 = 𝑤𝑖𝑑𝑡ℎ × 𝑙𝑒𝑛𝑔𝑡ℎ ×  ℎ𝑒𝑖𝑔ℎ𝑡 = 121 𝑚𝑚 × 101 𝑚𝑚 × 17 𝑚𝑚 = 201757 𝑚𝑚
3. The 
volume of one muscle fibre was 𝑉𝑜𝑛𝑒 𝑚𝑢𝑠𝑐𝑙𝑒 𝑓𝑖𝑏𝑟𝑒 = 𝜋 ∙ 𝑟𝑎𝑑𝑖𝑢𝑠
2 ∙  𝑙𝑒𝑛𝑔𝑡ℎ = 3.14 ∙ 1 ∙ 100 =
314 𝑚𝑚3. The total scattering volume was 𝑉𝑎𝑙𝑙 𝑚𝑢𝑠𝑐𝑙𝑒 𝑓𝑖𝑏𝑟𝑒𝑠 = 60 ∙ 8 ∙  𝑉𝑜𝑛𝑒 𝑚𝑢𝑠𝑐𝑙𝑒 𝑓𝑖𝑏𝑟𝑒 =
156720 𝑚𝑚3. The difference between scattering and non-scattering volumes was 
𝑣𝑜𝑙𝑢𝑚𝑒_𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =
𝑉𝑏𝑜𝑥
𝑉𝑎𝑙𝑙 𝑚𝑢𝑠𝑐𝑙𝑒 𝑓𝑖𝑏𝑟𝑒𝑠
= 1.378. So the scattering coefficient in the fibres was 
increased to µ𝑠_𝑐𝑜𝑚𝑝𝑒𝑛𝑠𝑎𝑡𝑒𝑑
𝑚𝑢𝑠𝑐𝑙𝑒 = µ𝑠
𝑚𝑢𝑠𝑐𝑙𝑒  ∙ 𝑣𝑜𝑙𝑢𝑚𝑒𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  28.3267 · 1.378 = 39.046 𝑚𝑚
−1. 
The ultimate model of the muscle with a layer of skin and a layer of adipose fatty tissue is 
shown in Figure 6.9. Figure 6.9, b shows light scattering in one fibre. Figure 6.9, c shows a 
cross section of power in the muscle model. There are more scattering events along the fibres 
and a larger power flux inside the fibres. This demonstrates the concept of how such geometrical 
arrangements of the fibres provide different scattering properties in transverse and longitudinal 
directions. 
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Figure 6.9: Optical model of 3D anisotropic muscle and the sensor. a – The 
arrangements of the OLED and the phtodiodes. b – modelling of light propagation in one muscle 
fibre. c – modelling of power flux in muscle array. d – light propagation in the skin, adipose 
tissue and muscle fibres. 
The ultimate light propagation in the muscle is elongated (has a more elliptical profile 
compared to the simplified model) (Figure 6.10). The same simulations were done for two- and 
three-layered tissue. 
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Figure 6.10: Light propagation from SY polymer in layered tissue. 
Simulated power at two pairs of detectors (parallel and transverse) showed that there 
was more light backscattering along the fibres than across (Figure 6.11). The signal intensity 
decreased with the distance, however, the discrimination between the two directional scatterings 
increased. So the optimal separation of the source and the detectors was a trade-off between 
the signal intensity and the sensitivity.  
When a 2 mm thick layer of skin and a 2 mm thick layer of adipose fatty tissue was 
placed on top of the muscle, the difference in the two directional scatterings decreases 
dramatically. At small distances between the source and the detector the signal was far too 
diffused and the difference between the two direction backscatterings was almost insignificant. 
At larger distances such as 20 mm the signal was very weak, but still allowed for discrimination 
between the two directional scatterings. At 20 mm distance the powers at the parallel and 
transverse detectors 𝑃×2 𝑑𝑒𝑡𝑒𝑐𝑡𝑜𝑟𝑠 𝑎𝑙𝑜𝑛𝑔 𝑡ℎ𝑒 𝑚𝑢𝑠𝑐𝑙𝑒 = 8.08 ∙ 10
−12 𝑊, and the power at left and right 
detectors was 𝑃×2 𝑑𝑒𝑡𝑒𝑐𝑡𝑜𝑟𝑠 𝑎𝑐𝑟𝑜𝑠𝑠 𝑡ℎ𝑒 𝑚𝑢𝑠𝑐𝑙𝑒 = 2.94 ∙ 10
−12 𝑊. The energy of one orange photon 
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from the SY polymer 𝐸𝑝ℎ𝑜𝑡𝑜𝑛(580 𝑛𝑚) =
ℎ𝑐
𝜆
=  3.43 ∙ 10−19 𝐽. There were 
2.94· 10−12𝐽
3.43· 10−19𝐽
= 8.5 ·
106 photons detected at the detectors across the muscle in this model.  
 
Figure 6.11: Simulated power at the detectors along and across the muscle. The 
selectivity of the sensor increases with the distance between the source and the detector; 
however, the power drops down substantially. In the model with 2 mm layer of skin and 1 mm 
adipose tissue the discrimination between the two direction backscattering decreases; it 
becomes more difficult to measure muscle activity. 
6.4 Conclusion 
My own work in the development of the optical organic muscle contraction sensor 
included optical modelling of light propagation in muscle at the wavelength of interest. This 
modelling helped to establish the design of the sensor, in particular to define and justify optimal 
distances between the light source and the detectors. Also it helped with understanding 
important processes such as how far light penetrates in muscle and at what depth the sensor is 
capable of probing the muscle activity. In addition the chapter investigated adverse effects of 
skin and fat in the operation of the sensor and helped to establish the limitations and ways to 
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optimise the performance. In particular it was shown that although the signal drops in intensity 
with the increase in the separation between the source and the detectors, the discrimination 
between the two directions of the scattering increases. This is crucial for optical sensing of the 
contractions. A two directional (longitudinal and transverse with respect to muscle fibres) 
anisotropic scattering model was implemented together with the standard one dimensional (in 
depth of muscle) anisotropic Henyey-Greenstein scattering model to describe light propagation 
in muscle in three dimensions. The model was applied to understand the operation of a muscle 
contraction sensor. The fully flexible organic muscle contraction sensor was demonstrated as a 
good candidate for application in improved functionality prosthetic devices. Not only can it add 
ability to better mimic the motion by distinguishing isotonic and isometric contractions, but is also 
insensitive to electromagnetic interference and immune responses. Implementation of the 
muscle contraction sensor using organic optoelectronics demonstrated the potential of using this 
appealing technology for a new generation of wearable devices which can revolutionize 
ambulatory healthcare, strengthen telemedicine, and find application in the gaming industry and 
other human-machine interactions.  
Developed optical modelling approaches allowed for evaluating the performance of 
biomedical sensors using optical models of tissue. The modelling demonstrated that the choice 
of the optimal distance between the source and the detectors in the muscle contraction sensor 
was based on the drop of intensity at large distances but increased sensitivity for two directional 
scattering; it was chosen to be 20 mm. The light emitted by the Super Yellow polymer allowed 
for sensing the signals at approximately 20 mm in depth of the tissue.  
Skin and adipose tissue have very strong diffusing properties. At short distances between 
the source and the detectors the sensor becomes insensitive to two directional scattering. For 
thick adipose tissue the signal penetrates only at shallow layers and requires at least 20 mm of 
separation between the source and the detectors.  
In future the simulations could help to calibrate the sensor for each skin type to 
compensate for the differences in absorption. The absorption in skin type I is much lower than in 
skin type VI (by Fitzpatrick scale). When the sensor was tested, there was two orders of 
magnitude difference in the voltage measured on a bicep muscle for skin type II (white) and skin 
type V (dark brown). This means that if the prosthetic limb was calibrated to move as if the 
person wearing it had skin type V, but in fact the person wearing the limb had skin type II, the 
limb would hugely over respond to the measured signals; for intended small motion the limb 
would generate maximum range of the motion. In the opposite scenario, the limb intended to 
work for skin type II placed on skin type V would not be responsive to the low levels of signals. 
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So the modelling could give a guidance of the expected levels of the signals and help to adjust 
the calibration to each individual.  
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Chapter 7 
7. Conclusion 
Science never solves a problem without 
creating ten more. 
― George Bernard Shaw (1856-19550), 
Irish playwright, critic, political activist 
 
The energy and the wavelength of visible light are comparable to the energy transitions 
and the sizes of living cells, large proteins and organelles. This makes it possible to use the 
energy of light to trigger many processes in cells and tissue, and also to visualize and sense 
many biological parameters. But if we go to shorter wavelengths (XUV-UV) the photons are 
already too energetic; their energy is absorbed by proteins, molecules and viruses. If we go even 
shorter wavelengths, X-rays and gamma rays, the energy of these photons is even more 
energetic; these rays mostly break the bonds in proteins and molecules. An example is 
radiotherapy, proton or ion-beam therapy for cancer where the energy of the beams is used to 
destroy the DNA in cancer cells1. Then if we go to the other side of the visible spectrum, to the 
far IR region, the energies of these photons are too low; the wavelengths are too long; so they 
are only absorbed by water and dissipate into heat. Beyond IR, in the millimetre range we, 
humans, are already transparent to this energy. So there is a so called optical window from 400 
nm to 1.3 µm with little absorption, and mostly scattering in tissue2. This window allows 
penetration and interaction with tissue for sensing and treatment. 
This thesis explored a few processes in the area of light-tissue interactions which were 
important for improvements in the Photodynamic therapy (PDT) of non-melanoma skin cancer 
(NMSC), developing new light sources for ambulatory treatment and other optical wearable 
devices such as for muscle contraction sensing.  
PDT is a well-established treatment modality for NMSC with excellent cosmetic outcome, 
yet the response is only up to 80 % on average among the reports (a median clearance was 
73% at a 6 months median follow-up, Ibbotson et al3; Morton et al4 reported 90% clearance for 
actinic keratosis (AK) at a 3 month follow up, 80-97% clearance for superficial basal cell 
carcinoma (sBCC) at a 3 month follow up, 78% clearance for basal cell carcinoma (BCC) at a 48 
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month follow up). So the majority of the work in this thesis was aimed at investigating possible 
improvements in terms of expanding the knowledge of PpIX metabolism and also studying light 
transport in tissue with the view to optimise treatment light sources. 
One of the key parameters involved in the treatment investigated in this thesis was the 
metabolism of a photosensitizer Protoporphyrin IX (PpIX) in healthy and diseased skin. The 
highest concentrations of PpIX formed after continuous application of 5-Aminolevulinic acid 
(ALA) and Methyl Ester 5-Aminolevulinic acid (MAL) precursors were observed at 24 hours (in 
BCC and healthy skin)5 and 13-18 hours (in BCC and AK)6 correspondingly. The highest 
specificity of accumulation of PpIX from ALA precursor was 2-4 hours, so the study [5] suggested 
that the optimal time to start ALA PDT treatment was any time after 2 hours from the application 
of an ALA precursor. In the case of application of the MAL precursor, PpIX concentration 
continued to increase over 13 hours6. The study recommended starting the treatment at 3 hours 
after the application of MAL. However, the graphs of the lesion to normal skin selectivity ratio did 
not show any obvious difference in the specificity of PpIX accumulation in lesions compared to 
healthy skin during 13 hours of MAL application while the fluorescence in lesions continued to 
grow6. So one of the questions investigated was how Ameluz gel (ALA precursor) and Metvix® 
cream (MAL precursor) are metabolised to PpIX during the three hours of recommended waiting 
time before commencing treatment. In addition there was interest in seeing if there were any 
particular fluorescence fingerprints in PpIX metabolic maps between the lesions or if there was 
any difference between the creams. By correlating the follow up data about the lesions’ 
response to the treatment the hope was to find a positive correlation which could help to predict 
the PDT outcome on the day of the treatment. Chapter 2 addressed a clinically-driven need to 
develop a convenient hand-held instrument which allowed for quick measurements of PpIX 
fluorescence on healthy volunteers and patients following simple protocols. The method 
developed and image analysis enabled robust referencing of the fluorescence images to the 
skin, which was important for the study of the formation of PpIX fluorescence patterns in time. 
The camera was able to visualise fluorescence in standard Coproporphyrin fluorescent solution, 
in-house made PpIX fluorescent phantoms and in-vivo from the skin of a healthy volunteer after 
administration of Ameluz gel and in AK and BCC lesions administered Ameluz and Metvix® 
PDT. This simple and handy device and the method demonstrated the potential to answer many 
clinically relevant questions. 
In the future, it would be desirable to upgrade the current device to enable multi-band 
PpIX imaging. It is a known fact that blue light such as 405 nm wavelength which was used in 
the current version of the fluorescence camera penetrates only at superficial layers in skin 
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therefore exciting superficial PpIX fluorescence. Red light such as 632 nm which corresponds to 
one of the PpIX absorption peaks penetrates deeper in skin. So measuring fluorescence excited 
with this wavelength would give information about PpIX distribution at a greater depth. Another 
important imaging modality would be to add imaging of green auto-florescence emission excited 
by the same 405 nm wavelength. Auto-fluorescence can be helpful to observe structural 
changes in tissue due to the change in production of collagen, elastin and keratin in malignant 
cells. White light imaging using a colour camera would be useful to monitor the development of 
erythema (skin redness condition developed due to an inflammation) which only recently was 
associated with pain and the response to PDT7. 
In Chapter 3 the prototype device was used in a small study on 11 healthy volunteers 
and 13 patients. PpIX formation was studied over three hours with a 10 minute interval (three 
hours is the recommended metabolism time before commencing PDT treatment).  
Healthy volunteers were administered Ameluz gel (n=5) and Metvix® cream (n=6). The 
study area was the middle back avoiding paravertebral regions as the skin is the most uniform 
here. Also healthy skin on the back was developing average PpIX intensities compared to the 
other sites of the body8,9. This made this site most suitable for the baseline. The results showed 
that the fluorescence distribution was mostly uniform in all subjects. The fluorescence varied 
between the subjects and continued to grow over three hours of the measurement time. There 
was no statistical significance between the Ameluz and the Metvix® groups (p-value>0.005 in a 
two sample t-test with unequal variances). This suggested that healthy skin metabolises PpIX 
equally efficiently from both creams during three hours of the measured time and there were no 
specific fluorescence patterns in the uniform healthy skin on the back. 
The results of PpIX fluorescence time course in 13 lesions of 13 patients (AK 
administered Ameluz PDT: n=5, AK administered Metvix® PDT: n=2, biopsy confirmed BCC 
administered Metvix® PDT: n=5) concurred with the findings in the healthy volunteers’ cohort 
that the fluorescence varied and continued to grow during three hours of the measurement in all 
subjects. There was no statistical significance between the creams or between the lesions (p-
values>0.05 for all groups: AK Ameluz vs AK Metvix vs BCC Metvix; AK (both creams) vs BCC). 
There was no significant correlation of the fluorescence to pain. The results of a 3 months (n=6) 
and a 1 year (n=6) follow up showed that PpIX fluorescence does not correlate to the lesions 
clearance. Although, it was demonstrated that PpIX fluorescence diagnostics can distinguish 
with a high degree of accuracy pre-clinical malignant changes in skin not visible to the naked 
eye, absence of correlation of PpIX fluorescence to the lesion clearance supports the opinions 
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that PpIX fluorescence alone is not the most reliable optical diagnostics technique for NMSC or 
for predicting PDT outcomes.  
However, there are still no better ways of studying PpIX metabolism in-vivo than by 
measuring its fluorescence. The device and the method developed allowed for selecting and 
integrating fluorescence over an area in the time course images compared to one point 
measurement in the conventional fibre optics spectroscopes. Fluorescence time course analysis 
showed that in small regions on the same lesion with only 2-3 mm distance between the regions 
there was a 2-3 times difference in the fluorescence intensity. So integrating the fluorescence 
over an identical region of interest increases accuracy in the time course measurements 
compared to a one point measurement with an optical fibre. Another advantage is low excitation 
irradiance which was equal to 0.1 mW/cm2.This, combined with synchronisation of the 
illumination during image acquisition reduces sensitivity to ambient light and the delivered light 
dose during the measurements. A small light dose eliminates the possibility of induced 
photobleaching of PpIX during the experiments. 
The body sites were not specified in the patients’ inclusion criteria as this would reduce 
the recruitment rates. In the end it was found to be the only significant factor influencing the 
fluorescence time course. The groups of “the head & neck” vs “trunk & hands” vs “lower leg & 
feet” were statistically significant (p-value<0.05). PpIX metabolism was higher in the head and 
the neck compared to the lower leg. It was found that fluorescence had a positive correlation to 
skin temperature across the body. This is of great relevance to PDT treatment, as the waiting 
times before commencing the treatment could be shortened by increasing the skin temperature, 
or ambient temperature for daylight PDT should be considered. Also it could explain the fact that 
cooling air for pain management reduces PDT outcomes. 
This developed camera proved itself as a useful and accurate tool and enabled the 
discovery of interesting processes such as body site dependence of PpIX metabolism. 
Considering the capabilities of current camera technology, miniature LED, fast prototyping 
equipment, instrument development becomes easy, fast and relatively cheap. Therefore an 
upgrade of the current instrument to a multi-band imaging system could be easily implemented 
by adding extra red and white LED in the current illuminator PCB. Extra filters could be slided in 
and out with slight modification of the plastic casing of the camera yet keeping it compact and 
handheld. The current USB control module has the capability to drive another 6 channels of 
different colour wavelength illumination. Alternatively monochromatic CCD could be replaced by 
a colour camera, green and red pixels could be separately analysed in Matlab to separate auto-
fluorescence and PpIX fluorescence as was implemented by Kurachi and Bagnato group10.  In 
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order to keep high selectivity to PpIX narrow band pass filters such as was used in the 
fluorescence camera could be used in addition with a colour CCD sensor and the images could 
be converted in black and white to be able to analyse the fluorescence intensity. 
In addition to multi-band fluorescence imaging, the future studies should include 
temperature measurement in order to provide more evidence to support the findings discovered 
in this study. Temperature distribution at large area of the body sites where the lesions are 
located could be imaged once before the treatment with an infrared camera, before PDT, then in 
the middle and after the treatment. Before the application of the cream the skin will have a base 
line temperature. Considering the fact that the cream is covered with an occlusive dressing the 
temperature may rise during the three hours of PpIX metabolism under the cover so it would be 
necessary to monitor the change of the temperature due to the dressing. Also it would be 
interesting to monitor the temperature change and the erythema development before during and 
after the PDT. This information will be useful to investigate the correlation of PpIX metabolism, 
the development of erythema, pain and PDT responses and to support the hypothesis that 
natural temperature distribution across the body pays a role in PpIX metabolism and PDT 
outcomes. PpIX photobleaching during PDT remains useful parameter for improving PDT 
dosimetry and predicting the outcomes, so similar to measuring the temperature it would be 
useful to measure PpIX fluorescence in the middle and after the treatment. Also, it becomes 
evident that PDT response can be predicted by the development of erythema on the next day 
after the PDT7 so this would also be relevant to investigate in the future studies.  
Alongside expanding the knowledge on the photosensitizer side, the work also focused 
on improving the other PDT treatment factor – light penetration into skin. Chapter 4 focused on 
the development of an optical apparatus to study light transport in tissue. The high priority in this 
chapter was to apply commercial optical design software for the modelling. This would open up 
opportunities to design and optimise the devices.  
The modelling was applied to simulate optical wireless power transmission through a 
brain phantom for potential applications in implantable robots. The power transmission was 
measured by a solar panel made of a few commercial photodiodes in a gel brain phantom. It 
was possible to collect 0.1 % of the source power at 5 cm in depth in the phantom, and 10 % at 
1 cm depth. According to reports in the literature on power consumption of miniature robots, the 
current set up could allow powering a small robot deeper than 3 cm in the brain phantom. 
However, the current size of the solar panel and the size of the existing robots have to be 
miniaturised at least ten times before it would be possible to implant them in a real brain. There 
are many possible applications for such developments; one of the examples, collecting signals in 
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the brain during normal daily activity could help to learn about the hard problem of 
consciousness11.  
This project validated the software on a direct power comparison and gave confidence to 
use it for modelling of PDT light sources and light transport in skin. Even illumination is important 
in PDT devices. The modelling investigated how natural diffusion processes in skin can help to 
reduce non-uniformities in the model of the Ambulight PDT device. If incident illumination was 25 
% non-uniform, at 1 mm in depth of skin it is compensated by 10 % leaving 15 % of ultimate 
non-uniformities. This is still not enough to compensate large especially very localized variations 
in incident irradiance and even illumination is essential in treatment PDT light sources. By using 
many LEDs and adding two diffusers to it, even illumination is achieved in the Ambulight PDT 
device, but at the cost of considerable complexity and thickness. OLEDs are desirable for 
application in ambulatory PDT devices because they are thin single-component surface-emitting 
light sources, they provide uniform emission and they do not require the use of the diffusers. A 
test OLED device from a potential supplier was characterised for future ambulatory PDT light 
sources. The OLED was modelled based on the measured characteristics. The result showed 
that the size of the device should be substantially larger to compensate for the drop of the 
intensity at the edges because of Lambertian emission. For instance for a 2 cm diameter treated 
area the OLED diameter should be approximately 3.5 cm.  
The observations from Chapter 4 led to the hypothesis that PDT light sources could 
benefit from forward scattering in skin. This was investigated in Chapter 5. Directional emission 
could improve light transport. Directionality from OLEDs can be less than 15° 12. Modelling 
suggested it would be possible to achieve 10 % improved light transmission in skin from such 
OLEDs. However, the measurement of light transmission from organic light emitting films with 
structured and Lambertian emission through fresh porcine skin did not show the expected 
improvement. During this study it was discovered that pig skin may not be the best choice for 
optical measurements as a surrogate of human skin and also as a robust phantom due to non-
uniform structure, variation of optical properties between the animals and as a result of skin 
treatment by the butchers and during the measurements, etc. Therefore, the most robust optical 
measurement would be to use well-established phantoms. Intralipid with blood becomes a 
golden standard for representing absorption and scattering properties of skin13. Measurements 
on liquid phantoms in cuvettes or custom containers would enable simple protocols and avoid 
many assumptions and complications with measurement on fresh tissue. However, considering 
that there are so many differences for in-vivo and ex-vivo light transport in skin, probably the 
ultimate solution to investigate whether directionality can bring significant improvements in PDT 
7 Conclusion 
189 
 
treatment would be a randomised double-blind clinical trial comparing directional and Lambertian 
OLEDs. There is no reason to believe that PDT outcomes should be worsened by using 
directional OLEDs compared to identical Lambertian OLEDs. Taking into account the experience 
in the group and the collaborating hospital where the first time OLED devices were successfully 
used in a clinical trial for ambulatory PDT14,15 already established protocols and routines for 
implementing a trial could be adjusted for a new trial comparing directional and Lambertian 
OLEDs.  
In Chapter 6 optical modelling was used to understand the design of a different 
wearable device – a muscle contraction sensor. In this case also different light-tissue interaction 
processes were employed – anisotropic scattering by muscle. Due to the fibrous structure of 
muscle there is more light scattering along than across the fibres. When muscle contracts the 
aspect ratio of the fibres changes which results in the relative change in scattering in the parallel 
and the perpendicular direction to the muscle fibres. Detecting this change enables 
measurement of the degree and the type of muscle contraction16. The reported inorganic sensor 
was implemented on a flexible substrate with all organic flexible components and made on a 
wearable bandage. The signals measured by the sensor were used to actuate a robotic arm to 
mimic the motion of the arm of the person wearing the sensor17,18. This demonstrated the 
potential to use this sensor in prosthetic devices. The fact that the sensor successfully 
distinguished two types of contractions which has not been achieved by the electromyography 
(EMG) sensors so far, demonstrates the superiority of optical sensors to EMG sensors. For the 
actuation of prosthetic devices it means that optical sensors can offer improved functionality by 
mimicking the motions requiring resisting or withstanding pressure which relates to isometric 
contractions. In addition organic optoelectronics avoids the problems of electromagnetic 
interference. Optical sensing is non-invasive; it does not cause an immune response and 
eliminates the need to replace degradable EMG and the performance of a simple but still a 
surgical procedure. In addition the sensor can be thin and flexible conforming body shape and 
easily integrating in the design of prosthetic devices. 
Optical modelling helped to understand the performance of the sensor and find an 
optimal distance between the light source and the detectors. The results showed that the light 
from an OLED made of a Super Yellow polymer allowed penetration and probing of muscle 
activity to approximately 20-25 mm in depth. The largest and optimal distance between the 
source and the detector in a model with a 2 mm thick layer of skin on top of the muscle can be 
20 mm. At this distance the discrimination between the two signals relating to backscattering in 
parallel and perpendicular direction with respect to muscle fibres is the largest while the intensity 
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of the signal is still sufficient for optical detection. Adipose fatty tissue has adverse effects on the 
detected signals. Because of high scattering and low absorption, fatty tissue diffuses the light, 
reduces penetration depth and the discrimination between the transverse and longitudinal 
backscattering. After a layer of fatty tissue 5 mm thick the light interacted with only a shallow 
layer of the muscle; it would not be possible to detect muscle activity in individuals with a much 
thicker layer of fatty tissue. The measurements in skin type II and V (by Fitzpatrick scale) 
showed that the levels of the signal varied by two orders of magnitude (because of the difference 
in absorption). For the application of the sensor in prosthetic devices it means that the sensor 
calibrated for one type of the skin would over respond or would be insensitive to the signals 
measured on individuals with different skin type. So another useful application of the modelling 
could be to help with the calibration of the sensor on the levels of the signals and the degree of 
the motion of the prosthetic devices by taking into account the differences in absorption of 
different skin types. 
Overall, the work in this thesis demonstrates the great potential of light to revolutionise 
current health care by employing various processes of how light interacts with tissue. Only a few 
processes were covered in this thesis, but there are many more which can be pursued with the 
same or similar approaches. Light can be used in treatment of many diseases. The thesis has 
shown that new light emitting devices such OLEDs can be tuned, shaped, structured and 
implemented on wearable bandages for ambulatory treatment and point of care diagnostics. 
Optical modelling helps with the design of the devices. The simulations improve our 
understanding of how light interacts with different types and layers of tissue. Diffuse reflectance 
measurement and regression modelling allows for extraction of optical properties. Fluorescence 
and thermal imaging can help to monitor PDT, diagnose malignant changes in skin and provide 
information about relevant biological factors such as temperature and PpIX concentration in skin 
to improve the treatment. All of these methods (optical sensing, imaging, and modelling) could 
be combined. Monitoring of PpIX fluorescence, measuring optical properties of skin and blood 
volume in the skin could allow for controlling light delivery during PDT in real time.  
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By believing passionately in something that still 
does not exist, we create it. The non-existent is 
whatever we have not sufficiently desired. 
― Franz Kafka (1883-1924), 
German-speaking Jewish writer 
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Introduction 
Photodynamic therapy (PDT) is an effective treatment for superficial non-
melanoma skin cancers (NMSC) and dysplasia with excellent cosmetic outcome, [1]. 
Topical PDT describes light activation of  a photosensitiser (PpIX) derived  from a 
pro-drug in a cream (methyl aminolevulinate acid [Metvix®], aminolaevulinic acid 
[Ameluz®]), in the presence of  molecular oxygen, which together activate PplX. 
Concentration and distribution of the drug in the skin is one of the most important 
parameters influencing efficacy of treatment. Information about the amount of 
photosensitiser present can be acquired by measuring its fluorescence. For PpIX, the 
fluorescence is red light (635 nm wavelength) emitted by healthy and diseased skin 
following application of the drug.  Fluorescence occurs when violet or blue light (405 
nm wavelength) illuminates the skin containing the photosensitiser. Routinely Wood’s 
light (405nm is used to qualitatively estimate the fluorescence from the lesion before 
PDT treatment. The optical biopsy system, (OBS) is used as a quantitative tool to 
measure average fluorescence intensity over wavelength ranges at specific sites. 
The fluorescence intensity is measured at several points on the lesion and the result 
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is averaged. During PDT the concentration of PpIX decays which is called 
photobleaching. The OBS is used in photobleaching experiments to gain information 
about the average concentration of the photosensitizer present and photobleached 
during treatment. Photobleaching experiments help expand the knowledge regarding  
how PDT works and optimal treatment parameters.  
 
This study aims to quantitatively measure fluorescence intensity at each point 
on the skin. Fluorescence will be imaged with a camera we have developed, and 
quantified with a computer program. Fluorescence imaging is a powerful tool for PDT 
diagnostics and has been used in a number of qualitative and quantitative clinical 
studies at the Photobiology Unit (PBU), Ninewells Hospital, Dundee and other 
institutions, [2-6]. Unlike the OBS, fluorescence imaging gives information about 
spatial distribution of fluorescence. These images show how well the cream is 
absorbed by skin and converted into the photosensitiser and how uniformly this is 
distributed over the treated area.  
 
The two key differences between an earlier photobleaching study we have 
undertaken in the department, which employed the OBS, A Quantitative Study of In 
Vivo Protoporphyrin IX Fluorescence Photobleaching during Photodynamic Therapy*, 
and the current study are that during the previous photobleaching experiments* data 
were taken infrequently during treatment and were point source measurements, 
whereas the current study aims to image spatial distribution and amount of 
fluorescence using a camera system each 10-15 minutes over 3 hours after cream 
application. The data gathered during the current fluorescence imaging experiments 
will help to determine the optimal time when the treatment should start. The study will 
also compare the effectiveness of two PDT creams, Metvix® and Ameluz®. Imaging 
two types of lesions, basal cell carcinoma (BCC) and actinic keratosis (AK), will 
improve understanding of the response to PDT of different people and with different 
diagnoses. 
 
For the healthy volunteer cohort, study participation will last one day and is not 
expected to cause any discomfort or side effects. Five volunteers will have Metvix 
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applied to a selected skin site and five volunteers will have Ameluz applied to a 
selected skin site. 
 
For the patient cohort, the study will be carried out on the day of the planned 
PDT treatment. Five patients diagnosed with AK will have Ameluz® applied, five will 
have Metvix® applied, and five patients with BCC will have Metvix® applied. The 
fluorescence imaging procedure is not expected to cause any discomfort or side 
effects to the patient and should have no influence on treatment outcome.  
 
Aims 
This research aims to improve our understanding of how we can optimise PDT 
treatment by identifying the peak time(s) of fluorescence under the experimental 
conditions studied.  
We are also aiming to compare the efficiency of the creams, Metvix® and 
Ameluz®, at producing PplX and the response of two lesions, BCC and AK, to PDT.  
 
Research questions 
1. How much, how uniformly and how fast is the photosensitiser being formed 
from 
    the pro-drug cream in healthy and diseased skin?   
2. What is the optimal time to start treatment? 
3. Is fluorescence intensity, distribution or photobleaching associated with 
    persistence or recurrence of BCC and AK 
 
Study Design 
On the day of the study, the cream will be applied to a small area of up to 2 cm 
by 2 cm to the skin of healthy volunteers or to the lesion of patients. A disposable 
alignment pattern will be used to accurately position the camera for taking fluorescent 
images. The contour along the alignment pattern will be drawn. The camera will be 
aligned with the contour. The parameters of the camera will be set based on 
preliminary experimental data. The images of the spot will be taken every 10-15 
minutes for three hours. For healthy volunteers; after three hours the remaining 
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cream will be wiped off and the area will be covered with a small occlusive dressing 
to prevent reaction of the skin to the sunlight. Their participation will be completed 
and the volunteers will be free to go. For the patients; after the last measurement the 
cream will be wiped off and they will have their planned PDT treatment. Both patients 
and volunteers will be advised to contact the research group if they have any 
questions or concerns. 
 
Study Population 
The study will include:  
 5 healthy volunteers administered Metvix®  
 5 healthy volunteers administered Ameluz®  
 5 patients diagnosed with AK and administered Ameluz® PDT  
 5 patients diagnosed with AK and administered Metvix® PDT  
 5 patients diagnosed with BCC and administered Metvix® PDT 
  
Potential participants with superficial non-melanoma skin cancer and dysplasia 
who are suitable for the study will be identified by a consultant dermatologist (Chief 
Investigator) during screening of referral letters of patients referred for PDT and an 
invitation to consider this study and Participant Information Sheet will be sent out with 
the PDT appointment letter. The study will then be discussed with the patient when 
they attend clinic, by which time they will have received and read the Participant 
Information Sheet. Written informed consent will be obtained at that stage if the 
patient is happy to go ahead and participate in the study. 
  
Healthy volunteers will be identified from the healthy volunteer database and 
will be contacted by the Clinical Trials Coordinator as previously arranged (email or 
text). If they reply with interest, they will be sent the study Participant Information 
Sheet (PIS). All subjects will be given at least 24 hours to read the PIS and have the 
opportunity to have any questions answered. If willing to proceed, informed consent 
will be obtained by the consultant dermatologist or a delegated suitably qualified 
member of the research team. 
 
Inclusion Criteria (patient cohort) 
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1. Patients presenting with superficial non-melanoma skin cancer and 
dysplasia. 
2. Age 18 years and over 
3. Males and females 
4. Capable of giving informed consent 
5. Able to understand and adhere to protocol requirements 
 
Inclusion Criteria (healthy volunteer cohort) 
1. Age 18 years and over (age matched to patient cohort as is practicably 
possible) 
2. Males and females 
3. Capable of giving informed consent 
4. Able to understand and adhere to protocol requirements 
 
Exclusion Criteria 
1. Patient's skin lesion has had previous treatment within the last four months. 
2. Unable to give informed consent 
3. Known allergy to Metvix or Ameluz 
4. Known to have a light sensitivity disorder 
 
Study Procedure 
On the day of the study, after informed consent has been taken, a baseline 
reading of the skin site will be taken. Then the cream will be applied by technical staff 
to healthy or diseased skin of the subject and left for absorption. Every 10-15 
minutes, images of fluorescence will be taken. Before taking an image the cream will 
be wiped off. After taking the image a small amount of the cream will be re-applied 
and covered again. Ambient light will be kept low to prevent exposure of the skin site 
during the procedure of taking images. The images will be recorded for further 
processing and stored on a secure NHS Tayside computer. After three hours, when 
the measurement will have finished, the remaining cream will be wiped off the skin 
and the skin will be covered with a small occlusive dressing to the site for 24 hours to 
prevent exposure from daylight causing photobleaching of reaccumulated PplX.  
After that the subject will have completed the study. 
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Patients will have their planned PDT treatment straight after the last 
measurement. 
 
Equipment Description 
The camera being used to take fluorescence images of healthy and diseased 
skin has a UV flash with the power of  0.1 mW/cm2 with the duration of the pulse of 
less than one second, depending on the exposure time of the camera. Total dose 
delivered to the skin is much below MPE and exposure time. The camera has a filter 
to pass only red fluorescence. The field of view of the camera is 23 x 31 mm. The 
size of the image is 480 x 640 pixels. The camera has fixed focal distance of 8.5 cm. 
The camera is USB powered. The camera connects to a laptop with user interface. 
Although not CE marked, the use of the camera in clinical research has been 
approved by the Instrumentation Department of NHS Tayside Medical Physics. 
 
Checking System Performance 
The camera will be checked periodically, twice a month, against a 
fluorescence standard solution coproporphyrin III regularly used in the PBU to check 
the performance of the optical biopsy system (OBS) which is used for photobleaching 
experiments during PDT treatment. Also, the camera will be checked against 
fluorescent phantoms, fabricated at School of Physics, University of St Andrews, 
which have the same fluorescence intensity as is expected from the skin with 
accumulated drug after three hours of cream application. Fluorescent patterns will be 
used to check the focus of the camera. This process will assess the ability of the 
system to produce fluorescence images with consistent intensity at 635 nm ensuring 
repeatability and reproducibility.  
 
Incidental Findings 
Although we do not foresee any adverse events, any abnormal reactions 
detected will be managed in the conventional manner, i.e., the participant will be 
reviewed by a consultant dermatologist in the Photobiology/Dermatology department. 
 
Reimbursement 
204 
 
Healthy volunteers will receive £50 as reimbursement for inconvenience and 
travel expenses.  Patients will not receive reimbursement as will be attending for 
treatment anyway. 
 
Statistical Analysis 
The images will be analysed using digital image processing algorithms. 
Comparisons of fluorescence time course between and within individuals will be 
performed using Student’s t-test or equivalent non-parametric methods where 
applicable. As this is a pilot study a power calculation is not applicable but the 
numbers stated are considered realistically achievable for these investigations. 
 
Feasibility 
The study is a straightforward and non-invasive procedure.  
 
Conclusion 
We are planning the study to gather fluorescence images from healthy and 
diseased skin. This information will enable us to develop better understanding of how 
the cream used for PDT works, how well it is absorbed by the skin and converted into 
the drug PpIX and how uniform it distributes over an area of healthy skin and 
diseased skin. We will also collect data on different lesions, AK and BCC, which will 
help us to understand how different lesions respond to PDT treatment. Finally, the 
information on fluorescence intensity during three hours of cream application will help 
to identify the optimal time when the treatment should start. All of the aspects of the 
study will help to optimise PDT treatment protocols. 
 
 
Dissemination of Knowledge Gained 
Finalised anonymous data will be presented at scientific meetings and 
conferences, published thesis and scientific journals. 
 
 
205 
 
References 
 
1. National Health Service (NHS), UK (Last reviewed: 03/10/2012). 
http://www.nhs.uk/Conditions/Cancer-of-the-
skin/Pages/Introduction.aspx 
2. Hewett, J., McKechnie, Sibbett, W., Ferguson, J, Clark, C., Pdgett, M. 
“Fluorescence detection of superficial skin cancers”, Journal of Modern 
Optics, 2000. 40 (11): p. 37-41. 
3. Sandberg, C., Paoli, J., Halldin, C. B., Gillstedt, M., Larkö, O., Wennberg, 
A.M., “Photodynamic therapy for “difficult-to-treat” basal cell carcinomas. 
Do poorly responding BCCs lack accumulation of protoporphyrin IX after 
ALA/MAL application?”, Proc. of SPIE, 2009. 7380 (73805K) 
4. Sandberg, C., Paoli, J., Gillstedt, M., Halldin, C.B., Larkö, O., Wennberg, 
A.M., “Fluorescence diagnostics of basal cell carcinomas comparing 
methyl-aminolaevulinate and aminolaevulinic acid and correlation with 
visual clinical tumour size”, Acta dermato-venereologica, 2011. 91 (4): p. 
398-403 
5. Togsverd-Bo, K., Idorn, L. W., Philipsen, P., Wulf, H. C., Hædersdal, M., 
“Protoporphyrin IX formation and photobleaching in different layers of 
normal human skin: methyl- and hexylaminolevulinate and different light 
sources”, Experimental dermatology, 2012. 21 (10): p. 745-750 
6. Tyrrell, J., Campbell, S., Curnow, A., “Validation of a non-invasive 
fluorescence imaging system to monitor dermatological PDT”, 
Photodiagnosis and photodynamic therapy, 2010. 7 (2): p. 86-97 
  
206 
 
Appendix III: Capturing fluorescence –Device 
assessment for clinical trials 
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Appendix IV: Capturing fluorescence – Standard 
Operating Procedure (SOP)  
 
Standard Operating Procedure SOP 001 cleaning of 
fluorescence device 
Document Number: SOP 001 
 
 
Title: Cleaning of fluorescence imaging device 
 
Version: 1.0 
 
Authors:  Olena Kulyk 
 
 
Effective from: 01 November 2013 
Valid to: 31 October 2014 
Superceded Version Number & Date (if applicable)  
 
 
 
 
Revision History: This is the original version of this document 
 
Comments:  
 
Reviewed by:  
 
 
Signature:   
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1. Purpose/Background  
      To ensure safe and effective standard of hygiene of the imaging device 
      being used in a patient/volunteer clinical study. 
 
2.  Scope  
      Applies to all research team members who handle the imaging device 
 
3.  Responsibilities  
      All research team members are responsible for reading this SOP and signing 
      to state that they understand this SOP. 
 
 
4.  Procedure 
o Device ‘patient contact’ area to be covered with TegadermTM dressing 
when in use. 
 
o TegadermTM dressing to be replaced after each subject. 
 
o Device to be cleansed between subjects using ‘azowipes’ as supplied in 
the clinical area of the Photobiology Unit 
 
o Once cleaned, the device should be allowed to air dry. 
 
o Device to be stored in a clean, dry secure area  
 
 
5. Related documents   
NHS Tayside Infection Control Policy (13/09/2013) 
 
6. Approval and sign off  
 
Author: 
Name: Olena Kulyk    
Designation:  Researcher    
Signature:     Date: 10 October 2013 
 
Approved by: 
Name:  
Designation: Clinical Trials & Project Coordinator 
Signature:     Date: 
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Member of staff 
 
PRINT NAME 
Version 
number of 
SOP 
SOP read and understood 
(sign) 
Date 
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Appendix V: Capturing fluorescence – Healthy 
Volunteer Participant Information Sheet PIS v.2 
17.12.2013PIS  
 
                                                                                                                                                
 
 
 
 
PARTICIPANT INFORMATION SHEET 
HEALTHY VOLUNTEER COHORT 
 
 
Capturing fluorescence imaging of the skin: patients 
with skin tumours and healthy volunteers 
My name is Olena Kulyk and I am a 2nd year PhD Physics Student at the 
University of St. Andrews.  I am required to undertake a project as 
part of my course and invite you to take part in the following study.  
However, before you decide to do so, I need to be sure that you 
understand firstly why I am doing it, and secondly what it would involve if 
you agreed.  I am therefore providing you with the following information.  
Please read it carefully and be sure to ask any questions you might have 
and, if you want, discuss it with others including your friends and family.  
I will do my best to explain the project to you and provide you with any 
further information you may ask for now or later. 
 
Why are we doing this study? 
Photodynamic therapy is a treatment used to treat areas of sun damage 
and skin cancer.  It works by applying a cream which contains a 
chemical in it which is taken up into the skin and converted to another 
chemical which is light sensitive.  This light sensitive chemical fluoresces 
(produces a crimson red light) when blue light is shone on it.  This 
crimson red fluorescence can be detected by an imaging camera.  This 
allows us to work out how much accumulates in normal skin and whether 
there are increased amounts present in abnormal diseased skin.  We 
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hope that monitoring fluorescence of this chemical (protoporphyrin IX, 
PpIX) will increase our understanding of how PDT works and allow us to 
improve treatment regimes.   
 
Why have I been chosen? 
One part of our study is to try and increase our understanding of what 
happens when the cream applied in PDT is applied to normal skin, and 
when the peak fluorescence occurs and it is because you are a healthy 
normal volunteer that you have been selected to participate. 
 
Do I have to take part? 
Participation in this study is entirely voluntary and you are free to refuse 
to take part or to withdraw from the study at any time without having to 
give a reason and without this affecting any future healthcare. 
 
What will happen to me if I take part? 
We will invite you to come to the Photobiology Unit, Level 8, Ninewells 
Hospital & Medical School, Dundee to speak with one of our Research 
Team when you will be given the opportunity to ask any questions you 
may have regarding the research study. If you agree to take part in the 
study, a member of the research team will then ask you to sign a consent 
form and the study procedure will be performed. You will receive a copy 
of this Participant Information Sheet and signed Consent Form to keep.  
 
Once the PDT cream has been applied we will take measurements of the 
study skin site every 10 -15 minutes throughout the three hour period. 
The cream will be removed and we will apply a small adhesive dressing 
to the site. You will then be free to leave. This will complete your 
participation in the study. 
 
What are the possible discomforts, risks and side effects? 
We do not anticipate any study-specific side-effects, however, there may 
be some redness and slight itch or discomfort at the site of cream 
application, especially if exposed to bright light for up to 48 hours after 
application. This will be minimized by keeping the area covered for this 
period.  
Your health and safety are the most important considerations to the 
doctors performing this study. The research team will take responsibility 
for your clinical care during the study. They will halt your participation at 
any time if it is felt that continued participation would be detrimental to 
you in any way.  There are certain things you should consider about the 
procedure in the study which may affect your willingness to participate. 
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What are the possible benefits of taking part? 
There are no personal benefits to you as a volunteer. However, this 
study may influence patient care and treatment in the future 
 
How long will my participation last?  
Your participation in this study will consist of one study visit which will 
last approximately four hours. We understand that this may impact on 
you financially and so we will reimburse you with £50 to cover expenses 
and inconvenience. 
 
Is there a person I can speak to about the research study who is 
independent from the research team? 
Yes, you can contact: 
 
 
 
 
 
 
What if something goes wrong? 
If you have a complaint about your participation in the study you should 
first talk to a researcher involved in your care. You can ask to speak to a 
senior member of the research team or the Complaints Officer for NHS 
Tayside.  In the event that something goes wrong and you are harmed 
during the study there are no special compensation arrangements.   
If you are harmed and this is due to someone’s negligence then you may 
have grounds for a legal action for compensation against the University 
of Dundee or NHS Tayside but you may have to pay your legal costs. 
The normal National Health Service complaints mechanisms will still be 
available to you (if appropriate). 
 
Complaints and Claims Manager 
 
 
 
 
Some insurance companies consider that participation in medical 
research such as this is a ‘material fact’ which should be mentioned in 
any proposal for health-related insurance, or which could influence their 
judgement in consideration of claims made under existing insurance 
policies. You should check that participation in this research does not  
affect any policy you might be thinking about taking out or any existing 
policy. 
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Will my taking part in the study be kept confidential? 
All the information collected will be kept strictly confidential. The 
information will be kept in a locked room and held on a secure password 
protected computer with your name and other identifying details 
removed.  Only the researchers involved in the study and the regulatory 
authorities will have access to the information.  We will keep the non-
identifiable information for five years after completion of the study. With 
your permission, we will notify your GP of your participation in this study.  
 
What will happen to the results? 
The results will be examined by the researchers who have organised the 
study, and a short report will be produced.  You will not be identified in 
this report. The results may then be published in the PhD thesis and 
scientific journals and presented at academic meetings. Again, you will 
not be identified in the thesis, any journal articles or presentations.   
 
Who is funding and organising this research? 
The study has been sponsored by the University of Dundee and NHS 
Tayside, organised by . The Photobiology Trust is funding this study. 
 
Who has reviewed this study? 
The East of Scotland Medical Research Ethics Service REC 1 which has 
responsibility for scrutinising proposals for Medical Research on Humans 
in Tayside, has examined the proposal and has raised no objections 
from the point of view of Medical Ethics.  It is a requirement that your 
records in this research together with any relevant medical records be 
made available for scrutiny by monitors from NHS Tayside, University of 
Dundee and University of St. Andrews. 
 
For further information contact: 
 
 
Thank you for reading this information sheet and considering 
taking part in this study
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Appendix VI: Capturing fluorescence – Patients 
Participant Information Sheet PIS v.2 17.12.2013 
 
                                                                                                                                                
 
 
 
 
 
PARTICIPANT INFORMATION SHEET 
PATIENT COHORT 
 
 
Capturing fluorescence imaging of the skin: 
patients with skin tumours and healthy volunteers 
My name is Olena Kulyk and I am a 2nd year PhD Physics Student 
at the University of St. Andrews.  I am required to undertake a project 
as part of my course and invite you to take part in the following 
study.  However, before you decide to do so, I need to be sure that you 
understand firstly why I am doing it, and secondly what it would involve if 
you agreed.  I am therefore providing you with the following information.  
Please read it carefully and be sure to ask any questions you might have 
and, if you want, discuss it with others including your friends and family.  
I will do my best to explain the project to you and provide you with any 
further information you may ask for now or later. 
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Why are we doing this study? 
Photodynamic therapy is a treatment used to treat areas of sun 
damage and skin cancer.  It works by applying a cream which contains a 
chemical in it which is taken up into the skin and converted to another 
chemical which is light sensitive.  This light sensitive chemical fluoresces 
(produces a crimson red light) when blue light is shone on it.  This 
crimson red fluorescence can be detected by an imaging camera.  This 
allows us to work out how much accumulates in normal skin and whether 
there are increased amounts present in abnormal diseased skin.  We 
hope that monitoring fluorescence of this chemical (protoporphyrin IX, 
PpIX) will increase our understanding of how PDT works and allow us to 
improve treatment regimes.   
 
Why have I been chosen? 
You have been diagnosed as having sun damaged skin/ a non-
melanoma skin cancer (basal cell carcinoma)/ pre-cancer (Bowen’s  
 
Disease) or actinic keratosis and have been referred to the 
Photobiology Unit to have photodynamic therapy (PDT).  
 
Do I have to take part? 
Participation in this study is entirely voluntary and you are free to 
refuse to take part or to withdraw from the study at any time without 
having to give a reason and without this affecting any future healthcare. 
If you would like to discuss taking part in the study, please fill in the 
attached slip and send it back in the stamped addressed enveloped 
which has been supplied or phone any of the people listed at the end of 
this information leaflet. 
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What will happen to me if I take part? 
We will invite you to come to the Photobiology Unit, Level 8, Ninewells 
Hospital & Medical School, Dundee to speak with one of our Research 
Team when you will be given the opportunity to ask any questions you 
may have regarding your treatment and the research study. If you agree 
to take part in the study, a member of the research team will then ask 
you to sign a consent form. You will receive a copy of this Participant 
Information Sheet and signed Consent Form to keep.  
Once the PDT cream has been applied we will take photographic 
measurements of the study skin site every 10 -15 minutes throughout the 
three hour period. You will then have your PDT treatment and be allowed 
to go home. This one visit completes your participation in this research 
study.  
 
What are the possible discomforts, risks and side effects? 
We do not anticipate any study-specific side effects, however, there 
may be some redness at the treatment site which is expected as a 
normal response to PDT. Your consultant will have explained how PDT 
works and the measures that we take to minimise any pain or discomfort 
you may experience.   
Your health and safety are the most important considerations to the 
doctors performing this study. The research team will take responsibility 
for your clinical care during the study. They will halt your participation at 
any time if it is felt that continued participation would be detrimental to 
you in any way.  There are certain things you should consider about the 
procedure in the study which may affect your willingness to participate. 
 
What are the possible benefits of taking part? 
There is no personal benefit to you as a patient. However, this 
study may influence patient care and treatment in the future. 
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Will I have extra visits to the hospital? 
No, we will be taking measurements every 10-15 minutes during 
the  routine three hours cream application and after the last 
measurements you will have your planned PDT treatment. 
 
Is there a person I can speak to about the research study who 
is independent from the research team? 
Yes, you can contact: 
 
 
 
 
  
 
What if something goes wrong? 
If you have a complaint about your participation in the study you 
should first talk to a researcher involved in your care. You can ask to 
speak to a senior member of the research team or the Complaints Officer 
for NHS Tayside.  In the event that something goes wrong and you are 
harmed during the study there are no special compensation 
arrangements.   
If you are harmed and this is due to someone’s negligence then 
you may have grounds for a legal action for compensation against the 
University of Dundee or NHS Tayside but you may have to pay your 
legal costs. The normal National Health Service complaints mechanisms 
will still be available to you (if appropriate): 
 
Complaints and Claims Manager 
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Some insurance companies consider that participation in medical 
research such as this is a ‘material fact’ which should be mentioned in 
any proposal for health-related insurance, or which could influence their  
judgement in consideration of claims made under existing insurance 
policies. You should check that participation in this research does not 
affect any policy you might be thinking about taking out or any existing 
policy. 
 
 
Will my taking part in the study be kept confidential? 
All the information collected will be kept strictly confidential.   
The information will be kept in a locked room and held on a secure 
password protected computer with your name and other identifying 
details removed.  Only the researchers involved in the study and the 
regulatory authorities will have access to the information.  We will keep 
the non-identifiable information for five years after completion of the 
study.   
 
What will happen to the results? 
The results will be examined by the researchers who have 
organised the study, and a short report will be produced.  You will not be 
identified in this report. The results may then be published in scientific 
journals and presented at academic meetings. Again, you will not be 
identified in any journal articles or presentations.   
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Who is funding and organising this research? 
The study has been sponsored by the University of Dundee and 
NHS Tayside and organised by  
 
 
The Photobiology Trust is funding this study. 
 
Who has reviewed this study? 
The East of Scotland  Medical Research Ethics Service which has 
responsibility for scrutinising proposals for Medical Research on Humans 
in Tayside, has examined the proposal and has raised no objections 
from the point of view of Medical Ethics.  It is a requirement that your 
records in this research together with any relevant medical records be 
made available for scrutiny by monitors from NHS Tayside and the 
regulatory authorities. 
 
For further information contact: 
 
 
 
 
 
 
 
 
Thank you for reading this information sheet and considering 
taking part in this study 
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--------------------------------------------------------------------------------------------------------------
---------- 
 
I agree to discuss participating in the study. 
 
I understand that this study will take place when I am attending the 
Photobiology Unit  
for photodynamic therapy. 
 
Name ………………………………………   Date of birth 
……………………. 
 
Telephone No. ……………………………… 
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Appendix VII: Capturing fluorescence – Healthy 
Volunteer Consent Form 21.10.2013 V.1 
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CONSENT FORM 
(healthy volunteer cohort) 
 
Subject Identification Number for this study: 
 
 
Title of Project: Capturing fluorescence imaging of the skin: patients with skin tumours and  
                         healthy volunteers  
 
 
Chief Investigator:  
                                                                                                                        Please initial box 
 
1. I confirm that I have read and understand the information sheet dated     /    /2013 
    (version   ) for the above study. I have had the opportunity to consider the information,  
    ask questions and have had these answered satisfactorily.     
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
   without giving any reason, without my medical care or legal rights being affected.   
 
3. I understand that data collected during the study, may be looked at by individuals from  
   NHS Tayside, where it is relevant to my taking part in this research. I give permission for 
   these individuals to have access to my records. 
 
4. I agree to digital images being taken of the study skin sites to be used for presentation,  
    publication and research purposes. 
 
5. I agree to take part in the above study. 
 
 
 
_______________________            _________________          ___________________________ 
Name of Participant                             Date                                    Signature 
 
________________________            _________________          ___________________________ 
Name of Person taking consent          Date                                    Signature 
When completed, 1 for participant; 1 for researcher file 
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Appendix VIII: Capturing fluorescence – Patient 
Consent Form 21.10.2013 V.1 
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                                CONSENT FORM 
(patient cohort) 
 
Subject Identification Number for this study: 
 
 
Title of Project: Capturing fluorescence imaging of the skin: patients with skin tumours and  
                            healthy volunteers   
 
Chief Investigator:  
                                                                                                                        Please initial box 
 
1. I confirm that I have read and understand the information sheet dated     /     /2013 
    (version   ) for the above study. I have had the opportunity to consider the information,  
    ask questions and have had these answered satisfactorily.     
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
   without giving any reason, without my medical care or legal rights being affected.   
 
3. I understand that relevant sections of my medical notes and data collected during the  
    study, may be looked at by individuals from NHS Tayside, where it is relevant to my  
    taking part in this research. I give permission for these individuals to have access to my  
    records. 
 
4. I agree to digital images being taken of the study skin sites to be used for presentation,  
    publication and research purposes. 
 
5. I agree to take part in the above study. 
 
 
_______________________            _________________          ___________________________ 
Name of Participant                             Date                                    Signature 
 
_______________________           _________________          __________________________ 
Name of Person taking consent          Date                                    Signature 
 
When completed, 1 for participant; 1 for researcher file; 1 to be kept in medical notes   
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Appendix IX: Capturing fluorescence – Letter of 
Invitation v.1 21.10.2013 
 
                             
 
 
 
                                                                                                                             
 
 
 
 
 
 
 
 
 
 
Dear   
 
 
Research Study: Capturing fluorescence imaging of the skin: patients with skin 
tumours and healthy volunteers  
 
I am writing to invite you to participate in the above research project. You have 
been identified as a possible participant in this study because you have been referred 
to the Photobiology Unit for photodynamic therapy. 
For your information, I have enclosed a copy of the Participant Information Leaflet. 
Please let me know if you have any questions about this when you attend for your 
treatment. 
 
 
Yours Sincerely 
 
 
 
Consultant Dermatologist 
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Appendix X: Capturing fluorescence – Participant 
Travel Expenses Form 2013 V.1 
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Appendix XI: Capturing fluorescence – Sponsor Letter 
Insurance Note 2013DS03 
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Appendix XII: Capturing fluorescence – East of 
Scotland Research Ethics Service EoSRES Favourable 
Opinion Letter 
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Appendix XIII: Capturing fluorescence – University of 
St Andrews Teaching and Research Ethics Committee 
UTREC Approval Letter 10.02.2014 
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Appendix XIV: Capturing fluorescence – Fluorescence 
Imaging System Specifications v.1 09.10.2013 
  Fluorescence imaging system 
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The fluorescence imaging system records images of PpIX fluorescence and processes 
the images. The system consists of a CCD camera and collection optics, laptop, custom 
illuminator assembled with low power LED, a USB control. All components are comprised in 
a custom PMMA plastic casing. The camera has a fixed focal distance of 8.5 cm. The 
illumination, 405 nm LED, is controlled via a user interface and turns on for less than 1 s 
when an image of fluorescence is acquired. The user interface has such functions as recording 
fluorescence images, subtracting background, reducing noise, analysing fluorescence intensity 
in various regions of an image, plotting the 2D and 3D fluorescence intensity, and analysis of 
multiple images.  
 
 
Components 
1. A Lumenera LM075M USB 2.0 powered CCD camera 
2. The Collection optics: a Thorlab interference band pass filter, FL635 – Ø1ʺ 
CWL 635±2 nm, FWHM 10±2 nm threaded to screw into an optical lens M118FM16, 
focused at 8.5 cm 
3. A laptop 
4. A custom illuminator – a ring of 14 low power  405 nm LEDs built on a 
custom made round shaped PCB with a hole in the middle, LED VAOL-5GUV0T4 Ø5 mm 
through hole, (160 mcd, 3 V, 20 mA), connected to a INFINEON BCR402W/SOT343 LED 
drive, and a MMBF170L/SOT23 N-MOSFET switch; with an optical output equal to 0.1 
mW/cm
2 
at the end of the rectangular tube, 8.5 cm, around 1 s pulse;  
5. A custom made bio-thermoplastic casing containing the battery, the 
illumination PCB and the camera 
6. 9V battery 
7. A flash control: a USB 2.0 Parallel FIFO interface (TTL) development module 
UM245R connected via a 2.0 Type-A Male to Type-B Male USB cable to a laptop 
8. Matlab Graphical User Interface  
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The intensity of the illuminator and the LED emission spectrum  
 
The emission of one of the LEDs was measured using an Ocean Optics spectrometer 
(Fig 1). Spectral power for UV-A and Vis was calculated in %.  
 
Fig 1 – Emission spectrum of UV LED used for illumination 
 
Power = (Counts / sec) x Energy of Photon @ wavelength  
Spectral power in UV-A, % = Power in 340-399 nm range / Power for full spectrum x 
100% 
Spectral power in Vis, % = Power in 400-700 nm range / Power for full spectrum x 
100% 
32 % spectral power in 340 – 399 nm 
68 % spectral power in 400 – 700 nm 
The output intensity of the illuminator for the fluorescence imaging system 
The output power at a distance of 8.5 cm which corresponds to the end of the cylinder 
of the illuminator was measured using a Thorlabs PM100D power meter (Appendix 1). 
Measured power = 0.074 mW  
Are of the sensor = π x r2 = 3.14 x 0.4752 cm2 = 0.7085 cm2 
Intensity = Measured power / Area of the sensor = 0.074 mW / 0.7085 cm
2
 = 0.1 
mW/cm
2
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Appendix 1: The optical power output measurements for the fluorescence 
imaging system 
 
Parameters of the Thorlabs PM100D power meter with S120C - Standard Photodiode 
Power Sensor, Si, 400 - 1100 nm, 50 mW 
Aperture Size: Ø9.5 mm sensor 
Wavelength Range: 400 nm – 1100 nm 
Power Range: 50 nW – 50 mW 
Detector Type: Si Photodiode 
Linearity: ±0.5% 
Resolution: 1 nW 
Measurement Uncertainty: ±3% (451 nm – 1000 nm), ±5% (over Rest of Range) 
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Appendix 2: The eye and the skin risk assessment of the optical power 
output for the fluorescence imaging system 
 
 
 
 
 
 
14th December 2012 
 
Illuminator for St Andrews’ Fluorescence Imaging System 
Risk Assessment: Non-coherent Optical Radiation 
 
Irradiance at end of the cylinder 
0.32 mW cm
-2
 (340-399 nm) 
0.68 mW cm
-2
 (400-700 nm) 
 
 UV exposure limit, Heff  = 30 J m
-2
  
Effective irradiance Eeff = measured irradiance weighted by Sλ.  
Simplifying assumption based on LED emission spectrum:  
Assume UV emission is at 380 nm. 
Sλ = 0.000064 
Eeff = 0.32 x 0.000064 = 2.05 x 10
-5
 mW cm
-2
  
MPE time = 30 x 10
-1
 / 2.05 x 10
-5
 sec > 8 hours 
 
 UVA exposure limit, HUVA = 10
4
 J m
-2
  
UVA irradiance, EUVA = 0.32 mw cm
-2
  
MPE time = 10
4
 x 10
-1
 / 0.32 sec  = 52 min 
 
 Blue light exposure limit is 100 W m-2 sr-1  
Blue light irradiance LB = measured irradiance weighted by Bλ. 
Simplifying assumption based on LED emission spectrum: 
Assume 300-700 nm emission is at 400 nm. 
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Bλ = 0.1 
Effective irradiance = 1.0 x 0.1 = 0.1 mW cm
-2
  
Solid angular subtense = 0.7085 / 8.5 x 8.5 = 0.01 sr 
LB = 0.1 / 0.01 = 10 mW cm
-2
 sr
-1
 = 100 W cm
-2
 sr
-1
  
The exposure limit is 100 W m
-2
 sr
-1
 
The blue light exposure limit value is not exceeded. 
 
 CONCLUSIONS 
Heff exposure limits are not exceeded. No special precautions are required to protect 
from short wavelength UV radiation. 
HUVA limit is exceeded if exposure exceeds 52 minutes. Eye exposure should not exceed 53 
minutes. 
Blue light weighted radiance at the end of the cylinder is equal to the exposure limit. The 
device should not be placed on the unprotected eye. 
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Appendix XV: Capturing fluorescence – Printed Circuit 
Board PCB  
The drawings for the custom printed circuit board for the illuminator for the fluorescence 
system have been developed using DipTrace electronics design software and can be used 
for PCB cutting (outline drawing), printing coper traces (top and bottom traces drawing), 
drilling holes (holes drawing) and as a guidance for the assembly (assembly drawing). 
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Appendix XVI: Capturing fluorescence – 3D Plastic 
Casing Design 
The design of the casing has been developed in Rhino 4.0 3D CAD software.  
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 Appendix XVII: Capturing fluorescence – The 
Software Installation and Operation Instructions 
The software for the fluorescence system has been developed in Matlab. The archive with all 
the necessary installation files: the Lumenera software from the manufacturer of the camera, 
the manufacturer’s Matlab adapter for the camera, the manufacturer’s USB FTDI UM245R 
driver and Matlab adapters, and the written Matlab software with all the functions’ files are 
provided on a CD in a folder titled FluoImLu3.rar.  
The system requirements are Windows 7 64-bit operating system or higher and Matlab 
2012b or higher with the installed Image Acquisition Toolbox, and the Image Processing 
Toolbox. Matlab Computer Vision Toolbox is necessary at later stages for image processing. 
Installation procedure 
1. Run installation for the software for the Lumenera camera. The installation file is 
called LuCamSoftware-v6.0.3.exe. 
2. Extract and install Matlab driver from the archive called Lumenera Matlab Driver 
V2.0.1.rar. Read ReadMe.txt file for the installation instructions and setting up the 
path in Matlab, the installation file is called install.bat 
3. Run install.bat file for LumCamPlug-in. 
4. Install FTDI driver for UM245R USB module. Run CDM20824_Setup which is located 
in FTDI USB245 folder. 
5. Add USB245.mex32 or USB245.mex32 in the Matlab directory and add them to the 
path. The explanation of the commands in Matlab to control the USB unit can be 
found at this link.  
http://apps.usd.edu/coglab/psyc770/USB245.html. Make sure that the folder contains 
all mex-files and a Matlab functions for both the camera and the USB control before 
the operation.  
Operation procedure 
1. Start Matlab. Set the correct working directory. Open FluoImLu3.fig graphical user 
interface. 
2. Open Lumenera software. Set the exposure time, the gain, and start live preview for 
camera’s focus, if necessary use the button LEDsOn in the FluoImLu3.fig window to 
turn the illumination. 
Figure 1 shows the graphical user interface FluoImLu3 written in GUI Toolbox, Matlab. Each 
button has Matlab function in the root folder of the archive. 
Record test and Record control buttons on the GUI initiate the camera, the illuminator USB 
control unit, send high and low signals to the DB7 pin which controls a MOSFET switch 
which turns on the power for illumination. Once the illumination is on an image is acquired. 
The Lumenera software is in sync with the Matlab GUI, the Matlab GUI reads the exposure 
and the gain set in the Lumenera software. After the image is acquired, the illumination is 
turned off and the image is saved automatically with a given name which is the current date 
and time. A folder with a given name of the current date is created in the working directory of 
Matlab when the first image is taken. Once the folder is created all the following images will 
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be saved in this folder on that day. The format for the folder is dd-mmm-yyyy. The format for 
the images is Test_dd-mmm-yyyy_hhmmss.jpeg or Control_dd-mmm-yyyy_hhmmss.jpeg 
when the Record Test or Record Control buttons are pressed correspondingly. The only 
difference between the test button and the Control button is that the Test button records a 
series of 3 images, and the Control button records one image at a time. The Control button 
gives faster readings as less time is needed for the exposure and saving of images. 
LEDsOn and LEDsOff buttons turn the illumination on and off and also initiate the driver. An 
error message can occur in the Matlab window (error: No FTDI USB devices attached. FTDI 
installation failed!) when the FTDI module is not plugged into the computer or the driver 
needs an update. Sometimes it takes some time before automatic installation of the driver is 
complete. Typical debugging procedure is to press the Reset LED button which will re-install 
the USB driver. If the message still appears, restart the computer making sure that the 
operating system and the dirvers are up to date.  
The rest of the buttons open and display images, cross sections and export the data into 
excel files for convenience.  
 
Figure 1 FluoImLu3 Graphical User Interface 
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FluoImLu3 Matlab software script 
FluoImLu3.m 
function varargout = FluoImLu3(varargin) 
%{  
FLUOIMLU3 MATLAB code for FluoImLu3.fig 
Written by O. Kulyk,  
St Andrews, 13.05.2013 */ 
/* FLUOIMLU3, by itself, creates a new FLUOIMLU3 or raises the existing singleton 
H = FLUOIMLU3 returns the handle to a new FLUOIMLU3 or the handle to the existing 
singleton*. 
FLUOIMLU3('CALLBACK',hObject,eventData,handles,...) calls the local function named 
CALLBACK in FLUOIMLU3.M with the given input arguments. 
FLUOIMLU3('Property','Value',...) creates a new FLUOIMLU3 or raises the existing singleton*.  
Starting from the left, property value pairs are applied to the GUI before FluoImLu3_OpeningFcn gets 
called. An unrecognized property name or invalid value makes property application stop.  All inputs are 
passed to FluoImLu3_OpeningFcn via varargin. 
*See GUI Options on GUIDE's Tools menu.  Choose "GUI allows only one instance to run 
(singleton)". 
See also: GUIDE, GUIDATA, GUIHANDLES 
Edit the above text to modify the response to help FluoImLu3 
Last Modified by GUIDE v2.5 13-May-2013 21:07:59 %} 
 
% Begin initialization code - DO NOT EDIT 
gui_Singleton = 1; 
gui_State = struct('gui_Name',       mfilename, ... 
                   'gui_Singleton',  gui_Singleton, ... 
                   'gui_OpeningFcn', @FluoImLu3_OpeningFcn, ... 
                   'gui_OutputFcn',  @FluoImLu3_OutputFcn, ... 
                   'gui_LayoutFcn',  [] , ... 
                   'gui_Callback',   []); 
if nargin && ischar(varargin{1}) 
    gui_State.gui_Callback = str2func(varargin{1}); 
end 
 
if nargout 
    [varargout{1:nargout}] = gui_mainfcn(gui_State, varargin{:}); 
else 
    gui_mainfcn(gui_State, varargin{:}); 
end 
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% End initialization code - DO NOT EDIT 
 
% --- Executes just before FluoImLu3 is made visible. 
function FluoImLu3_OpeningFcn(hObject, eventdata, handles, varargin) 
% This function has no output args, see OutputFcn. 
% hObject    handle to figure 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    structure with handles and user data (see GUIDATA) 
% varargin   command line arguments to FluoImLu3 (see VARARGIN) 
 
% Choose DefaultShutter command line output for FluoImLu3 
handles.output = hObject; 
 
% Update handles structure 
guidata(hObject, handles); 
 
% UIWAIT makes FluoImLu3 wait for user response (see UIRESUME) 
% uiwait(handles.figure1); 
 
% --- Outputs from this function are returned to the command line. 
function varargout = FluoImLu3_OutputFcn(hObject, eventdata, handles)  
 
% Get DefaultShutter command line output from handles structure 
varargout{1} = handles.output; 
 
% --- Executes on button press in pushbutton1. 
function pushbutton1_Callback(hObject, eventdata, handles) 
RecordImageLu; 
%Fun1RecordImage; 
 
% --- Executes on button press in pushbutton2. 
function pushbutton2_Callback(hObject, eventdata, handles) 
Fun5ThreeDPlotCompensIm; 
 
% --- Executes on button press in pushbutton3. 
function pushbutton3_Callback(hObject, eventdata, handles) 
Fun2OpenImagePixels; 
 
% --- Executes on button press in pushbutton8. 
function pushbutton4_Callback(hObject, eventdata, handles) 
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Fun3OpenImageLine; 
 
% --- Executes on button press in pushbutton2. 
function pushbutton5_Callback(hObject, eventdata, handles) 
Fun4PlotPhotobleachOver21Min; 
 
% --- Executes on button press in pushbutton2. 
function pushbutton6_Callback(hObject, eventdata, handles) 
LEDsOn; 
 
% --- Executes on button press in pushbutton2. 
function pushbutton7_Callback(hObject, eventdata, handles) 
LEDsOff; 
 
% --- Executes on button press in pushbutton2. 
function pushbutton8_Callback(hObject, eventdata, handles) 
ResetUSB245; 
 
% --- Executes on button press in pushbutton8. 
function pushbutton9_Callback(hObject, eventdata, handles) 
CloseAllClearAll; 
 
% --- Executes on button press in pushbutton10. 
function pushbutton10_Callback(hObject, eventdata, handles) 
RawImage; 
 
% --- Executes on button press in pushbutton11. 
function pushbutton11_Callback(hObject, eventdata, handles) 
ExportToExcel; 
 
function [Exposure_Value, varargout] = edit_Callback(hObject, eventdata, handles) 
% Hints: get(hObject,'String') returns contents of edit as text 
%str2double(get(hObject,'String')) returns contents of edit as a double 
%set(hObject,'String',num2str(1200)); %set value in the edit box 
%get(hObject); %get properties of hObject 
%Shutter_Value = str2double(get(hObject, 'String')); %gets Shutter_Value from edit box  
handles = get(hObject, 'String'); 
Exposure_Val = str2double(handles); 
Exposure = 'ExposureFileLu.mat';  
/*changes the excel file ExposureFileLu.mat*/ 
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save(Exposure, 'Exposure_Val'); 
 
% --- Executes during object creation, after setting all properties. 
function edit_CreateFcn(hObject, eventdata, handles) 
% hObject    handle to edit (see GCBO) 
% eventdata  reserved - to be defined in a future version of MATLAB 
% handles    empty - handles not created until after all CreateFcns called 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), get(0,'defaultUicontrolBackgroundColor')) 
set(hObject,'BackgroundColor','white'); 
end 
 
% --- Executes on button press in pushbutton10. 
function pushbutton10_Callback(hObject, eventdata, handles) 
 
% --- Executes on button press in pushbutton11. 
function pushbutton11_Callback(hObject, eventdata, handles) 
 
function edit2_Callback(hObject, eventdata, handles) 
 
% Hints: get(hObject,'String') returns contents of edit2 as text 
%        str2double(get(hObject,'String')) returns contents of edit2 as a double 
handles=get(hObject, 'String'); 
x_val = str2double(handles); 
x = 'xFileForPlot.mat'; 
save(x, 'x_val'); 
 
% --- Executes during object creation, after setting all properties. 
function edit2_CreateFcn(hObject, eventdata, handles) 
 
% Hint: edit controls usually have a white background on Windows. 
%       See ISPC and COMPUTER. 
if ispc && isequal(get(hObject,'BackgroundColor'), get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
function edit3_Callback(hObject, eventdata, handles) 
 
handles=get(hObject, 'String'); 
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y_val = str2double(handles); 
y = 'yFileForPlot.mat'; 
save(y, 'y_val'); 
 
% --- Executes during object creation, after setting all properties. 
function edit3_CreateFcn(hObject, eventdata, handles) 
 
if ispc && isequal(get(hObject,'BackgroundColor'), get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
 
% --- Executes on button press in pushbutton12. 
function pushbutton12_Callback(hObject, eventdata, handles) 
TwoDPlotY; 
 
 
% --- Executes on button press in pushbutton13. 
function pushbutton13_Callback(hObject, eventdata, handles) 
TwoDPlotX; 
 
function edit8_Callback(hObject, eventdata, handles) 
 
handles = get(hObject, 'String'); 
Gain_Val = str2double(handles); 
Gain = 'GainFileLu.mat'; 
save(Gain, 'Gain_Val'); 
 
% --- Executes during object creation, after setting all properties. 
function edit8_CreateFcn(hObject, eventdata, handles) 
 
if ispc && isequal(get(hObject,'BackgroundColor'), get(0,'defaultUicontrolBackgroundColor')) 
    set(hObject,'BackgroundColor','white'); 
end 
 
% --- Executes on button press in pushbutton20. 
function pushbutton20_Callback(hObject, eventdata, handles) 
RecordTestLu; 
 
% --- Executes on button press in pushbutton21. 
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function pushbutton21_Callback(hObject, eventdata, handles) 
RecordControlLu; 
 
% --- Executes on button press in pushbutton22. 
function pushbutton22_Callback(hObject, eventdata, handles) 
ResetImaqDevice; 
 
Fun5ThreeDPlotCompensIm.m 
 
function Fun5ThreeDPlotCompensIm () 
%{ This function opens a fluorescence image, compensate it on optical distortions using scale 
factor which is estimated by imaging an even surface and adjusting each pixel on the non-uniformity, 
and performs 3D display in calibrated x, y coordinates in real size, 23 mm x 31 mm, at 8.5 cm 
distance. The function will be executed when pushbutton2 - 3D Plot button is pressed.  
Written by O. Kulyk, St Andrews, 14.05.2014 %} 
 
Scale=load('ScaleFactor.mat'); 
Scale = getfield(Scale,'ScaleFactor'); 
 
RawImage = imread(uigetfile({'*.jpeg'}));  
RawImage_Norm = double(RawImage)./250; 
 
[n, m] = size(RawImage); 
[x, y] = meshgrid(1:m, 1:n); 
c1 = double(RawImage_Norm); 
 
figure, 
colormap('jet'); 
cbar1 = colorbar; 
set(get(cbar1, 'ylabel'),'String','Fluorescence, au', 'Rotation', 90); 
hold on, 
surf1 = surf(x./640.*31, y./480.*23, c1,'FaceColor', 'texturemap', 'EdgeColor', 'none'); 
hold on, 
axis([0 31 0 23]); 
get(gcf); 
get(gco); 
get(gca); set(gca,'YDir','reverse'); 
xlabel('x, mm'); ylabel('y, mm'); zlabel('Fluorescence, a.u.'); 
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hold off; 
Fun2OpenImagePixels.m 
function Fun2OpenImagePixels () 
%{This function opens an image and displays it in impixelregion Image Processing Tool . The 
function will be executed when pushbutton3 button is pressed.  
Written by O. Kulyk, St Andrews, 16.11.2012%} 
 
Im = imread(uigetfile({'*.jpeg'})); 
 
figure; 
impixelregion(imshow(Im)); 
colorbar; colormap('jet'); %shows pixelregion of an image 
Fun3OpenImageLine.m 
function Fun3OpenImageLine () 
%{This function displays a cross section profile of an image along a selected interactive line in 
the Matlab image viewer. The function will be executed when the Line Profile button is pressed.  
Written by O. Kulyk, St Andrews, 16.11.2012%} 
 
Im = imread(uigetfile({'*.jpeg'})); 
ImNormalised = double(Im)./250; 
 
figure; 
[CX,CY,C]=improfile(imshow(ImNormalised));colormap('jet'); colorbar; 
hold on; 
improfile(ImNormalised,CX./640.*41,CY./480.*31); 
grid on; 
hold off; 
figure;plot(C);xlabel('distance, pixel');ylabel('Fluorescence, au'); 
 
LEDsOn.m 
function LEDsOn () 
%{ This function turns the LED on by clearing the cache data in Matlab, re-configuring FTDI 
circuit and sending high signal to the DB7 pin. The function will be executed when LEDsOn button is 
pressed.  
Written by O. Kulyk, St Andrews, 16.11.2012%} 
clear all; 
config_ftdi; 
writeUSB245(128); 
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LEDsOff.m 
function LEDsOff () 
%{ This function turns the LED off by clearing the cache data in Matlab, re-configuring FTDI 
circuit and sending low signal to the DB7 pin. The function will be executed when LEDsOff button is 
pressed.  
Written by O. Kulyk, St Andrews, 16.11.2012%} 
clear all; 
config_ftdi; 
writeUSB245(0); 
ResetUSB245.m 
function ResetUSB245() 
%{ This function resets the LED off by clearing the cache data in Matlab, re-configuring FTDI 
circuit and sending low signal to the DB7 pin. The function will be executed when Reset LED button is 
pressed.  
Written by O. Kulyk, St Andrews, 15.11.2012%} 
clear all; 
config_ftdi; 
writeUSB245(0); clear all; 
CloseAllClearAll.m 
function CloseAllClearAll () 
%{ This function ends the session by closing all Matlab windows, clearing Matlab editor 
window and cache memory. The function will be executed when CloseAllClearAll button is pressed.  
Written by O. Kulyk, St Andrews, 15.11.2012%} 
close all; clear all; clc; end 
RawImage.m 
function RawImage () 
%{ This function displays an image in Matlab viewer on a ‘jet’ false colour map without any 
modification to the image. The function will be executed when Raw Plot button is pressed.  
Written by O. Kulyk, St Andrews, 29.11.2012%} 
RawImage = imread(uigetfile({'*.jpeg'}));  
figure;imshow(RawImage);colormap('jet');colorbar; 
 
ExportToExcel.m 
function ExportToExcel() 
%{ This function converts 480 x 640 pixel image into 23 mm x 31 mm x- and y-axis calibrated 
at 8.5 cm distance from the lens plane of the fluorescence imaging system. The function extracts the 
values with 1 mm step (23 x 31 array of values), substracts background fluorescence values, applies 
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digital filters to smoothen out random noise and exports the values into *.xls spreadsheet for 
convenience.  
Written by O. Kulyk, St Andrews, 02.06.2013%} 
 
Scale=load('ScaleFactor.mat'); 
Scale = getfield(Scale,'ScaleFactor'); 
 
RawImage = imread(uigetfile({'*.jpeg'}));  
Bckgr= imread(uigetfile({'*.jpeg'}));  
 
RawImageScaled = double(RawImage).*(1-Scale)./250; 
BckgrScaled = double(Bckgr).*(1-Scale)./250; 
CompensImage = RawImageScaled-BckgrScaled;  
 
FilteredImage_Median = medfilt2(CompensImage, [3 3]); 
Filter_Gaussian = fspecial('gaussian',[15 15], 0.9); 
FilteredImage_Median_Gaussian = imfilter(FilteredImage_Median, Filter_Gaussian, 
'replicate'); 
 
[n, m] = size(RawImage); 
[x_axis, y_axis] = meshgrid(1:m, 1:n); 
c = double(FilteredImage_Median_Gaussian); 
 
i=1:31; 
indexi=round(i.*20.6452); 
j=1:23; 
j_=j'; 
indexj=round(j.*20.6452); 
Fluorescence = c(indexj,indexi); 
file = 'Results.txt'; 
save(file,  '-ascii', '-tabs','Fluorescence'); 
 
TwoDPlotY.m 
function TwoDPlotY () 
%{ This function a plots fluorescence cross section along y-line from 1-31 mm. The function 
will be executed when “Plot along y-axis, fixed x” button is pressed.  
Written by O. Kulyk, St Andrews, 02.06.2013%} 
 
Scale=load('ScaleFactor.mat'); 
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Scale = getfield(Scale,'ScaleFactor'); 
 
x=load('xFileForPlot.mat'); 
x_val = getfield(x,'x_val'); 
 
% y=load('yFileForPlot.mat','y'); %for plot along x-axis  
% y_val = getfield(y, 'y'); 
 
RawImage = imread(uigetfile({'*.jpeg'}));  
RawImageScaled = double(RawImage).*(1-Scale)./250; 
AverageImage = max(max(RawImageScaled));  
CompensImage = RawImageScaled-round(min(max(RawImageScaled)));  
%IntensityCompensImage = mean(mean(CompensImage)); 
 
FilteredImage_Median = medfilt2(CompensImage, [3 3]); 
Filter_Gaussian = fspecial('gaussian',[15 15], 0.9); 
FilteredImage_Median_Gaussian = imfilter(FilteredImage_Median, Filter_Gaussian, 
'replicate'); 
 
[n, m] = size(RawImage); 
[x_axis, y_axis] = meshgrid(1:m, 1:n); 
c = double(FilteredImage_Median_Gaussian); 
 
j = round(x_val*640/31); 
figure; 
plot(y_axis./480.*23.25, c(:,j)); 
xlabel('y, mm'); ylabel('Fluorescence, a.u.');grid on; 
 
figure; 
surf(x_axis./640.*31, y_axis./480.*23.25, c,... 
    'FaceColor', 'texturemap', 'EdgeColor', 'none'); 
axis([0 31 0 23.25]); 
get(gcf); 
get(gco); 
get(gca); set(gca,'YDir','reverse'); 
xlabel('x, mm'); ylabel('y, mm'); zlabel('Fluorescence, a.u.'); 
RecordTestLu.m 
function RecordTestLu() 
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%{ This function records 3 images, one after another, with the current fluorescence set up 
which has a Lumenera LM057m camera in it. The function creates a folder and automatically 
generates a name with the current date. It records 3 images with automatic names of date and time. 
The function will be executed when Record Test button is pressed.  
Written by O. Kulyk, St Andrews, 11.07.2013%} 
%write images with automatic names in specified folder 
 
folderName = sprintf(datestr(now,'dd-mmm-yyyy')); 
mkdir(folderName); 
p=pwd; 
addpath(p,folderName); 
 
config_ftdi; 
 
vid = videoinput('lumeneraimaqw64', 1, '640x480'); 
src = getselectedsource(vid); 
 
%this is optional, the gain and the exposure parameters are updated and taken from the 
Lumenera manufacturer’s software. 
Gain=load('GainFileLu.mat'); 
Gain_Val = getfield(Gain,'Gain_Val'); 
src.Gain = Gain_Val; %max 16 
Exposure=load('ExposureFileLu.mat'); 
Exposure_Val = getfield(Exposure,'Exposure_Val'); 
src.Exposure = Exposure_Val; %max 16 
vid.ReturnedColorspace = 'grayscale'; 
 
writeUSB245(128); 
start(vid); 
 
for i=1:1:3  
TempSnap=getsnapshot(vid); 
pause(1); 
filename = sprintf('%s','Test_',datestr(now,'dd-mmm-yyyy_HHMMSS'),'.jpeg') 
imwrite(TempSnap,fullfile(p,folderName,filename)); 
end 
writeUSB245(0); 
stop(vid); 
delete(vid); 
clear vid; 
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clear USB245; 
RecordControlLu.m 
function RecordControlLu() 
%{ This function records an image with the current fluorescence set up which has a Lumenera 
LM057m camera in it. The function creates a folder and automatically generates a name with the 
current date. It gives the image a name with the current date and time. The function will be executed 
when Record Control button is pressed 
Written by O. Kulyk, St Andrews, 11.07.2013%} 
%write images with automatic names in specified folder 
 
folderName = sprintf(datestr(now,'dd-mmm-yyyy')); 
mkdir(folderName); 
p=pwd; 
addpath(p,folderName); 
 
clear USB245; 
config_ftdi; 
 
%this is optional, the gain and the exposure parameters are updated and taken from the 
Lumenera manufacturer’s software. 
Gain=load('GainFileLu.mat'); 
Gain_Val = getfield(Gain,'Gain_Val'); 
src.Gain = Gain_Val; %max 16 
%for PpIX 
Exposure=load('ExposureFileLu.mat'); 
Exposure_Val = getfield(Exposure,'Exposure_Val'); 
src.Exposure = Exposure_Val; %max 16 
vid.ReturnedColorspace = 'grayscale'; 
writeUSB245(128); 
start(vid); 
TempSnap=getsnapshot(vid); 
writeUSB245(0); 
 
filename = sprintf('%s','Control_',datestr(now,'dd-mmm-yyyy_HHMMSS'),'.jpeg') 
imwrite(TempSnap,fullfile(p,folderName,filename)); 
 
stop(vid); 
delete(vid); 
clear vid; 
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clear USB245; 
ResetImaqDevice.m 
function ResetImaqDevice  
%{ This function resets an image acquisition device (whichever was initialised, Lumenera or 
Unibrain CCD cameras). The function will be executed when Reset Camera button is pressed.  
Written by O. Kulyk, St Andrews, 13.05.2013%} 
clear all; 
imaqreset; 
clear all; 
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Appendix XVIII: Capturing fluorescence – Image 
Processing  
Matching features algorithms – RANSAC Image transformation  
In order to compensate for camera displacement during the repetitive time course 
measurements an automated m-file has been written which asks to open a reference image, 
which would normally be a background image or the best aligned image. The algorithm will 
ask to open a second image which will be transformed using matching features (inliers and 
outliers points) on the reference fluorescent contour. Then RANSAC geometrical 
transformation is applied to the second image, the image is rotated and positioned to 
correspond to the position of the fluorescence reference contour of the first image, Figure 2. 
The algorithm then requests a name for the transformed image.  
 
Figure 2 RANSAC geometrical transformation – the blue and the red contours are the fluorescent 
reference contours of the first and the second images correspondingly. The inliers and the outliers are 
the corresponding points which allow the rotation and the positioning of the second image with the 
regard to the first image. 
% Written by Olena Kulyk, St Andrews, 2014 
% Matching features algorithms, P010 recovery reference image is 0 min 
% http://www.mathworks.co.uk/help/vision/ref/matchfeatures.html 
% align images by matching features 
% % image recovery by matching features 
% 
http://www.mathworks.co.uk/help/vision/ref/vision.geometrictransformestimat
or-class.html#btdyt0u 
%  
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%Detect, extract, and match SURF features from two images. 
  
%Read for the transform  
close all; clear all; 
Iin = imread(uigetfile({'*.*'})); imshow(Iin); title('Base image'); 
Iout = imread(uigetfile({'*.*'})); 
figure; imshow(Iout); title('For the transform'); 
  
%Detect and extract features from both images. 
  
ptsIn  = detectSURFFeatures(Iin); 
ptsOut = detectSURFFeatures(Iout);  
[featuresIn   validPtsIn]  = extractFeatures(Iin,  ptsIn); 
[featuresOut validPtsOut]  = extractFeatures(Iout, ptsOut); 
  
%Match feature vectors. 
  
index_pairs = matchFeatures(featuresIn, featuresOut); 
  
%Get matching points. 
  
matchedPtsIn  = validPtsIn(index_pairs(:,1)); 
matchedPtsOut = validPtsOut(index_pairs(:,2)); 
figure; showMatchedFeatures(Iin,Iout,matchedPtsIn,matchedPtsOut); 
title('Matched SURF points, including outliers'); 
  
%Compute the transformation matrix using RANSAC. 
http://www.mathworks.co.uk/discovery/ransac.html?refresh=true 
  
gte = vision.GeometricTransformEstimator; 
gte.Transform = 'Nonreflective similarity'; 
[tform inlierIdx] = step(gte, matchedPtsOut.Location, 
matchedPtsIn.Location); 
figure; 
showMatchedFeatures(Iin,Iout,matchedPtsIn(inlierIdx),matchedPtsOut(inlierId
x)); 
title('Matching inliers'); legend('inliersIn', 'inliersOut'); 
  
%Recover the original image. 
  
agt = vision.GeometricTransformer; 
Ir = step(agt, im2single(Iout), tform); 
figure; imshow(Ir); title('Recovered image'); 
imwrite(Ir,uiputfile('*.jpeg')); 
 
Cropping images algorithm for reference contour removal 
The fluorescent reference contour is cropped from the images. The cropped area is 
540 x 380 pixels area (for some cases is smaller, up to 380 x 380 pixels due to reduced 
study area) out of 640 x 480 pixels of not cropped image. A Matlab file is created which 
contains the information on cropping coordinate for each patient. An example of such Matlab 
script is provided below. 
% Written by Olena Kulyk, St Andrews, 2014 
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% Cropping Images algorithm 
   
close all; clear all; 
  
Iin = imread(uigetfile({'*.*'})); imshow(Iin); title('Base image'); 
 
%identify one reference corner and a crop area for all the fluorescence 
images 
Iout = imcrop(Iin,[63,39 540, 380]); imshow(Iout); title(Cropped image'); 
  
imwrite(Iout,uiputfile('*.jpeg')); 
 
Integrated intensity algorithm, image sectioning and correlation 
analysis 
The fluorescence pattern is visually assessed and the fluorescence images are 
sectioned into the areas of interest which are “Area 1” - a peak fluorescence area, “Area 2” – 
an area with middle fluorescence and “Area 3” – the area with the lowest fluorescence. 
A Matlab file is created for each area which contains the coordinates of the area and 
calculates integrated fluorescence over this area, correlates it to the monochromatic image of 
the skin and writes the results into an excel file. 
An example of a Matlab file for such image processing is provided below. 
% Written by Olena Kulyk, St Andrews, 2014 
%for image batch processing look at 
http://uk.mathworks.com/help/vision/ug/batch-process-image-
files.html?refresh=true 
%Integrated intensity for a data region algorithm, 540x380 size, minus 100 
pixels each side 
  
close all; clear all; 
  
fileFolder = 
fullfile('C:\Users\ok4\Dropbox\WorkFiles\MATLAB\FluoresecnceImagingSoftware
2\data_region\Proccessing Matlab\Recovered images\Cropped rect 540 x 380 
ref X47 Y35'); 
dirOutput = dir(fullfile(fileFolder,'*c.jpeg')); 
  
Image0 = imread('0c.jpeg'); 
Image1 =   imread('10c.jpeg'); 
Image2 =   imread('20c.jpeg'); 
Image3 =   imread('30c.jpeg'); 
Image4 =   imread('40c.jpeg'); 
Image5 =   imread('50c.jpeg'); 
Image6 =   imread('60c.jpeg'); 
Image7 =   imread('70c.jpeg'); 
Image8 =   imread('80c.jpeg'); 
Image9 =   imread('90c.jpeg'); 
Image10 =  imread('100c.jpeg'); 
Image11 =  imread('110c.jpeg'); 
Image12 =  imread('120c.jpeg'); 
Image13 =  imread('130c.jpeg'); 
Image14 =  imread('140c.jpeg'); 
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Image15 =  imread('150c.jpeg'); 
Image16 =  imread('160c.jpeg'); 
Image17 =  imread('170c.jpeg'); 
Image18 =  imread('180c.jpeg'); figure; imshow(Image18); 
tumour = imread('tumourc.jpeg'); 
  
Image0 = Image0(218:263, 199:283); %the area of interest - dimensions 
Image1 =   Image1(218:263, 199:283); 
Image2 =   Image2(218:263, 199:283); 
Image3 =   Image3(218:263, 199:283); 
Image4 =   Image4(218:263, 199:283); 
Image5 =   Image5(218:263, 199:283); 
Image6 =   Image6(218:263, 199:283); 
Image7 =   Image7(218:263, 199:283); 
Image8 =   Image8(218:263, 199:283); 
Image9 =   Image9(218:263, 199:283); 
Image10 =  Image10(218:263, 199:283); 
Image11 =  Image11(218:263, 199:283); 
Image12 =  Image12(218:263, 199:283); 
Image13 =  Image13(218:263, 199:283); 
Image14 =  Image14(218:263, 199:283); 
Image15 =  Image15(218:263, 199:283); 
Image16 =  Image16(218:263, 199:283); 
Image17 =  Image17(218:263, 199:283); 
Image18 =  Image18(218:263, 199:283); figure; imshow(Image18); 
tumour = tumour(218:263, 199:283);figure; imshow(tumour); 
  
mean_data_region = [mean2(Image0), mean2(Image1), mean2(Image2), 
mean2(Image3), mean2(Image4), mean2(Image5), mean2(Image6),... 
    mean2(Image7), mean2(Image8), mean2(Image9), mean2(Image10), 
mean2(Image11), mean2(Image12), mean2(Image13),... 
    mean2(Image14), mean2(Image15), mean2(Image16), mean2(Image17), 
mean2(Image18)]; 
mean_data_region_comp = mean_data_region - mean2(Image0); 
mean_data_region_norm = mean_data_region_comp./255; 
time = 0:10:180; 
t = {'time'}; 
%'Mean Fluorescence over an Image', 'B2' 
xlswrite('data_region.xls', mean_data_region', 'B2:B20'); 
xlswrite('data_region.xls', mean_data_region_comp', 'C2:C20'); 
xlswrite('data_region.xls', mean_data_region_norm', 'D2:D20'); 
xlswrite('data_region.xls', time', 'A2:A20'); 
xlswrite('data_region.xls', t, 'A1:A1'); 
xlswrite('data_region.xls', {'Mean Fluorescence'}, 'B1:B1'); 
xlswrite('data_region.xls', {'Minus Bckgr'}, 'C1:C1'); 
xlswrite('data_region.xls', {'Normilised'}, 'D1:D1'); 
 
% Fluorescence image correlation to the background 
cor_to_0 = [corr2(Image0, Image0),... % Image correlation to itself 
    corr2(Image0, Image1),... 
    corr2(Image0, Image2),... 
    corr2(Image0, Image3),... 
    corr2(Image0, Image4),... 
    corr2(Image0, Image5),... 
    corr2(Image0, Image6),... 
    corr2(Image0, Image7),... 
    corr2(Image0, Image8),... 
    corr2(Image0, Image9),... 
    corr2(Image0, Image10),... 
    corr2(Image0, Image11),... 
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    corr2(Image0, Image12),... 
    corr2(Image0, Image13),... 
    corr2(Image0, Image14),... 
    corr2(Image0, Image15),... 
    corr2(Image0, Image16),... 
    corr2(Image0, Image17),... 
    corr2(Image0, Image18)]; 
xlswrite('data_region.xls', {'cor_to_0'}, 'E1:E1'); 
xlswrite('data_region.xls', cor_to_0', 'E2:E20'); 
 
% Fluorescence images correlation to the last reading at 180 min 
cor_to_18 = [corr2(Image18, Image0),... 
    corr2(Image18, Image4),... 
    corr2(Image18, Image2),... 
    corr2(Image18, Image3),... 
    corr2(Image18, Image4),... 
    corr2(Image18, Image5),... 
    corr2(Image18, Image6),... 
    corr2(Image18, Image7),... 
    corr2(Image18, Image8),... 
    corr2(Image18, Image9),... 
    corr2(Image18, Image10),... 
    corr2(Image18, Image11),... 
    corr2(Image18, Image12),... 
    corr2(Image18, Image13),... 
    corr2(Image18, Image14),... 
    corr2(Image18, Image15),... 
    corr2(Image18, Image16),... 
    corr2(Image18, Image17),... 
    corr2(Image18, Image18)]; 
xlswrite('data_region.xls', {'cor_to_18'}, 'q1:q1'); 
xlswrite('data_region.xls', cor_to_18', 'q2:q20'); 
 
% Fluorescence image correlation to the tumour 
cor_to_tumour = [corr2(tumour, Image0),... 
    corr2(tumour, Image4),... 
    corr2(tumour, Image2),... 
    corr2(tumour, Image3),... 
    corr2(tumour, Image4),... 
    corr2(tumour, Image5),... 
    corr2(tumour, Image6),... 
    corr2(tumour, Image7),... 
    corr2(tumour, Image8),... 
    corr2(tumour, Image9),... 
    corr2(tumour, Image10),... 
    corr2(tumour, Image11),... 
    corr2(tumour, Image12),... 
    corr2(tumour, Image13),... 
    corr2(tumour, Image14),... 
    corr2(tumour, Image15),... 
    corr2(tumour, Image16),... 
    corr2(tumour, Image17),... 
    corr2(tumour, Image18)]; 
xlswrite('data_region.xls', {'cor_to_tumour'}, 'r1:r1'); 
xlswrite('data_region.xls', cor_to_tumour', 'r2:r20'); 
xlswrite('data_region.xls', {'data_region'}, 'A22:A22');  
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Appendix XIX: Diffuse reflectance measurements in 
phantoms 
Measured 
voltage 
@2,38 MV/A 
gain at 50 
Ohm load, V 
Current 
@2,38 
MV/A 
gain, A 
Absolute 
current, A 
Absolute 
power, W Power, au 
Simulated 
power, W Power, au 
1,14E-04 2,29E-06 9,6E-13 1,48E-12 1 5,29E-09 1 
2,42E-05 4,85E-07 2,04E-13 3,13E-13 0,212106 1,34E-09 0,2532235 
7,07E-06 1,41E-07 5,94E-14 9,15E-14 0,061894 5,07E-10 0,0958453 
3,84E-06 7,69E-08 3,23E-14 4,97E-14 0,033638 2,18E-10 0,0412034 
1,32E-06 2,64E-08 1,11E-14 1,71E-14 0,011567 8,49E-11 0,0160458 
6,72E-07 1,34E-08 5,65E-15 8,69E-15 0,00588 4,38E-11 0,0082808 
3,16E-07 6,32E-09 2,66E-15 4,09E-15 0,002765 2,69E-11 0,0050788 
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Appendix XX: Light transmission in brain phatnoms 
BPW34 X 6 (in tissue phantom); LED = 1 A; Photodiodes response 0,48 A/W 
Distance 
(mm) 
Short circuit 
current (A) 
Measured 
peak power 
from voltage-
load, W 
Measured 
power from 
current, W 
Measured 
power from 
current, au 
Simulated 
power, W 
Simulated 
power, au 
5 0,01505 0,017533164 0,031354167 1 8,568557 1 
10 0,007375 0,012586761 0,015364583 0,490033223 10,52536 1,22837 
15 0,004655 0,008924327 0,009697917 0,309302326 13,08922 1,527587 
20 0,002668 0,005391684 0,005558333 0,177275748 15,33258 1,7894 
30 0,000521 0,001069741 0,001085417 0,03461794 20,19089 2,356394 
50 0,0000338 5,21678E-05 7,04167E-05 0,002245847 30,03729 3,505525 
 
SLSD-71N300 (in tissue phantom) LED = 1 A; Photodiode response 0,55 A/W 
Distance 
(mm) 
Short 
circuit 
current (A) 
Measured 
peak power 
from voltage-
load, W 
Measured 
power from 
current, W 
Measured 
power from 
current, au 
Simulated 
power, W 
Simulated 
power, au 
5 0,07594 0,079897441 0,138072727 1 1,21797 1 
10 0,0597 0,064144081 0,108545455 0,786146958 0,910321 0,747408 
15 0,02204 0,031057824 0,040072727 0,290229128 0,958836 0,787241 
20 0,010695 0,016134987 0,019445455 0,14083487 0,554922 0,455612 
30 0,001782 0,002709916 0,00324 0,023465894 0,36136 0,29669 
50 0,000117 0,000141919 0,000212727 0,00154069 0,176415 0,144844 
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Appendix XXI: Ambulight PDT model 
Table – Position of LED in Ambulight PDT devices 
Number of LED X position, mm Y position, mm 
1 -4 10 
2 0 10 
3 4 10 
4 8 6 
5 3 6 
6 -3 6 
7 -8 6 
8 -8 2 
9 -2 2 
10 2 2 
11 8 2 
12 8 -2 
13 2 -2 
14 -2 -2 
15 -8 -2 
16 -8 -6 
17 -3 -6 
18 3 -6 
19 8 -6 
20 4 -10 
21 0 -10 
22 -4 -10 
23 -10 -13 
24 10 -13 
25 -4 13 
26 0 13 
27 4 13 
28 10 10 
29 12 6 
30 13 2 
31 13 -2 
32 12 -6 
33 10 -10 
34 4 -13 
35 0 -13 
36 -4 -13 
37 -10 -10 
38 -12 -6 
39 -13 -2 
40 -13 6 
41 -12 10 
42 -10 13 
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Table – Power and irradiance simulations of Ambulight device with removing 
LEDs from the array 
Amount 
of LEDs 
removed 
Number of LED taken out Power, 
mW 
Irradiance, 
mW/cm2 
0 All in 50.816 7.19264 
1 1 49.47 7.002123 
1 2 49.44 6.997877 
1 25 49.467 7.001699 
1 23 50.42 7.136589 
1 21 49.375 6.988677 
2 21, 2 47.991 6.792781 
2 23, 24 50.031 7.081529 
4 23, 24, 21, 2 47.255 6.688606 
8 23, 24, 21, 2, 25, 27, 34, 36 43.122 6.103609 
10 23, 24, 21, 2, 25, 27, 34, 36, 9, 13 40.175 5.686483 
12 23, 24, 21, 2, 25, 27, 34, 36, 9, 13, 4, 16 37.404 5.294268 
14 23, 24, 21, 2, 25, 27, 34, 36, 9, 13, 4, 
16, 7, 19 
34.623 4.900637 
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Appendix XXII: Test OLEDs characterisation 
Luminance and irradiance of OLED have been measured using Minolta luminance 
meter LS-100. For Minolta luminance meter the following settings were used:  
 C.C.F. (colour correction factor) ON. CCF is used to adjust the response of the meter 
to measure colours greatly different from the calibration standard. CCF of 1.05 of 
three band fluorescence lamp is used. 
 Peak mode ON. When peak mode is on only peak measurement is displayed taken 
during trigger time. 
In order to convert luminance, cd/m2 into irradiance, mW/cm2 the following formulas 
are used (*): 
k =  
∑ 𝐸 𝑉
∑ 𝐸 
, 𝑒𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒 𝑠𝑝𝑒𝑐𝑡𝑟𝑢𝑚 
E – spectrum 
V – eye response  
Km =  683.002
𝑙𝑚
𝑊
, 𝑚𝑢𝑙𝑡𝑖𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 
Irradiance,
mW
cm2
= 𝐿𝑢𝑚𝑖𝑛𝑎𝑛𝑐𝑒,
𝑐𝑑
𝑚2
∗ 𝑠𝑜𝑙𝑖𝑑 𝑎𝑛𝑔𝑙𝑒(𝜋 𝑓𝑜𝑟 𝐿𝑎𝑚𝑏𝑒𝑟𝑡𝑖𝑎𝑛 𝑒𝑚𝑖𝑡𝑡𝑒𝑟)/(k · Km) 
 
Table – Test OLED devices optical power output 
Test OLED 33788-02 
    Minolta Luminance measurements 
Current, mA Voltage, V Luminance, cd/m2 Irradinace, mW/cm2 
10 3.18 101.7 0.18516 
50 4.39 850 1.54756 
100 5.19 1778 3.23713 
150 5.79 2665 4.85206 
200 6.24 3527 6.42147 
250 6.6 4402 8.01455 
300 6.9 5238 9.53662 
350 7.18 6092 11.09147 
370 7.16 6463 11.76693 
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Figure - Angular emission from test OLEDs device for potential application in 
ambulatory devices for non-melanoma cancer treatment measured by a former group member 
Dr Shuyu Zhang. 
 
Figure - The angular dependent emission was measured when the sample was at fixed 
position and the detector fibre was rotated to detect the emission from the OLED. The blue 
line on the graph is the emission from the OLED and the dark red line is a typical Lambertian 
angular distribution. 
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Figure - The test OLED emission spectrum measured with an Ocean Optics fibre based 
spectrometer. 
 
